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Abstract  
Herpes Simplex Encephalitis (HSE) is a lethal brain inflammation induced by Herpes Simplex 
virus (HSV), mainly HSV-1 subtype. Brain damage associated with HSE is reported to be 
caused directly by the virus and indirectly by the host immune responses. 
Aciclovir, the gold standard anti-viral therapy, targets HSV replication but not brain 
inflammation. Hence, administration of anti-inflammatory drugs alongside aciclovir may 
improve outcome in HSE patients. However, clinicians worry that immune-modulating 
drugs may enhance HSV replication during acute HSE. A few small clinical studies have 
demonstrated that administering glucocorticoids in combination with aciclovir improve patient 
outcome. However, change in HSV viral load was not examined. Interestingly, tumor 
necrosis factor alpha (TNF-α), a known pro-inflammatory mediator, exhibits high levels 
in cerebrospinal fluid among HSE patients. To date, there are no studies examining anti-
TNF therapy in HSE patients or human models. Further studies need to be performed to 
investigate the effect of anti-TNF agents and glucocorticoids on human brain cell survival 
and HSV viral load, to support future clinical studies.  
In my thesis, I have studied the impact of dexamethasone (a glucorticoid) and infliximab 
(an anti-TNF agent) in acute (up to 72 hours post-infection) HSV-1-infected human brain 
cell models. My study shows dexamethasone and infliximab administered in combination 
with aciclovir were not detrimental to cell viability or cell activity (as measured by 
mitochondrial activity) among HSV-1-infected neuroblastoma or microglia. I also 
showed these drugs do not enhance HSV-1 replication in these cells. Interestingly, 
Infliximab (in a single dose) was protective against HSV-1 infection in neuroblastoma 
and microglia cells. It led to a rapid reduction of HSV DNA abundance in the culture 
medium of the infected cells and slowed reduction in live cell number and activity. 
Nonetheless, neither dexamethasone nor infliximab showed a significant benefi t in 
combination with aciclovir compared to aciclovir alone. I have also developed co-culture 
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models of HSE using primary astrocytes or neuroblastoma cells co-cultured with 
microglial cells to begin to enable evaluation of drug therapies in more complex models.  
My results highlight that adjunctive anti-inflammatory therapies do not enhance HSV 
replication during acute infection of human brain cells. My findings also suggest 
infliximab may have potential, in different dose regimens, as a future adjunctive therapy 
in HSE.  
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Chapter 1 
 
1.1. Herpes Simplex Virus type 1 (HSV-1) 
1.1.1. Classification and structure of HSV-1 
HSV-1 (Herpes Simplex virus type 1) is a double-stranded (ds) DNA virus, belonging to the 
group I of the Baltimore classification. It is a member of the Herpesvirales order, 
Herpesviridae family and Alphaherpesvirinae subfamily, along with Varicella Zoster virus 
(VZV). Like Herpes Simplex virus-2 (HSV-2), its genus is simplex virus. The full particle of 
HSV is spherical with a diameter of around 225 nm1. It consists of a central core, an 
icosahedral nucleocapsid containing 152-155 kilo base-pairs (kbp) of dsDNA, which is 
surrounded by an amorphous matrix of viral proteins called the tegument, and the envelope 
(fig 1.1A). The envelope, the outer layer of the viral particle includes a lipid bilayer derived 
from the host cell, in which 600 to 750 surface glycoproteins, such as gB, gD, gH, or gL are 
anchored and form numerous spikes1. Surface glycoproteins are essential for HSV entry in 
host cells. gD is the main entry receptor of HSV and although it is able to bind both the surface 
molecules nectin-1 and Herpes Virus Entry Mediator (HVEM) on the host cell plasma 
membrane, the binding to nectin-1 appears to have a more crucial role in Herpes Simplex virus 
Encephalitis (HSE) pathogenesis in mice2. gB is a fusion protein that is only functional when 
partnered with the heterodimer gH/gL3,4. The HSV genome consists of two DNA blocks: one 
short and one long, each containing a unique sequence flanked by inverted repeat regions 
(fig1.1B). The HSV genome consists of four different DNA isomers encoding at least 84 
multifunctional proteins that play a crucial role in viral replication and immune evasion.  
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Figure 1.1. Structure of Herpes Simplex Virus type 1 (HSV-1). Source: Kukhanova et al. 
(Biochemistry, 2014, vol. 79, No. 13, pp. 1635-1652)5. (A) Structure of HSV-1. The HSV-1 
particle contains a central core, the capsid or nucleocapsid in which the viral DNA is packaged. 
The capsid is surrounded by an amorphous matrix of proteins called the tegument and by a 
lipid envelop originated from the host cell and in which viral envelop proteins are anchored. 
(B) Genome of HSV-1. (UL) Long Unique region, (US) Short Unique region, (IRL and TRL) 
Long Inverted Repeat sequences, (IRS and TRS) Short Inverted Repeat sequences.  HSV-1 
genome consists of 2 unique sequences, one short (US) and one long (UL), that are both flanked 
by inverted repeat sequences (IR and TR).  
 
1.1.2. Life cycle of HSV 
The HSV life cycle consists of (i) a lytic phase in which viral replication and production of 
virions in host cells occurs and ultimately leads to cellular destruction and (ii) a latent phase 
whereby the virus remains dormant within nerve cells (i.e. sensory ganglia such as the 
trigeminal ganglion).  
1.1.2.1. Lytic HSV replication in host cells 
HSV replication is the process whereby the virus replicates its genome and synthesises new 
viral proteins within host cells in order to produce new HSV particles6. This process is aided 
by the ability of the virus to hijack the host cell machinery. It is lytic as it leads to the 
A 
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destruction of host cells. Finally, the newly formed particles are released in the extra-cellular 
matrix and disseminated in the tissue for new host cell infections6.  
Once HSV gD binds host receptors, the viral envelope fuses with the plasma membrane thanks 
to the “fusogenic core” including the viral proteins gB and gH/gL3,4. The fusion allows the 
penetration of both the capsid and some viral tegument proteins into the host cell cytoplasm. 
Once the capsid reaches the nuclear pores, the HSV genome is released inside the nucleus6. 
The viral DNA is then replicated thanks to seven viral proteins including a DNA polymerase 
and transcribed by the host RNA polymerase II in the nucleus. New virions are also assembled 
inside the nucleus after translation of viral proteins in the cytoplasm. “Lytic” genes are HSV 
genes whose expression leads to the “lytic programme”. This programme drives HSV 
replication in host cells by (i) replicating the genome, (ii) producing viral proteins and (iii) 
assembling new HSV particles including viral genome and proteins. Transcription of “lytic 
genes” occurs  as a temporal cascade6. Firstly, immediate early (α) genes are transcribed; then 
early (β) genes and finally late (γ) genes. The α-gene products, such as ICP4, ICP22, ICP27, 
ICP47 and Us1.5 are involved in the β-gene transcription but also in the regulation of HSV 
replication7. The regulation of viral replication (and reactivation) is also ensured by other viral 
proteins such as the thymidine kinase or the ribonucleotide reductase8, 9, 10, 11. The expression 
of α-genes is necessary for a successful lytic viral replication, and their transcription is mainly 
triggered by the viral protein and transcriptional activator VP1612, 13, 14. The α-gene products 
not only promote lytic infection but also allow for the viral evasion of the host immune system. 
For example, in vivo, ICP27 is able to inhibit host mRNA translation while ICP47 can evade 
CD8+ T cell recognition by inhibiting the activity of the transporter protein TAP (Transporter 
associated with Antigen Processing) 15. The γ-proteins play a crucial role in the assembly of 
the capsid, tegument and envelope. Once the replicated viral DNA is packaged into the capsid, 
virions undergo steps of envelopment/de-envelopment by the membrane of the nucleus and 
Endoplasmic Reticulum (ER)6, 16. After the release into the cytoplasm, the capsid acquires a 
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mature envelop during the process of budding into endosome or Trans Golgi Network (TGN)-
derived vesicles16. The anterograde movement of HSV virions into the cytoplasm to the cell 
periphery is dependent on the action of microtubules aided by kinesin motor proteins16. 
Overall, HSV productive infection destroys host cells and allows the release of infectious 
particles into the tissue and subsequent infection of nearby cells. This occurs during 
symptomatic HSV infections of mucosal tissue for example, lips, oral cavity etc.  
1.1.2.2. Latency and reactivation 
HSV infections can also be non-replicative and lead to latency establishment like in nerve 
cells. This can happen in the trigeminal ganglion (TG) (or the sacral ganglion following genital 
infection) once HSV particles infect neurons and travel along sensory fibres.  
Latency is the ability of the virus to become dormant meaning the virus cannot replicate within 
the host cells during this phase. It allows the formation of stock of viruses within cells that can 
evade the host immune system. Latency is reversible, and reactivation is the process by which 
a latent infection turns back into a productive one, allowing the transmission to new hosts. 
Reactivation can be triggered by many stimuli such as stress, fever, immunosuppression and 
trauma6.  HSV reactivation can result, for instance, in the virus travelling back from the 
Trigeminal Ganglion (TG), through sensory nerves, to the cutaneous nerve endings where a 
localized vesicular eruption can occur. This phenomenon of reactivation is well-described for 
patients with recurrent episodes of Herpes labialis. Latent infection is characterised by the 
circularization of the viral DNA into an episome (DNA mainly silenced). The elevated 
expression of Latency-Associated Transcripts (LATs) associated with a repressed expression 
of lytic genes has been described in a crucial subset of HSV-1-latently-infected neurons both 
in mice and human6, 17,  18,  19. Interestingly, in vivo, it has been shown that the LATs expressed 
during latent infections originated from the same HSV-1 genome regions in both central 
nervous system (CNS) and peripheral nervous system (PNS) tissues20.  
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In a mouse model, LATs RNA were shown to play a role in maintaining the pool of latently-
infected neurons in the TG with their absence leading to a significant loss of this pool21. LATs 
are thought to promote cell survival potentially through an anti-apoptotic activity, which has 
been mapped to 3’-end of the first exon and the 5’-end of the stable 2kb LAT intron22. In 
mouse HSV-1-latently-infected neurons, LATs induced not only a decrease in expression of 
lytic genes but also a reduced viral reactivation after exposure to one stress stimulus23. Another 
study confirmed this result but also showed that following multiple stress stimuli, LAT-null 
viruses but not LAT-positive viruses lost their capacity to reactivate over time24.  
Overall, it seems that the expression of LATs in HSV-1-latently-infected neurons in the TG 
leads to (i) the repression of lytic gene expression, (ii) the maintenance of a pool of latently 
infected neurons and (iii) the maintenance of the competence of reactivation over time but 
used at low frequency. Interestingly, most scientists accept that LATs are not translated in vivo 
into functional proteins, thus emphasizing their interest in the latent HSV transcriptome to 
better understand the mechanisms of latency and reactivation during HSV infection7.  
1.1.3. Pathological manifestations of HSV infection 
Humans are the natural host of HSV. HSV infections occur worldwide and are not influenced 
by seasonality6. HSV transmission is thought to occur through close contact involving mucosal 
surfaces (i.e. oral cavity, genital mucosa) 6. Most HSV infections are asymptomatic and sub-
clinical, with the virus establishing latency in nerve cells (i.e. TG or sacral ganglia). The 
seropositivity of HSV-1 is extremely high and reached around 68% of the United States 
population in the period 1988-199425 26. In the same study, the seropositivity of HSV-2 and 
the seropositivity for both HSV-1 and HSV-2 were around 22% and 17%  respectively26. In 
2012, the HSV-2 prevalence among 15-49 years old was estimated around 10% worldwide27. 
One third of the world’s population is estimated to be affected by recurrent HSV 
(symptomatic) infections6. The main pathological manifestations of HSV infection includes 
  
 
6 
 
oral herpes, ocular herpes, genital herpes and herpes encephalitis. Oral herpes (known as cold 
sore, fever blister) is a rash of the skin and mucous membranes around the mouth, especially 
the lips (labialis herpes) characterised by lesions, blisters and mainly induced by HSV-128. In 
Europe, the incidence and prevalence of labialis herpes are estimated to be respectively at 1.6 
and 2.5 per 1000 patients and per year28. Herpetic gingivostomatitis is a specific presentation 
of oral herpes, within the mouth, describing an inflammation of both the oral mucosa and 
gingiva. In general, herpetic gingivostomatitis occurs in young children during a primary 
infection with HSV-1. Ocular herpes infection includes a spectrum of manifestations (i.e. 
stromal keratitis, endothelitis, superficial epithelial disease) depending on the part of the eye 
infected with HSV29. It is among the leading causes of visual morbidity29. In the United States, 
half a million of active ocular herpes simplex infections are diagnosed every year30. Genital 
herpes is clinically characterized by lesions and inflammation around the genital area, mainly 
the vulva and vagina for women and the shaft and the glans of penis for men. Five hundred 
million people are reported to live with genital herpes but this seems to be widely 
underestimated as there is an high proportion of patients unaware of their genital infection by 
HSV31. It is a very frequent sexually transmitted infection (STI) induced mainly by HSV-2 but 
also by HSV-1 for a high percentage of emerging first time cases. HSV-2 is mainly responsible 
for recurrent genital herpes infections. HSV-1 and 2 can also infect the nervous central system 
and cause other infectious diseases such as herpes simplex encephalitis and herpes simplex 
meningitis. Herpes simplex meningitis is an inflammation of the meninges, frequently 
recurrent, and usually caused by HSV-232. Finally, herpes encephalitis is an inflammation of 
the brain parenchyma induced by HSV-1 (mainly) and 2 and presenting the most severe and 
lethal type of HSV infections.  
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1.2. Herpes Simplex Encephalitis (HSE) 
1.2.1. HSE from a clinical perspective 
1.2.1.1. Clinical definition of HSE 
During the 1940’s, the first cases of HSE, inflammation of the brain due to HSV, were 
demonstrated in both adults and neonates thanks to the detection of intranuclear inclusion 
bodies and the isolation of HSV from brains affected by encephalitis during post-mortem 
studies33, 34. The most characteristic pathological findings in the autopsy of the brain of the 
adult affected by HSE were necrosis, gliosis, perivascular cuffs of lymphocytes, multiple small 
haemorrhages and intranuclear inclusions of the herpetic type33. Crucially, these changes were 
asymmetrical as they were mainly observed in one temporal lobe and represented late-stage 
HSE. A picture of perivascular infiltrates is shown in the figure 1.2. 
In a biopsy study of 12 subjects in 1984, very early signs of HSE in adult brain, including 
gliosis, glia nodules, perivascular inflammation and meningeal inflammation were described 
as being in mainly one temporal lobe of patient brain35. This is considered to correspond to the 
first week of neurological dysfunction in HSE35. Interestingly, at this stage of infection, neither 
necrosis nor haemorrhage were found in any of the brains of HSE patients. However, studies 
presenting acute HSE, and later stages of infection, revealed both the presence of necrosis and 
haemorrhages. Thus, in another clinical study, biopsy or necropsy of 22 acute HSE patients 
were done and revealed a majority of necrotizing encephalitis36. Furthermore, focal 
haemorrhages in the brain tissues could also be observed in this study. More recently, pictures 
of a brain biopsy of a HSE-affected 16-year-old male diagnosed and observed by Dr Dennis 
K. Burns (UT Southwestern Medical Center, Dallas, TX, United-States), showing brain 
necrosis in the right temporal cortex, was thoroughly described in the review of Kim et al37. 
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Interestingly, brain haemorrhages can also be a feature of HSE acute phase, despite normal 
results of CSF analysis, as shown by a case-report of Lever et al38. 
It is now thought that both necrosis and inflammation peak about 2-3 weeks after HSV brain 
infection, while viral antigen detection declines within the brain tissue35, 39.  Beyond necrosis 
and haemorrhages, within the brain tissue, the HSE acute phase can exhibit frequent Cowdry 
A intranuclear inclusions (masses of acidophilic material surrounded by clear halos within 
nuclei) in neurons, other direct signs of inflammation (i.e gliosis), vessel congestion, 
neuronophagia (destruction of neurons by phagocytosis), presence of cavitation and swellings 
in the temporal lobe36. In most HSE cases, liquefactive necrosis of the brain tissue occurs, 
which is a type of necrosis characterized by a liquid viscous mass of pus and other fluid 
remains. 
In HSE, the inter-human transmission of HSV is thought to occur via contact with mucosal 
surfaces or abraded skin essentially involving the area of the mouth. It was recently shown 
that HSV-1 could enter human keratinocytes by a mechanism of nectin-1-dependent plasma 
membrane fusion (at low temperature)40. Of note, HSV particles consequently undergo a 
retrograde transport, by a mechanism shared with pseudorabies virus41. Hence, by nerve axonal 
flow, HSV may establish latency in the dorsal root ganglion or in the CNS targeting the TG, 
the olfactory bulb or the brain as shown in vivo42. However, direct productive infection of the 
brain following HSV primo-infection is possible43, 44, 45. The majority of HSE patients 
contracting a primary infection are under 18 years old45.  Although, HSE can be the result of a 
primary infection, HSE is mainly due to reactivation of HSV from latency into nerves.  
Reactivation of HSV in CNS may occur in the brain tissue, olfactory bulb and trigeminal 
ganglia. 
Animal studies demonstrate that the route of HSV access to the brain includes both olfactory 
and trigeminal nerves pathways. In humans, the main hypothesis favours the route through the 
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olfactory nerves. Contrary to the trigeminal nerve pathway, the olfactory pathway leads to both 
temporal lobes and limbic areas, which are probably the main sites of brain tissue damage 
during HSE. This hypothesis has been further reinforced by the demonstration of HSV 
particles in necrotic olfactory bulbs in HSE cases46. 
 
 
 
 
 
 
 
Figure 1.2. Histopathological changes of the temporal cortex in a patient who died from 
HSE. Source: Prof T. Solomon47, pictures originally from Dr D. Crooks. Important 
perivascular infiltrate (activated microglia, macrophages and lymphocytes). Staining by 
Haematoxylin-Eosin. 20 x magnification.  
 
1.2.1.2. Epidemiology 
HSE is the most commonly diagnosed viral encephalitis in western countries and the most 
common infectious cause of sporadic encephalitis worldwide43. However, it is a rare disease 
with an annual incidence of 1 in 250,000 - 500,000 individuals worldwide43. A very recent 
study estimated the annual hospitalisation rate for HSE at 10.3 ± 2.2 cases/million in neonates, 
2.4 ± 0.3 cases/million in children and 6.4 ± 0.4 cases/ million in adults in the US48. Excluding 
very young children (under 3 years of age), HSE peaks over the age of 50 and affects both 
sexes equally43. Currently, HSV-1 accounts for around 90% of HSE cases49. 
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1.2.1.3. Clinical manifestations 
The most frequent clinical signs associated with HSE include fever, severe headache, nausea, 
vomiting, lethargy, altered mental state, focal neurological deficit, behavioural changes, 
seizures and evidence of brain inflammation such as cerebro-spinal fluid (CSF) pleocytosis (≥ 
5 nucleated cells/ml)32, 45, 43. Magnetic Resonance Imaging (MRI) of brains affected by HSE 
usually demonstrates specific abnormalities, such as focal enhancement in the temporal lobe 
or adjacent structures (fig 1.3) 39, 47. In 45 HSE patients, MRI has shown that the areas of 
involvement were mainly the temporal lobe (87.5%) but also the insula (70%), the frontal lobe 
(67.5%) and the thalamus (27.5%)50. By this same technique, HSE due to HSV-2 has shown 
more heterogeneous spread compared to the HSV-1 encephalitis. Furthermore, MRI is more 
sensitive than Computed Tomography (CT) scanning for detecting early changes of HSE200. 
In another HSE clinical study, favourable initial Electroencephalogram (EEG) findings were 
correlated with good 6-month clinical outcomes51. 
CNS complications such as seizures (38%), status epilepticus (5.5%), acute respiratory failure 
(20.1%), ischemic stroke (5.6%) and intracranial hemorrhages (2.7%) were found relatively 
frequent among HSE patients and associated with mortality48.  
Of note, some patients seem to develop HSE after having received neurosurgical procedures, 
CNS radiation therapy or immune therapies especially natalizumab or TNF inhibitors39. HSE 
can also affect immunocompromised patients, however there is no evidence that HSE is more 
prevalent in this population39. HSE in immunocompromised patients exhibits less extensive 
CSF pleocytosis, more widespread CNS lesions and higher mortality rate39. 
Without treatment, more than 70% of HSE patients die and less than 3% completely recover a 
normal neurologic status52. The most frequent neurological sequelae observed in HSE are 
memory impairment, personality and behavioral changes, speech abnormalities, epileptic 
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seizures and anosmia53. HSE survivors can also experience permanent seizure disorder or 
motor deficit32. 
 
 
 
 
 
 
 
 
 
Figure 1.3. Right temporal lobe hyperintensity observed by T2-weighted MRI in a 
patient with HSE. Source: Prof T.Solomon47. 
 
1.2.2. HSE pathogenesis 
1.2.2.1. HSV pathogenesis at the cellular level  
HSV-1 modulates major cellular functions including mitochondrial functions, mRNA and 
protein synthesis and synaptogenesis during the infection of brain cells.  
Following HSV-1 lytic infection, a shutoff of host mRNA has been observed in diverse 
mammalian non-CNS cells. This appeared to be due to several actions of viral proteins on host 
cellular machinery such as (i) host mRNA degradation by virion host shutoff (vhs) protein, (ii) 
impairment of the host mRNA splicing induced by ICP27 and (iii) suppression of host mRNA 
synthesis by targeting RNA polymerase II activity, particularly through ICP2254, 55, 56, 57, 58, 59. 
In the host cell machinery, PP1-α has the ability to induce protein synthesis as it leads to the 
dephosphorylation of eiF2-α so as to reverse the PKR-induced inhibition of protein synthesis60.  
Regarding the modulation of protein synthesis by HSV-1, it was shown that the interaction 
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between the viral protein ICP34.5 and eiF2-α is crucial for the specific dephosphorylation of 
eiF2-α by PP161. Hence, HSV-1 is able to modulate protein synthesis potentially to facilitate 
viral replication.  
Interestingly, the amino-terminally truncated form of the viral protein UL12 could induce a 
complete depletion of the mitochondrial DNA leading to higher requirements in pyruvate and 
uridine cell consumption62. A post-mortem transcriptomic study showed a preferential 
reduction in expression of mitochondrial genes such as cytochrome c oxidase 1 (CO1) in HSE 
cases compared to control subjects63. The loss of CO1 gene expression was confirmed in in 
vitro HSV-1 infection of primary human astrocytes and shown to be prior to the decrease in 
the nuclear DAD-1 gene expression. In mitochondria, the loss of enzymatic activity of 
mitochondrial genome-encoded CO1 was also seen before that of the nuclear genome-encoded 
mitochondrial enzyme SDH. The infection was associated with temporal sequence of 
mitochondrial integrity damage (i.e. loss of granularity, membrane fragmentation) starting 
prior to the nuclear morphologic changes. Altogether, this suggests that the alteration of 
mitochondrial functions in brain cells may be an early event of HSE pathogenesis. 
Interestingly, the antibiotic drug minocycline was found to increase cell viability, CO1 gene 
expression and mitochondrial activity in HSV-1-infected astrocytes63. 
In neurons, HSV-1 was shown to induce microtubule dynamic alterations, τ 
hyperphosphorylation and resulting axonal disruption64.  HSV-1-infected neurons are also 
affected by a synaptic dysfunction characterized by (i) a reduced production of presynaptic 
proteins, (ii) an impaired synaptic transmission and (iii) a reduced plasticity due to GSK-3 
activation and a subsequent intraneuronal accumulation of amyloid-β proteins65. 
Hence, during HSE, neurons and other brain cells undergo diverse and various alterations of 
their organelles (microtubules, mitochondria, nucleus) and functions (energy production, 
cytoskeleton intracellular transport, mRNA splicing, protein synthesis). Ultimately, these 
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pathogenic changes can lead to the brain cell death and liquefactive necrosis of targeted 
regions of the brain tissue affected by HSE. 
1.2.2.2. Immune response involved in HSE pathogenesis 
It has been demonstrated that the severity of histopathologic changes and neurological clinical 
signs does not correlate well with the viral load in the CSF66. However, HSV replication is in 
balance with the immune response suggesting the latter can also be involved in detrimental 
brain cell damage and HSE pathogenesis67.  
1.2.2.2.1. Leukocyte infiltration, microglia activation and Blood Brain Barrier (BBB) 
permeability following HSV-1 brain infection and their role in HSE pathogenesis 
The phenotypes and kinetics of leukocyte infiltration have been assessed in an in vivo model 
of HSE68. Macrophages and neutrophils were the first immune cells to invade the brain several 
days after infection, followed by T lymphocytes (2-4 weeks after the infection) at a 
(CD8+)/(CD4+) ratio of 3/168. In parallel, within the brain tissue, microglia, the resident 
macrophages, markedly up-regulated their MHC II expression (2-4 weeks after infection), as 
a sign of their activation. In response to HSV-1, lymphocytes, macrophages and microglia 
presented a marked increase in the gene expression of one key pro-inflammatory molecule 
each: IFN-γ, TNF-α and IL-1β, respectively68. Crucially, the transfer of activated immune cells 
in an in vivo model of HSE led to an earlier mortality68. Similarly, Lundberg et al. have shown 
after HSV-1 corneal inoculation that (i) mice susceptible to HSE, but not the resistant 
counterparts, presented intense focal inflammatory brain stem lesions of primarily F4/80+ 
macrophages and Gr-1+ neutrophils and (ii) the depletion of these cells in the susceptible mice 
led to an enhancement of their survival69. Finally, in response to an in vivo intranasal HSV 
infection, there were also significant increases in the percentage of macrophages and INF-γ-
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producing CD8 T cells in the trigeminal ganglion70. Altogether, this suggests that leukocyte 
infiltration and microglia activation may participate in HSE pathogenesis. 
In HSE patients, the levels of two markers of  T cell activation, sIL-2R and sCD8, peaking at 
convalescence stage, suggest that the immune response following leucocyte infiltration may 
also play a role in patient outcome after the acute phase both in relapse and neurological 
sequelae71. Interestingly, B-cells have been shown to decrease the susceptibility to HSE in 
mice by reducing viral multiplication, most probably through antibody secretion72. Among 
patients with proven HSE, a high proportion (74-84%) presented with at least a 4-fold increase 
in CSF IgG73. However, CSF anti-HSV-IgG levels did not influence the outcome of HSE-
patients treated with ACV74.  
Leukocyte infiltration is dependent on the blood brain barrier (BBB) permeability. Of note, a 
retrospective study demonstrated that the BBB permeability was negatively correlated with 
CSF IL-10 among patients with encephalitis and, interestingly CSF IL-10 was positively 
correlated with a normal coma score at admission75. This suggests that an increased BBB 
permeability may reflect the high degree of unconsciousness at admission among patients with 
encephalitis. 
1.2.2.2.2. TLRs, signalling pathways and some pro-inflammatory cytokine profiles associated 
to detrimental or protective effects during HSE 
Among transmembrane proteins, Toll-like receptors (TLRs) are pattern-recognition receptors 
(PRR) found in innate immune cells such as neutrophils and macrophages (like microglial 
cells in the brain) 76. Their role is to recognize a very wide repertoire of pathogen-associated 
patterns (PAMPS) and, upon activation, to initiate the immune response to infectious agents.  
In humans, 10 TLRs have been discovered (TLR1-TLR10)76. They own an extracellular 
leucine-rich domain especially mediating the immune response to bacterial surface-associated 
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PAMPS such as LPS or viral structural proteins. The leucine-rich TLR binding surface has 
been structurally characterized and appears to be 10-fold greater than the ones of antibodies 
or T-cell receptors77. TLR1, 2, 4, 5 and 6 are found on the plasma membrane76.  TLR3, 7, 8 
and 9 are observed within the cells, on the surface of endosomes and can target bacterial or 
viral nucleic acids76. For instance, TLR3 responds to double-stranded RNA and activate the 
PI3K-Akt pathway while TLR9 is activated following viral CpG DNA recognition78, 79.The 
cooperation between different TLRs such as TLR2 and 6 is essential for host response against 
invading agents like bacteria or yeast80.  
Other PRRs such as C-type lectin receptors, NOD-like receptors, RIG-I-like receptors or 
cytosolic DNA sensor (i.e. cGAS) have been discovered more recently. Their cross-talk with 
the TLRs is essential for innate immune initiation76, 81, 82. For example, it was shown that NOD-
1 combined with TLR7 induced a higher proliferative response in peripheral B cells compared 
to the effect of TLR7 alone82. PRRs are also involved in the activation of the adaptative 
immune system by inducing dendritic cells (DCs) maturation. It is the case of TLR5 following 
bacterial flagellin challenge83. 
The TLR activation triggers different intracellular signalling pathways modulated by kinases 
(such as Mitogen Activated Protein Kinases (MAPK) including c-Jun N-terminal Kinase 
(JNK) or p38 mitogen-activated protein kinases) and leads to the expression of different 
transcription factors including NF-kB or Interferon Regulatory Factor 3 (IRF3). In turn, it 
leads to the production of cytokines, chemokines and Reactive Oxygen Species. As an 
illustration, epithelial TLR5, after flagellin challenge, induces p38 activation that leads, in 
turn, to an increase in IL-8 expression84. 
Lokensgard et al. showed that HSV-1-infected human foetal microglia underwent a limited 
viral replication but release considerable amounts of TNF-α, IL1-β, CXCL10/IP-10 and 
RANTES whereas (human foetal) astrocytes and neurons were fully permissive to HSV but 
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did not release any of the aforementioned cytokines or chemokines 85. Other scientists found 
that the cytokines IL-1β, IL-6, TNF-α, IL-18, IL-12β and CXCL2 were produced, in a TLR2-
dependent way, by murine microglia following in vitro HSV infection 86.  
CD118-/- mice, compared to WT, showed a pathological enlargement of lateral ventricles 
associated with their absence of type I INF pathway in microglia87. The worse outcome in this 
CD118-/- population was associated with an increase in CXCL1 and CXCL10 levels in the 
CSF, an increased TNF-α expression in the ependymal region and a brain invasion of 
neutrophils87. Another in vivo study revealed that the absence of the adaptor MyD88, inducer 
of NF-κB, was associated with a decrease in macrophages TNFα production and severe 
encephalitis in mice 88. Cyclic GMP-AMP synthase (cGAS) is a PRR that can sense viral DNA 
in the cytosol and induce a type I IFN response through the adaptor protein stimulator of type 
I INF genes (STING). In an ocular HSE mice model, it was found that mice deficient in cGAS-
STING presented a higher susceptibility to HSE with an impaired antiviral defence 89. In vitro, 
the same authors showed that the administration of IFN α/β at the time of infection induced a 
decrease in viral titres in neurons (only for WT mice), astrocytes (WT and “STING KO” mice) 
and microglia cells (WT and “STING KO” mice) 89. Hence, this suggests a crucial role of type 
I IFN for the initial control of HSV-1 replication in vivo induced by the cGAS-STING 
activation. Furthermore, IFN- α/β Receptor knock-out (IFN α/β KO) mice were shown to 
present earlier mortality, higher brain viral titres and increased brain IFN- β expression in 
another HSE in vivo model90. This same study showed that both TLR2-/- and WT mouse 
populations exhibited similarly a low mortality and few signs of encephalitis after HSV-1-
infection70. However, TLR9-/- and TLR2/9 -/- mice were much more affected with 60% and 
100% mortality respectively. They exhibited considerable histopathological changes such as 
intense leptomeningitis associated with oedema, white matter vacuolization, endothelial 
reactivity, perivascular oedema and focal encephalitis (characterized by mononuclear cell 
infiltrates, activated microglia and perivascular cuffing). The most significant changes seen in 
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microscopy concerned the TLR2/9-/- population. Regarding the gene expression profile, the 
bad outcome in TLR2/9-/- was associated with increased CCL2/MCP-1, CXCL10/IP-10 and 
decreased IL-1β and INF-γ levels in both brain and TG.  
Nevertheless, other researchers found the absence of TLR2 to be protective in HSE in vivo 
models. Thus, it was observed that HSV-1 intraperitoneally-infected TLR2-/- mice, 
independently of the virus titers in brain, exhibited a blunted cytokine/chemokine response 
associated with reduced levels of serum IL-6, brain MCP-1/CCL2, fewer histopathological 
changes, a reduced inflammation in cerebellum and a decreased mortality91. 
The unclear outcome of TLR activation and its upstream release of pro-inflammatory 
cytokines and chemokines following in vivo HSV-1 infection in CNS could be due to the 
difference in mice strains, CNS regions studied, HSV-1 administration mode (intranasal vs 
intraperitoneal), HSV-1 strains or MOI used in the in vivo models. Alternatively, this may just 
reflect the fact that effects of cytokine and chemokine effects following HSV-1-brain infection 
are the results of a sum of interactions between cytokines and chemokines up or down 
regulated rather than that of an action of one individual pro-inflammatory molecule. 
Ex vivo brain slices showed that HSV-1 infection induced a slight increase in IFN-β gene 
expression and a more marked increase concerning the expression level of the Interferon-
stimulated-gene Mx192.  
In HSE-affected patients, it has been found that during the acute phase (first week of illness), 
the CSF pro-inflammatory molecules IL-6 and IFN-γ levels were elevated71. Then, during a 
convalescence stage, high levels of TNF-α, sIL2R and sCD8 were observed. Another study 
showed that high CSF values of INF-γ at the time of admission and high maximum CSF value 
of IL-6 (103-104 pg/ml) were predictors of poor outcome93. A significant increase in the CSF 
levels of two markers of immune system activation, neopterin and β2M,  has also been 
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observed in HSE patients compared to a group of patients affected by other neurological 
diseases (mainly non-HSV encephalitis) during the acute phase94. Crucially, high levels of 
neopterin correlated with worse outcomes during this phase. Finally, high levels of this 
molecule were still found in the CSF of HSE patients in the convalescent phase emphasizing 
the persistence of immune activation, after the acute phase, in HSE. Hence, clinical studies 
associate high CSF levels of some key pro-inflammatory molecules with HSE and potentially 
with clinical bad outcome.  
On the other hand, innate defects in the pro-inflammatory TLR3 signalling pathway have been 
correlated with a reduced anti-HSV-1 response and high susceptibility to HSE95, 96, 97. Among 
a cohort of sixteen adult patients with HSE, different mutations in  molecules associated with 
the TLR3 or IFN receptor pathways (IRF3, TRIF, STAT1, TLR3 and TBK1) in PBMCs were 
identified by whole-exome sequencing95. Most of these patients exhibited PBMCs with 
impaired expression in IFN-β, CXCL10 and/or TNF α. Moreover, TLR3 mutations were also 
associated with HSE in children97.  Altogether, this suggests that defects in the early innate 
immune response to HSV-1 could lead to HSE predisposition. 
1.2.2.2.3. Role of ROS and associated pro-inflammatory cytokines in HSE pathogenesis 
Reactive oxygen species (ROS) are chemical molecules containing oxygen, produced by cells 
under normal conditions with crucial functions in cell signalling and homeostasis98. During an 
infection, their production is increased and they have been shown to have antimicrobial 
properties. However, an excessive production of ROS can lead to oxidative stress and cell 
damage98.  
Concerning HSE, it has been found that (i) an increase in oxidative products and (ii) a high 
inducible-Nitric Oxide Synthase (iNOS) and Heme Oxygenase (HO)-1 transcript abundance 
were associated with brain damage following in vivo HSV-1 brain infection98. HO-1 catalyses 
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heme degradation. The major source of the related nitric oxide (NO) production was the 
population of microglia CD45(int)/CD11b(+) 98. In vitro, increased intracellular production of 
ROS after HSV-1 infection has been observed in wild-type (WT) microglia compared to the 
TLR2-/- ones99. This TLR2-dependent production of ROS in microglia was associated with the 
activation of the p38 MAPK-p44/42 signalling pathways and with neural oxidative damage 
and toxicity99.  
However, other researchers have found a protective role for iNOS and NO in HSE. Indeed, 
iNOS-/- mice, after HSV-1 infection, presented with earlier mortality and showed an increased 
gene expression of the viral transcript VP16 as well as the TNF-α, MCP-1, RANTES and IP-
10 host pro-inflammatory molecules compared to the WT counterparts in the TG100. 
Interestingly, an in vitro study showed that ROS can drive the TNF-α, IL-1β cytokine and the 
CCL2 or CXCL10 chemokine expression through p38 MAPK-p44/42 activation in HSV-1-
infected microglia101.  
Altogether, the data suggests a HSV-1-induced and TLR2-dependent ROS production by 
microglia/macrophages, which can be either detrimental or beneficial to the brain tissue during 
HSE. This dual effect of ROS in HSV-1-infected brain cells could be dependent on (i) its 
variable concentration into their brain tissue and/or (ii) its ability to induce the expression of 
different pro-inflammatory molecules depending on the infection stage and the 
microenvironment and/or (iii) the different models, cell lines and Multiplicity of Infection 
(M.O.I) used from one experiment to another.  
1.2.2.2.4. Programmed cell death following HSV-1-infection and its role in HSE pathogenesis 
Both HSV-1 and HSV-2 can trigger or block apoptosis, depending on the cell type. Many in 
vitro and in vivo studies reported diverse HSV proteins as modulators of apoptosis. In Hep-2 
strain of HeLa cervical adenocarcinoma cells, HSV-1 triggered apoptosis and later blocked it 
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by de novo protein synthesis at a critical time period called the “prevention window” 102. The 
expression of the HSV immediate early gene ICP0 seems to play a key role in initiating 
apoptosis103. Nevertheless, the viral proteins ICP27 (indirectly), gD, gJ, Us3, latency-
associated transcript (LAT) and ribonucleotide reductase large subunit (R1) were shown to 
exhibit anti-apoptotic functions. These anti-apoptotic functions were induced by: (i) activation 
of NF-kB signalling and subsequent expression of anti-apoptotic genes103 and/or (ii) 
inactivation of caspase-3 activation and/or (iii) inactivation by phosphorylation of Bcl-2 
family pro-apoptotic proteins103. During HSV-1 latent infection of neuron-like cells, Latency-
Associated Transcripts (LATs) were abundantly expressed and could counteract apoptosis 
induced by T-cells by interfering in the  “caspase 3/granzyme B” interaction104.  
In an in vitro study using HSV-infected human hippocampal neurons, HSV-1 triggered 
apoptosis through c-Jun/Jnk pathway activation while HSV-2, inducing neither increase in 
apoptosis nor HSE, highly activated the MEK/ERK1/2 survival pathway but not c-Jun/Jnk105. 
Interestingly, HSV-1 and HSV-2 replicated similarly in hippocampal neurons suggesting that 
the induction of apoptosis only by the subset HSV-1 is independent of the viral replication but 
due to specific “HSV-1 versus host brain cells” molecular interactions leading to c-Jun/Jnk 
pathway and caspase-3 activation. In human HSE brain slices, there was also a good 
correlation between areas of HSV-1 infection, apoptosis and JNK activation105. An in vitro 
study from murine cells showed HSV-1-induced apoptosis in microglia cells was dependent 
on TLR2106. We could hypothesize for c-Jun/Jnk a role of mediator of TLR2 activation in 
HSV-infected microglia since this has already been shown in human corneal epithelial cells 
following TLR2 ligand challenge107. 
The difference in activation of c-Jun/JNK and MEK/ERK1/2 signalling pathways in 
hippocampal neurons between HSV-1 and HSV-2 infection leading to a higher induction of 
apoptosis and HSE with HSV-1 could be explained by the anti-apoptotic activity of the viral 
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protein kinase (PK) ICP10 only possessed by HSV-2108. Indeed, HSV-2 ICP10 PK decreased 
apoptosis by phosphorylating ERK1 and ERK2 and increasing the expression of the anti-
apoptotic proteins c-Raf-1 and Bag-1. Meanwhile, HSV-1 ICP6, homologue of HSV-2 ICP10, 
had no effect on apoptosis in neurons. The difference in apoptosis between HSV-1 and HSV-
2 infection in hippocampal neurons was confirmed in cortical neurons. Interestingly, apoptosis 
in HSE is triggered both by the external (FasL, TNF) and the internal/mitochondrial (c-Raf-1 
and Bag-1) apoptotic pathways. 
In the majority (75%) of HSE brains studied by Aurelian et al., neuronal apoptosis was 
observed and the sites of apoptosis matched with the location of viral antigens suggesting a 
HSV-1-induced apoptosis in neurons67. Another study also showed that, in general, the brain 
regions with high rates of apoptotic brain cells matched with areas of productive viral infection 
but did not co-localize with immune CD3+ cells109. Interestingly, in the latter study, not all the 
apoptotic brain cells expressed viral antigens suggesting that apoptosis in HSE may be due to 
viral infection but also to bystander mechanisms triggering apoptosis in uninfected cells 
nearby infected cells. 
The presence of apoptosis in neurons and glia cells and high level of HSV particles in patient 
brain tissue are only restricted to the acute phase of HSE109. Interestingly, apoptotic microglial 
and satellite cells were also found in human HSE-affected brains110. 
Crucially, more severe outcomes were observed for HSE patients with a high increase in the 
CSF level of sFas, a soluble protein involved in apoptosis initiation by the external apoptosis 
pathway, over the course of infection111. Moreover, INF-γ protected against detrimental HSE 
by decreasing apoptosis in mice brain112. Altogether, this suggests a role of HSV-1-induced 
apoptosis modulated by the immune response of brain cells in HSE neuropathogenesis.  
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Necroptosis can be considered as a programmed necrosis, a back-up process to eliminate cells 
when apoptosis is altered. TNF-α is an initiator of necroptosis in a mouse fibrosarcoma cell 
line113. Interestingly, in the presence of apoptosis inhibitors, TNF-α in murine embryonic 
fibroblasts but also FasL, activated TNF-R1, Fas or TRAIL-R in Jurkat cells can also trigger 
necroptosis initiation113. Following initiation, an activation of the receptor-interacting kinase 
3 (RIP3 or RIPK3) is needed to complete necroptosis. Interestingly, HSV R1 protein has been 
revealed as an actor influencing necroptosis signalling through a RHIM-dependent modulation 
of RIP3 suggesting necroptosis could be another mechanism triggering HSE pathogenesis and 
dependent on the immune response114.  
1.2.2.2.5. Analysis of the HSE studies and their models published in the literature  
In conclusion, HSE is not only due to brain cell lysis via HSV but also to the subsequent 
inappropriate immune response as seen in numerous in vivo and in vitro aforementioned 
studies. CSF studies from HSE patients also suggest a detrimental immune response is 
involved into HSE pathogenesis. However, other studies have shown that some immune 
responses, especially from innate immunity, such as the activation of TLR3 pathway and 
subsequent type I IFN production in patients or in vivo models, are protective against HSE. 
This emphasizes the fact that the timing of HSV-1 infection is a key factor to consider and 
targeting the immune response too early in order to improve HSE treatment could be 
inefficient. Thus, an in vivo study showed that delayed but not early treatment of 
glucocorticoids was protective against HSE115. Finally, the presence of HSV-1-induced 
apoptosis during HSE also supports that HSE pathogenesis is not solely due to HSV lytic 
replication.  
The numerous differences between the models, cell lines and MOI used in HSE studies, likely 
explain, in part, the differences seen regarding the effect of pro-inflammatory molecules in 
HSE pathogenesis.  
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In in vivo studies, the differences in pathogenesis and HSE susceptibility observed between 
mouse models can be partly related to the animal genetic background. Indeed, while the 
C57BL/6 mouse strain was shown resistant to HSE, other strains including A/J, BALB/c or 
129S6SvEv/Tac were associated with more severe outcome116, 117. 118, 119.  
Of note, a more recent study showed that HSV-1 replication in the eyes, viral spread and the 
ability of inducing latent viral genomes in the TG were similar between C57BL/6 and BALB/c 
mice although the survival rate was still significantly higher for the C57BL/6 population120. In 
this study, severe combined immunodeficient (SCID) mice were also used to assess the 
differences in replication, spread and virulence of HSV-1 between mice with C57BL/6 and 
BALB/c genetic background. Based on the data obtained, the differences in genetic 
background between the two populations did not lead to significant changes in the resistance 
of SCID mice to HSV-1 pathogenesis. Since, SCID mice lack mature lymphocytes but not the 
components of the innate system, the authors suggested that “the resistance of C57BL/6 mice 
to HSV-1 pathogenesis is absolutely dependent on both (i) the development of a rapid IFN-
α/β response and (ii) the T-lymphocyte-mediated suppression of HSV-1 replication in infected 
tissues”.  
The inoculation route is also a key determinant of pathogenesis and severity in HSE mouse 
models. In mice, HSE can be induced by intracranial, intranasal, ocular, intraperitoneal or 
intravenous inoculation of HSV-1. Nevertheless, the two latter, although leading to lethal 
encephalitis, do not exhibit HSV titers in brain tissue and therefore seem less relevant for 
mimicking human HSE121. Intranasal inoculation is frequently used in HSE mice models and 
has been shown 100-fold more efficient than oral122. From the nasal epithelium, HSV-1 
reaches the brain though either olfactory or trigeminal nerves. The limitations of the nasal 
inoculation include the potential outbreak of lung infection leading to undesired systemic 
immune responses and the variation of animal breathing intensity potentially altering the 
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reproducibility of the experiment123. The direct inoculation of HSV into the CNS to mimic 
human HSE in mice can be preferred to the other methods of inoculation. Indeed it decreases 
the variations of HSE susceptibility due to genetic background and age by bypassing 
peripheral immunity123.  
Kollias et al. and Mancini et al. recently reviewed the literature from HSE mouse models and 
discussed in depth these differences between models, as well as the current understanding of 
HSE pathogenesis in these animals123, 121.  
1.3. Herpes Simplex Encephalitis (HSE) treatment 
1.3.1. Antiviral aciclovir as gold standard therapy for HSE treatment 
Currently,  intravenous aciclovir (ACV, acycloguanosine) (10mg/kg, three times daily, for 14 
days) is the recommended treatment for HSE in the UK and should be started before the results 
of laboratory analysis when HSE is clinically suspected39, 124. Research studies and clinical 
trials have shown that aciclovir (intravenous, 10mg/kg, three times daily, 14 days)  has the 
best efficacy relative to other used drugs such as vidarabine125, 53. It has reduced HSE mortality 
from 70% to 14-19%126. Of note, for patients with creatinine clearance <50mL/min, aciclovir 
dose should be adjusted. Moreover, oral valaciclovir should only be prescribed instead of 
intravenous aciclovir for patients presenting with clinical conditions precluding intravenous 
therapy.  
Aciclovir is a molecule that in vivo is both converted by HSV and cellular thymidine kinases 
to Aciclovir-TriPhosphates (ACV-TP). ACV-TP, in turn, is incorporated into the HSV DNA 
inhibiting the viral DNA synthesis and, thereby limiting HSV propagation and brain damage.  
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1.3.2. The limitations of aciclovir monotherapy 
Treatment of HSE with aciclovir does not guarantee survival since the mortality rate of patients 
treated with aciclovir is still as high as 14-19%126. Furthermore, a clinical study showed that 
45-60% of HSE survivors exhibited neurological sequelae, one year after the completion of 
aciclovir treatment126. In a similar study, a long-term examination showed that among 
survivors 69% had memory impairment, 45% experienced personality or behavioural 
abnormalities, and 20-35% lived with severe anxiety, impaired concentration, insomnia, 
irritability, fatigue, poor motivation or emotional lability53. Outcome assessment at 6-months 
post hospitalization on 97 HSE patients treated with aciclovir showed 8% died, 23% had no 
sequelae, 32% experienced mild sequelae, 19% moderate sequelae and 19% severe 
sequelae127. “Mild sequelae” were defined by “minor disability (…), able to work and function 
autonomously”; moderate sequelae by “major disability (…), cannot sustain a regular job” and 
“severe sequelae” by “major neuropsychiatric disability or chronic care patient (…), need 
constant help for daily routine”. A long duration of disease before hospital admission and 
extensive MRI brain involvement were associated with poor prognosis in this same 
retrospective study127. Although the majority of HSE survivors treated with aciclovir exhibited 
good recovery and regained independence in daily activities, most of them had persistent 
neurological sequelae.  
Despite the outcome of HSE-affected patients being markedly improved with the therapeutic 
use of aciclovir, the still possible fatal outcome and the high percentage of incomplete recovery 
in treated patients emphasises the need to identify new adjunctive therapies. Aciclovir only 
targets HSV replication through inhibition of viral DNA synthesis. Thus, in an in vivo model 
of HSE, aciclovir treatment was shown to reduce viral titers but not inflammation or 
mortality69 while HSE seems to be partly due to detrimental immune response (discussed 
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above). Altogether, this emphasises the interest of anti-inflammatory adjunctive therapy 
combined with aciclovir to improve HSE treatment.  
1.3.3. Adjunctive treatment in HSE  
1.3.3.1. Glucocorticoids 
Glucorticoids are used as medicines in a wide range of inflammatory, auto-immune and 
allergic diseases (e.g. rheumatoid polyarthritis, asthma) as inhibitors of the pro-inflammatory 
response. A case report showed a positive effect of high-dose of methylprednisolone, a 
member of the glucocorticoids, after aciclovir therapy improved the outcome of a HSE 
patient128. In children affected by HSE and treated with aciclovir, multiple case reports have 
suggested steroids improve cognitive and motor function as well as seizure frequency129. More 
compelling, a multiple logistic regression analysis performed retrospectively on 45 patients 
with HSE, defined corticosteroid treatment in combination with aciclovir as one of the 
predictors of good outcome130.  
 In vivo, following HSV-1 infection, delayed administration of both corticosterone and 
dexamethasone but not early administration of corticosterone resulted in a significant increase 
in mouse survival (with a greater impact for dexamethasone) 115. Interestingly, the effects of 
dexamethasone were correlated with a decrease in both the expression of pro-inflammatory 
genes (MCP-1, TNF-α, IL-1β, IP-10, iNOS) and viral replication. Another HSE in vivo study 
also showed that the combination of aciclovir/glucocorticoids did not influence viral 
replication but did significantly reduce the presence of MRI abnormalities compared to 
aciclovir alone or untreated counterparts131. Finally, a recent clinical study suggested 
corticosteroids decreased temporal lobe and total oedema volumes in HSE patient brains 
treated with aciclovir132. 
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1.3.3.2. TNF inhibitors (Etanercept, Infliximab) 
TNF protein and gene expression were shown to increase following HSV-1 infection in human 
foetal microglia85. Furthermore, TNF-α protein levels were elevated in HSE patient CSF 
during the convalescence stage71. This high CSF TNF level in the convalescence stage may 
indicate a detrimental immune response could persist after the acute phase HSE and induce 
either relapse or persistent neurological sequelae. Hence, the administration of TNF inhibitors 
together with aciclovir could benefit HSE patient outcome by targeting the TNF production of 
the HSE post-acute phase (or convalescence stage) starting around 7-10 days after the 
beginning of the acute phase. 
Today, TNF inhibitors such as infliximab (Remicade), etanercept (Enbrel), adalimumab, and 
certolizumab are used to also treat a wide range of inflammatory conditions including 
rheumatoid arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis. 
Biologically, these anti-TNF drugs prevent TNF from inducing biological responses through 
host cell surface TNF receptors (TNFR). Infliximab is a chimeric human/mice monoclonal 
antibody targeting the soluble and transmembrane human TNF-α protein. Etanercept is a 
dimeric fusion protein consisting of (i) the extracellular ligand-binding portion of human TNF 
receptor and (ii) the Fc portion of human IgG1. A treatment combining the antiviral 
valacyclovir and etanercept, significantly increased mouse survival following intranasal HSV-
1 challenge compared to untreated counterparts or mice treated with only one of these two 
drugs 133. Interestingly, mice treated with both therapies exhibited a decrease in brain TLR2 
and CCL2 gene expression compared to the group treated with antiviral only. Of note, in a 
mouse model of Japanese Encephalitis, etanercept was shown to significantly increase survival 
while reducing brain Japanese Encephalitis Virus (JEV) load and inflammation. The reduction 
of inflammation induced by etanercept was characterised by the restoration of blood-brain 
barrier integrity and the reduction of glial activation, glial nodule number, neuronal death and 
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perivascular cuffing number134. These observations are of major importance and may suggest 
a potential use of etanercept or other anti-TNF drugs for HSE treatment as the signs of 
inflammation induced by JEV inside the brain, and reduced by the drug, are similar to the ones 
characterised in HSE. Furthermore, the use of this same treatment in JEV-infected microglia-
neuronal cultures led to a decrease in the protein expressions of TNF-α, IL1-β, IL-6 and CCL2; 
all of them have also been shown increased in HSE or HSE models.  
1.4. Rationale, aim and objectives of my PhD project 
1.4.1. Summary of the rationale 
The limitation of aciclovir monotherapy in HSE and the need of adjunctive therapies have 
already been mentioned. Evidence of the involvement of detrimental immune responses in 
HSE pathogenesis has also been discussed. However, among the anti-inflammatory drugs, 
only a few glucorticoids have been assessed in HSE patients and, there is a lack of clear data 
to validate their impact on patient outcome and to understand the mechanisms of their potential 
effect128, 130. Interestingly, a beneficial effect of adjunctive anti-TNF therapy in a mouse model 
of HSE has been observed133. Therefore, although seen in a single in vivo experiment, we can 
hypothesize that anti-TNF therapies may also be of interest as adjunctive therapy for HSE 
treatment in human. They may have a positive impact on long-term outcome (i.e. neurological 
sequelae) potentially by targeting the high CSF TNF production during the convalescence 
stage (starting 7-10 days after the beginning of the acute phase)71. Crucially, the effects of both 
drug types, combined with aciclovir, in adult human brain cells infected by HSV-1 have never 
been assessed before this PhD project. Studying these effects is of major interest as it could 
give crucial insights to determine the importance of clinically assessing such drugs as 
adjunctive therapies for HSE treatment.  
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1.4.2. Hypothesis 
The main hypothesis of this work was that administering the anti-inflammatory drugs 
dexamethasone and infliximab in HSV-1-infected brain cells treated with aciclovir could 
improve their survival. 
1.4.3. Aim and main objectives 
Hence, the aim of this PhD was to assess the effects of these anti-inflammatory drugs, from 
glucocorticoid and anti-TNF families, combined with aciclovir in HSV-1-infected human 
brain cells. 
The main objectives of my PhD were: 
a) Establishing in vitro models of HSV-1-infection using human brain cells 
a1) Models using single cultures of human brain cells (Chapter 3) 
The human brain cells used in single culture to set up HSE models were neuroblastomas, 
immortalised microglia and primary astrocytes. Neuroblastomas were chosen as neuron-like 
cells. Neurons are extensively damaged during HSE both by necrosis and apoptosis39, 67. 
Astrocytes also undergo HSV-1-induced cell death during HSE by both ways39, 67. Microglia 
cells are the brain resident macrophages representing probably both the first line of defence 
against HSV-1 in the brain tissue and a source of damage to this same tissue through an 
overwhelming and detrimental release of ROS species, pro-inflammatory cytokines and 
chemokines98, 86, 87, 91. Hence, the long-term action of microglia cells during HSE could 
participate in the pathogenesis. Altogether, understanding better the effects of HSV-1 on 
neuroblastoma cells, astrocytes microglia cells is crucial for improving HSE therapy. 
Hence, I set up in vitro models of HSE using single cultures of these three human brain cell 
types targeted/eliminated by HSV-1 and/or potentially contributing to HSE pathogenesis.  
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These cell culture models were used to observe the effects of HSV-1 on (i) cell viability and 
morphology, (ii) viral replication and (iii) expression of inflammatory markers (TNF, INF-γ) 
during time-course experiments. 
a2) Models using co-culture of human brain cells (chapter 7) 
These particular models have been set up both (i) to get closer to in vivo models by getting 
two types of brain cells communicating together and (ii) to understand better the role of 
microglia following HSV-1-infection of nearby cells such as neuroblastomas and astrocytes. 
Indeed, as mentioned previously, the role of microglia cells in HSE is not fully understood 
with studies showing they are essential to protect brain cells from HSV-1 infection and others 
finding they are a source of detrimental immune response damaging these same cells 98, 86, 87, 
91. 
Using co-culture systems, HSV-1 replication and cell viability were assessed in all cell types 
at different time-points following infection.  
b) Assessment of anti-inflammatory drugs as adjunctive therapies for HSE treatment in vitro 
(chapters 4-6) 
For practical reasons and because of the time limitation of a PhD project, adjunctive therapies 
were assessed only in neuroblastomas and microglia monocultures. 
The anti-inflammatory drugs used, combined with aciclovir (effect of aciclovir alone in 
chapter 4), have been dexamethasone (chapter 5) and infliximab (chapter 6). Dexamethasone 
is used to treat inflammatory diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, 
cerebral oedema etc. This corticosteroid drug was chosen because different studies suggested 
a potential positive impact of dexamethasone and other corticosteroids in HSE treatment both 
in vivo and in clinical retrospective studies115, 131, 128, 130. Infliximab (Remicade) is a monoclonal 
antibody targeting human TNFα used clinically to treat various auto-immune diseases such as 
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Crohn’s disease, ulcerative colitis, rheumatoid/psoriatic arthritis, ankylosing spondylitis, 
plaque psoriasis. The choice of this particular human TNF inhibitor has been guided by 
practical reasons regarding access to anti-TNF drugs. Treatments with aciclovir, 
dexamethasone and infliximab were performed following HSV-1-infection (24h pi). 
Subsequently, viral replication, brain cell morphology and viability as well as TNF gene 
expression were performed from 30 h to 72 h pi (6 h-48 h post-treatment). 
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Chapter 2 Materials and Methods 
 
2.1. Introduction 
The main aim of my PhD is to assess the effects of dexamethasone and infliximab as adjunctive 
therapies to aciclovir. In vitro culture of human brain cells infected with HSV-1 has been used 
as model of HSE. During the first part of my PhD, I had to establish in vitro models of HSE 
using human brain cells both in single and co-culture. Then, I could assess the effects of 
dexamethasone and infliximab as adjunctive therapies for HSE treatments in some of these in 
vitro HSE models. These effects were assessed by measurement of cell viability, viral 
replication and host gene expression of key pro-inflammatory molecules (TNF-α, INF-γ). 
In this chapter, the materials and methods needed to fulfil these objectives are described. They 
include cell culture, HSV-1-infection, drug administration and assessments of cell viability, 
viral replication and the pro-inflammatory response. 
2.2. Materials and Methods 
2.2.1. Cell culture 
2.2.1.1. Cell incubation and storage 
2.2.1.1.1. Incubation of cells cultured 
Cells cultured were incubated in a humidified incubator (37 ℃, 5% CO2). 
2.2.1.1.2. Cell freezing 
After centrifugation (5 min, 300 x g) of the cell suspension, cell pellet was resuspended on ice 
in a solution of 90% FBS and 10% DMSO at a density of 1-2 x 106/mL (1-2 mL). This cell 
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suspension containing FBS and DMSO was then frozen in cryogenic vials for 24 h, at -80℃. 
Subsequently, they were frozen and stored in liquid nitrogen (-196 ℃). 
2.2.1.1.3. Cell Defrosting 
Cryogenic vials were defrosted in a water bath, at 37 ℃. Once defrosted, the cell suspension 
from one cryogenic vial was added to a pre-warmed adequate cell culture medium in one T75 
flask, which was then incubated at 37 ℃, 5% CO2. Twenty-four hours after incubation, cell 
culture medium was changed to preserve cells from DMSO toxicity. 
2.2.1.2. Mycoplasma assessment 
All primary cells and cell lines were tested for mycoplasma on a regular basis by qPCR testing 
on cell culture medium (every 2-3 months minimum) by the technical team of the Institute of 
Infection and Global Health (University of Liverpool).  
2.2.1.3. Primary astrocytes culture 
2.2.1.3.1. Pre-coating with poly-L-lysine 
Primary human astrocytes (HAs; Sciencell, Caltag, SC-1800-5) were semi-adherent and 
needed the use of a coating agent, poly-L-lysine (PLL), to facilitate their attachment and 
adherence to the flask surface.  Pre-coating consisted of adding 1 mL of PLL (15 µg/mL) per 
25 cm2 of the flask surface, followed by 1-2 hours incubation (at 37 ℃, 5% CO2) prior to 
addition of cells.  
2.2.1.3.2. Primary astrocyte culture 
Following pre-coating, flasks were filled with 15 mL of pre-warmed Dulbecco’s Modified 
Eagle’s Medium (DMEM)/ Ham’s Nutrient Mixture F12 (Sigma-Aldrich) in the presence of 
5% FBS, 1% Penicillin/Streptomycin (Sigma-Aldrich, 100X) and 1% L-Glutamine solution 
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(Sigma-Aldrich, 200 mM). Subsequently, a volume of 2-3mL of primary astrocytes, at a 
concentration of 106 cells/mL, was added into the flasks. Astrocytes were passaged at 80-100% 
confluence using Tryspin-EDTA 1X (1-2min at 37℃) solution to detach the cells. In all 
experiments, astrocytes used were between passages 3 and 9. 
2.2.1.4. Microglia culture 
The microglia cells used were SV40 immortalized human microglia cells (>99% purity) 
derived from primary human microglia cells (ABM company). They still have microglia 
markers such as CD68 and NGF.  They were adherent cells and cultured with DMEM (Sigma-
Aldrich) in the presence of 10% FBS, 1% Penicillin/Streptomycin (Sigma-Aldrich, 100 X), 
1% L-Glutamine solution (Sigma-Aldrich, 200 mM). They were sub-cultured at 100% 
confluence using Tryspin-EDTA 1X (1-2 min at 37 ℃) solution to detach the cells. 
2.2.1.5. Kelly neuroblastomas culture 
Kelly neuroblastomas (Sigma, 92110411) were adherent and cultured with RPMI 1640 
(Sigma-Aldrich) in presence of 10% FBS, 1% Penicillin/Streptomycin (Sigma-Aldrich, 
100X), 1% L-Glutamine solution (Sigma-Aldrich, 200mM) and incubated in a humidified 
incubator at 37 ℃. They were sub-cultured at 80% confluence using Tryspin-EDTA 1 X (1-2 
min at 37℃) solution to detach the cells. 
2.2.1.6. Vero cell culture 
Vero cells (Public Health England, culture collections, 84113001) were adherent and cultured 
with DMEM (Sigma-Aldrich) in presence of 10% FBS, 1% Penicillin/Streptomycin (Sigma-
Aldrich, 100 X), 1% L-Glutamine solution (Sigma-Aldrich, 200 mM). They were sub-cultured 
at 100% confluence using Tryspin-EDTA 1 X (1-2min at 37℃) solution to detach the cells. 
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2.2.1.7. Co-culture of astrocytes/microglia and neuroblastomas/microglia 
Co-culture of microglia with astrocytes or neuroblastomas was performed in 12 well-plates by 
using inserts (12 mm transwell with 0.4 µm pores, Corning (Sigma)) to create a top 
compartment in each well. Neuroblastomas or primary astrocytes were seeded at the bottom 
of the well (bottom compartment) while microglia were seeded in the insert (fig 2.1). The 
insert includes a membrane containing 0.4 µm pores that allows passage of fluid, small 
molecules and viruses from bottom to top compartment and vice-versa.  
 
 
 
 
 
Figure 2.1. Scheme of the co-culture of microglia with astrocytes or neuroblastomas. 
2.2.2. HSV-1-infection  
2.2.2.1. HSV-1 stocks and viral load quantification by plaque-assay 
2.2.2.1.1. Propagation and stocks of HSV-1 in Vero cells  
Herpes Simplex type 1 strain 17+ virus particles were propagated in Vero cells from the 
original virus stock (Public Health England, 0104151v). The infection was performed by 
removing medium from one confluent T75 flask of Vero cells and adding 2 mL of fresh 
medium containing 10 µL of the initial batch of HSV-1.  After incubating for 1 h (at 37 ℃, 
5% CO2), 13 mL of medium was added (t=0 of infection). Cells were then monitored every 
24 h. When more than 50% of the cells displayed effects of cytopathology (at 72 h pi), the cell 
microglia 
astrocytes or  
neuroblastoma
s 
Top 
compartment 
(insert) 
Bottom 
compartment 
(well) 
0.4µm pores-
containing  
membrane 
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monolayer was detached using Trypsin. The cells and the culture medium were harvested and 
removed from the flask together. Following centrifugation of the cell suspension (500 x g, 5 
min), the supernatant was removed and the pellet was resuspended in 1 mL of fresh medium 
before being frozen in aliquots of 10-20 µL (-80 ℃). Viral stocks were subsequently titered 
by plaque-assay to quantify the virus concentration. 
2.2.2.1.2. Quantification of HSV-1 by plaque-assay 
HSV-1 infection was performed using 500 µl of stock HSV-1 ten-fold serial dilutions in 6 
well-plates containing confluent Vero cells to assess viral titres.  After 1h of incubation (37 
℃, 5% CO2), a solution of carboxymethyl cellulose (CMC) 0.6%- DMEM (2 mL) was added 
in each well and then incubated at room temperature (RT) for 30 min-1 h at room temperature 
(RT). Plates were then incubated at 37 ℃, 5% CO2 for 48 h-72 h until plaques (rounded gaps 
in the monolayer due to HSV-1) were visible. The overlay was then removed and 10% 
formalin added (under fume hood). After 30 min at RT, formalin (Sigma) was removed (under 
fume hood) and wells stained with toluidine blue for 10 min. Plates were then washed carefully 
with water, dried and plaques counted. The counting of plaques results in an accurate 
quantification of the number of HSV-1 infectious particles in plaque-forming units (pfu) 
contained in the HSV-1 solution. 
2.2.2.2. HSV-1-infection time-course experiments in human brain cells 
2.2.2.2.1. Cell preparation before HSV-1-infection 
2.2.2.2.1.1. Coating with fibronectin for astrocyte attachment 
 
Experiments using astrocytes were performed in 12-well plates pre-coated with a solution of 
fibronectin-gelatin to facilitate their attachment. The solution of fibronectin-gelatin was 
prepared by diluting 1 mL of Fibronectin (Sigma-Aldrich, 1 mg/mL) in 199 mL of 0.02% 
gelatin (Sigma). Plates were incubated for 2 hours at 37 ℃, 5% CO2 with 500 µL of 
  
 
37 
 
Fibronectin-0.02% gelatin per well. Then, the solution of fibronectin-gelatin were carefully 
removed and cells seeded. 
 
2.2.2.2.1.2. Brain cell seeding in culture models of HSE 
 
For HSV-1-time-course experiments, two different plates were used. For cell counting using 
Trypan Blue exclusion staining, host gene expression and viral replication studies, HSV-1-
infection time-course experiments were performed in 12 well-plates. For WST-1 assay, the 
experiments were performed in 96 well-plates.  
The number of cells seeded, the volume of medium per well, the time between seeding and 
infection, the use of a potential coating agent to facilitate cell attachment (for astrocytes) were 
optimised to obtain even monolayers 80-100% confluence and presenting no signs of cellular 
stress or cell death (Tables 2.1 and 2.2).  
Table 2.1 summarises all of the cell seeding settings used for HSV-1-infection in single culture 
of brain cells. 
 
Table2.1. Summary of the different parameters used for brain cell seeding in single 
culture models of HSE. 
 
Cells
Coating agent NoNo Fibronectin 
Volume of 
medium/well
1mL 100uL 1mL 1mL 100uL
Single culture
4x10^5
15
5-10 
x10^4
4x10^5
1.5-3 
x10^4
24 15 15
12 well 96 well
Neuroblastomas Astrocytes Microglia
12 well12 well 96 well
Time before 
infection (h)
36
Number of 
cells/well
Plates
1x10^6
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For co-cultures, the seeding of neuroblastomas and microglia in co-culture differed only in 
that the volume was slightly smaller (800 µL) to decrease the chance of media cross-
contamination between the two compartments. Table 2.2 summarises all of the cell seeding 
parameters used for HSV-1-infection in co-culture of brain cells. 
 
 
 
Table2.2. Summary of the different parameters used for brain cell seeding in co-culture 
models of HSE. 
 
2.2.2.2.2. HSV-1-infection 
HSV-1 infection of monocultures in plates was performed in two steps. Firstly, just after 
removing culture medium, a small volume of HSV-1 solution (200 µL/well in 12 well-plates 
and 30 µL/well in 96 well-plates) was added in each well, to the cell monolayer. This small 
volume of HSV-1 contained appropriate cell culture medium and the number of viruses needed 
per monolayer (or well) to match the M.O.I (Multiplicity of Infection) chosen. The M.O.I, 
representing the number of viruses added per cells, was 0.01 (1 virus for 100 cells) for the 
majority of experiments. Cells were then incubated one hour (37 ℃, 5% CO2). Following the 
incubation, the second step consisted in topping up each well with medium (800 µL/well in 12 
well-plates and 70 µL/well in 96 well-plates). 
Cells
Coating agent
800uL 500uL
Time before 
infection (h)
Volume of 
medium/well
Insert (12 well-
plate)
Co-culture
0.5-3x10^5
14 (with astrocytes) 
35 (with 
neuroblastomas)
Plates
Number of 
cells/well
Bottom compartment (well)
12 well
1x10^6
36
Insert
Fibronectin No No
800uL
4x10^5
15
Neuroblastomas Astrocytes Microglia
12 well
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In co-cultures, infection was done only in the bottom compartment (neuroblastomas and 
astrocytes) following the same steps but topping up with 600 µL in the second step rather than 
800 µL to avoid cross-contamination between the two compartments (only in 12 well-plates).  
2.2.3. Treatments 
2.2.3.1. Aciclovir  
Aciclovir powder (Sigma) was dissolved in PBS at 400 µM before being added to the cells. In 
12 well-plates, per well, 50 µL of 400 µM of aciclovir in PBS was added to the cells in 950 
µL of culture medium. In 96 well-plates, per well, 5 µL of 400 µM aciclovir in PBS was added 
to the well containing cells in 95 µL of culture medium. Therefore, the final concentration of 
aciclovir used was 20 µM. The choice of this concentration was explained in the chapter 4 
(Introduction). 
2.2.3.2. Dexamethasone  
Dexamethasone (Dex)-soluble powder (Sigma) was dissolved in PBS before being added to 
cells. In 12 well-plates, per well, 50 µL of 20 X Dex in PBS was added to the cells in 950 µL 
of culture medium. In 96 well-plates, per well, 5 µL of 20X dexamethasone in PBS was added 
to the cells in 95 µL of culture medium. Different final concentrations (X) were assessed 
especially in the range 0.5-10 µM. However, the optimisation experiments determined that 0.5 
µM of dexamethasone was the best concentration to work with (detailed in chapter 5).  
2.2.3.3. Infliximab  
Infliximab powder (Remicade, 100mg) was dissolved in PBS before being added to cells. In 
12 well-plates, per well, 50 µL of 20X infliximab in PBS was added to the cells in 950 µL of 
culture medium. In 96 well-plates, per well, 5 µL of 20 X infliximab in PBS was added to the 
cells in 95 µL of culture medium. Different final concentrations (X) were assessed in the range 
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of 0.5-10 mg/mL. However, optimisation experiments determined that the concentration of 
0.5 mg/mL of infliximab was the best to work with (detailed in the chapter 6). 
2.2.4. Assessment of HSV-1 effects in human brain cells using microscopy and molecular 
biology techniques 
2.2.4.1. Quantification of HSV-1-replication by qPCR 
A way to assess the HSV-1-infection-time course and its severity is through detection of the 
viral genome from culture medium and cells by qPCR. Dual-labeled qPCR probe from the 
company Sigma was used to quantify HSV DNA (figure 2.2). Each assay consisted of (i) 
unlabelled primers, (ii) a probe with a FAM dye on the 5’end, and a nonfluorescent quencher 
(NFQ) on the 3’end, and (iii) a TaqMan gene expression master mix containing a Taq DNA 
polymerase and dNTPs (Thermofisher). The HSV-1 DNA primers (HSV-1 Forward: 5’-
GCAGTTTACGTACAACCACATACAGC-3’; HSV-1 Reverse: 5’-
AGCTTGCGGGCCTCGTT-3’) and the probe (5’-
CGGCCCAACATATCGCGTTGACATGGC-3’; Synthesis: 0.05 HPLC; 5’reporter dye: 
6fAM; 3’quencher dye: TAMRA; OD:1) were chosen to target HSV gene gB.  
 
 
 
 
 
 
 
 
Figure 2.2. Gene expression assay using a dual-labeled probe (Sigma). Source: 
Sigmaaldrich.com. (1) A Dual-labeled Probe is a single-stranded oligonucleotide labeled 
with two different dyes. A reporter dye is located at the 5’ end and a quencher molecule located 
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at the 3’ end. The quencher molecule inhibits the natural fluorescence emission of the reporter 
by fluorescence resonance energy transfer (FRET). (2) The primer is elongated by the 
polymerase and the probe binds to the specific DNA template. Hydrolysis releases the reporter 
from the probe/target hybrid, causing an increase in fluorescence. The measured fluorescence 
signal is directly proportional to the amount of target DNA. 
 
 
 
2.2.4.1.1. From brain cell nucleic acid extracts  
Nucleic acid extraction was performed using Phenol-chloroform extraction method. PCR 
reactions were performed in 96-well plates (Biorad). For one PCR reaction (25 µL) per well, 
12.5 µL of Master Mix (Thermofisher), 9.25 µL of nuclease-free-H2O, 0.5 µL of each HSV-
F and R primers and 0.25 µL of probe (Sigma) were added to samples of 100 ng of nucleic 
acid in 2 µL (measured by Nanodrop). The plate was centrifuged (20s, speed: 1000 x g) and 
placed in the thermal cycler (Biorad CFX connect). PCR parameters were : 95 ℃ for 10 min 
followed by a second step consisting of 15 s at 95 ℃, 30 s at 50 ℃ and 30 s at 72 ℃, which 
was repeated for 44 cycles.  
 
2.2.4.1.2. From cell culture medium 
PCR reactions were performed in 96-well plates (Biorad). For one PCR reaction (25 µL) per 
well, 12.5 µL of Master Mix (Thermofisher), 6.25 µL of nuclease-free-H2O, 0.5 µL of each 
HSV-F and R primers and 0.25 µL of probe (Sigma) were added to samples of 5 µL of cell 
culture medium. The plate was centrifuged (20s, speed: 1000 x g) and placed in the thermal 
cycler (Biorad CFX connect). PCR parameters were : 95 ℃ for 10 min followed by a second 
step consisting of 15 s at 95 ℃, 30 s at 50 ℃ and 30 s at 72 ℃, which was repeated for 44 
cycles.  
In a preliminary experiment, I studied the correlation between the number of active HSV-1 
particles estimated by plaque-essay in Vero cell culture and the Ct value obtained by HSV 
  
 
42 
 
DNA qPCR from culture medium. This is represented by the Figure 2.3. The correlation was 
statistically defined by a Pearson r coefficient of -0.94 and a R square of 0.88. 
 
 
Figure 2.3. Correlation between the number of HSV-1 particles in plaque-essay and the 
Ct values obtained by HSV DNA qPCR.  HSV-1 infection was done in Vero cells at different 
dilutions from the HSV-1 original stock (10-8-10-5). Plaque essay and HSV DNA qPCR from 
cell culture medium were performed at 72 h pi following the protocols described in the 
previous parts. Data from only one preliminary experiment. Pearson r = -0.94; R square = 0.88 
(correlation). 
 
2.2.4.2. Assessment of HSV-1-induced damage in human brain cells 
2.2.4.2.1. By light microscopy  
Clear signs of infection in HSV-1-infected brain cell monolayer can be easily detected by light 
microscopy from a 4x magnification. The most common signs are (i) cells rounding up and 
forming clusters, (ii) rounded gaps in the monolayer, (iii) high proportion of cells floating and 
(iv) syncitium-like-stuctures (multi-nuclei giant cells). The proportion of these signs varies by 
cell type and the MOI used. This will be described in the results chapters. 
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A protocol was used to quantify the area of attached cells in microscopy pictures (4 x 
magnification) using the software “ImageJ”. It was widely adapted from a protocol of “FITC-
dextran exclusion assay analysis using ImageJ software” done by S.Panagiotou and L.Jacques 
(Institute of Infection and Global Health, University of Liverpool). The image had first to be 
opened with “ImageJ” and “RGB color” was then selected. Subsequently, the image was 
adjusted to 8-bit to be converted into greyscale. The threshold was then adjusted. Once the 
threshold applied, the picture appeared in black and white (negative picture) with cells still 
attached to the well (and presumably alive) colored in black and spaces between them in white. 
The percentage of the black area on the picture could be measured by “ImageJ” and as a result 
be an estimation of attached cell area and cell viability. An example of the estimation of 
attached cell areas of HSV-1-infected neuroblastomas using the software “ImageJ” was 
performed using three different microscopy pictures and is presented in the figure 2.4. 
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Figure 2.4 Estimation of live cell area of HSV-1-infected cells of microscopy pictures 
using the software “ImageJ”. (A), (C) and (E) are the original microscopy pictures (4 x 
magnifications) assessed for live cell areas. (B), (D) and (F) are the negative images of (A), 
(B) and (E) respectively. They were obtained following the protocol described above. The 
estimation of live cell areas for each of the three pictures was written on the right side. 
 
2.2.4.2.2. Cell counting by Trypan blue exclusion staining and automated cell counter (Luna 
FL) 
Live and dead cells were counted using Trypan blue exclusion staining. Once the cells were 
homogeneously resuspended in culture medium, a 1/10 dilution in fresh culture medium 
A 
 
B 
 
C 
 
D 
 
E 
 
F 
 
51,86%% 
45,67%% 
59,38%% 
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followed by a 1/2 dilution in Trypan blue was performed. After 1-2 min in presence of Trypan 
blue, live cells (unstained) and dead cells (blue) were counted manually using a Neubauer 
chamber or automatically using the Luna FL automated cell counter. 
2.2.4.2.3. Calcein-AM and Propidium Iodide (PI) staining  
Calcein-AM (Sigma) is a cell-permeant fluorogenic dye which stains only live cells in green 
(emission at 520 nm) after hydrolysis by active cellular esterases following excitation at 490 
nm (figure 2.5).  
Figure 2.5. Conversion of calcein-AM in green fluorescent calcein by esterases of live 
cells. Source: R&D (Sigma) data sheet “calcein-AM, cell viability assay, catalog number: 
4892-010-K”. 
 
A calcein-AM stock solution of 2 mM was made by resuspending 50 µg of calcein-AM powder 
(Lifetechnologies) with 25 µL of DMSO. The working solution (c=0.5 µM) was made by 
diluting the stock solution 1 in 4000 clear DMEM medium (Sigma). After removing medium 
and washing cells with PBS, cells were incubated with 0.5 µM calcein-AM solution for 30min 
at 37 ℃, 5% CO2. Cells were then washed twice before the addition of clear DMEM medium. 
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Fluorescence could be directly quantified in plates using the FLUOstar Omega microplate 
reader or observed by fluorescent microscopy. 
Propidium Iodide (P.I) (Invitrogen) is a non-permeant dye, only penetrating dead cells (with a 
compromised plasma membrane). P.I is an intercalating agent that stains in red nucleic acid of 
dead cells red (617 nm) following excitation at 535 nm. P.I stock was made in deionized water 
at 1.5 mM (1 mg/mL). The working dilution (c=0.5 µM) was made by a 1/3000 dilution of the 
stock solution in clear DMEM medium (Sigma). After removing medium and PBS wash, cells 
were incubated with 0.5 µM P.I solution for 5 min at 37 ℃, 5% CO2. Cells were then washed 
twice before the medium was replaced. Fluorescence could be directly quantified in plates 
using the FLUOstar Omega microplate reader or observed in fluorescent microscopy. 
Dual staining with calcein-AM and P.I was also performed using the same working 
concentrations of both dyes. After removing medium and PBS wash, cells were incubated with 
0.5 µM calcein-AM solution for 25 min at 37 ℃, 5% CO2. Cells were washed again twice 
with PBS before a 5 min staining step at 37 ℃, 5% CO2 with 0.5 µM P.I solution. Cells were 
then washed twice before being put in presence with clear DMEM medium. Fluorescence of 
both calcein-AM and PI could be directly quantified in plates using the FLUOstar Omega 
microplate reader or observed in fluorescent microscopy. 
2.2.4.2.4. WST-1 
The WST-1 assay is colorimetric and designed to assess cell proliferation, viability and 
cytotoxicity by spectrophotometric quantification. The cell proliferation reagent WST-1 
(Roche-Sigma) is a tetrazolium salt associated with an electron coupling agent (figure 2.6). 
This assay is based on the ability of viable cells to produce NAD(P)H through glycolysis by 
the mitochondrial succinate-tetrazolium-reductase system (respiratory chain complex). When 
NAD(P)H is produced in presence of WST-1, slightly red, the latter is cleaved to soluble 
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formazan, revealing a dark red colour. As a result, the production of this dark red dye directly 
correlates to the number of cells metabolically active. 
 
Figure 2.6. Conversion of WST-1 to formazan by the respiratory chain of healthy cells. 
Source: Roche, data sheet. EC: electron coupling agent; RS: mitochondrial succinate-
tetrazolium-reductase system.  
 
In this end-point assay, cells were grown in 96-well plates. At the end-point, cells were stained 
with 10 µL of WST-1 (Roche) per well and incubated (37 ℃, 5% CO2) for 30 min before the 
plate was read at 450 nm (with wavelength correction at 600 nm) using a spectrophotometer. 
2.2.4.2.5. qRT-PCR targeting the housekeeping gene DAD-1 
DAD-1 is a housekeeping gene involved in the N-glycosylation process in eukaryotes. It was 
already validated in a published in vitro study of HSE135. qRT-PCR targeting DAD-1 can also 
estimate cell viability in samples although with low sensitivity. The technical details of the 
qRT-PCR targeting DAD-1 are described together with the ones of the qRT-PCR targeting 
pro-inflammatory genes in the part 2.2.4.3.3. 
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2.2.4.3. Assessment of host gene response by qRT-PCR 
2.2.4.3.1. Cell collection in 12 well-plates using Trizol 
In each well, culture medium was collected and centrifuged 5 min, at 300 x g to collect cells 
detached from the monolayer. After centrifugation, without touching the cell pellet, 
supernatant was discarded. The pellet containing the cells was then resuspended in 100 µL of 
culture medium. Cells still attached to the monolayer were trypsinised (150 µL per well) and 
resuspended in 850 µL of culture medium (volume total: 1 mL). This cell suspension of 1 mL 
was then pooled with the 100 µl of cell suspension from culture medium. After centrifugation 
of this cell suspension mixture, the supernatant was discarded and the pellet was resuspended 
in 50 µL of culture medium. Then 600 µL of Trizol (Sigma) was added to this last cell 
suspension before being vortexed and frozen at -80C.   
2.2.4.3.2. Nucleic acid (RNA) extraction 
The samples containing Trizol were defrosted at RT and vortexed. 100 µL of chloroform was 
added to the samples before vortexing (under fume hood). After phase separation, samples 
were centrifuged (4 ℃, 21000 x g, 30 min) before taking off the aqueous phase (under fume 
hood). A volume of 5 M NaCl equal to 10% of the aqueous phase, 10 µL of glycogene and 
500 µL of isoprapanol were then added to the aqueous phase before vortexing and placing the 
samples for 1 h at -80 ℃. After defrosting at RT, they were centrifuged again (30 min, 21000 
x g, 4 ℃) and the supernatant was removed. The pellet was then washed with 500 µL of 80% 
ethanol before a new step of centrifugation (10 min). The last two steps (wash and 
centrifugation) were then repeated again before drying the pellet. Once resuspended in 20 µL 
of nuclease-free water, nucleic acid was quantified (ng/uL), and the A260:280 and A260:230 
ratios were assessed by Nanodrop. 
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2.2.4.3.3. qRT-PCR targeting IL-1β, TNF-α, INF-γ, IL-6 and DAD-1  
2.2.4.3.3.1. The Reverse Transcription  
 
All of the RNA samples were diluted in 10 µL to get a RNA concentration of 100 ng/uL. To 
each diluted RNA sample, 10 µL of master mix was added. The master mix consisted of 2 µL 
of oligodT primers, 2 µL of 10 X  RT buffer, 4 µL of dNTP mix, 1 µL of RNase inhibitor and 
1 µL of MMLV RT enzyme. The samples were subsequently placed in a thermocycler for 1 h 
at 44 ℃, 10 min at 92 ℃ and 10 min at 4 ℃.  
 
2.2.4.3.3.2. qPCR step  
 
TaqMan technology was used for this qPCR step (figure 2.7). After reverse transcription, 1µL 
of cDNA solution (100 ng) was used with 19uL of a mix for one qPCR reaction. The mix was 
composed of 10 µL of TaqMan gene expression Master Mix (Lifetechnologies, 4369016), 8 
µL of H2O and 1µL of a commercial combination of target gene primers and TaqMan dual-
labelled probe (Sigma: Hs02912874_m1 DAD1 FAM-MGB; Hs00174128_m1 TNF FAM-
MGB; Hs00985639_m1 IL-6 FAM-MGB). After preparation of the reactions, the 96-wells 
plate was centrifuged (20s, speed: 1000) and placed in the thermocycler (Biorad, CFX-
connect). The cycle parameters were as follows: one 10 min step at 95℃, then 60 cycles of 15 
s at 95 ℃, 30 s at 50 ℃ and 30 s at 72℃. 
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Figure 2.7. TaqMan gene expression assay process. Source: Thermofisher.com. (1) 
Denaturation of the double-stranded cDNA as temperature is raised. The signal from FAM on 
the 5’end of the TaqMan probe is still quenched by the non-fluorescent quencher (NFQ) on 
the 3’end. (2) Annealing of primers and probe to their specific target sequences as temperature 
is lowered. (3) Synthesis of new strands by the Taq DNA polymerase thanks to the unlabelled 
primers and template. When the polymerase reaches a TaqMan probe, the polymerase 5’ 
nuclease activity leads to the cleavage of the probe. The latter results in the release of the 
fluorescent FAM finally separated from the NFQ. With each PCR cycle, there is an increase 
in fluorescence intensity proportional to the amount of amplicon synthesized. 
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2.2.4.4. ELISA targeting TNF protein 
A commercial kit (Peprotech; 900-K25) of ELISA sandwich was used to measure human TNF-
α protein from culture medium of uninfected and HSV-1-infected cells in my cell culture 
experiments. The ELISA assay was performed according to the manufacturer’s instructions 
(Preprotech). The principle of the ELISA sandwich is described in the figure 2.8. Briefly, the 
colour development was monitored with an ELISA plate reader at 405 nm with a wavelength 
correction at 600 nm. The concentration of TNF in samples was calculated using the TNF 
standards provided. The range of TNF detection of this kit was 31-2000 pg/ml.  
 
 
 
 
 
 
 
 
 
Figure 2.8 Sandwich ELISA mechanism. Source (online): Ozyme.fr (adapted). The 
sandwich ELISA detects and measures the amount of TNF proteins released by cells in the 
culture medium. Capture antibody (in grey), attached to the bottom of the well, can bind TNF. 
TNF is then bound to a second (primary) antibody (in grey), the detection antibody, recognized 
itself by a secondary antibody (in orange) conjugated to the enzyme horseradish peroxidase 
(HRP). Then, the cleavage of the substrate ABTS by HRP leads to the apparition of a green 
final product that can be measured by a spectrophotometer. The apparition of the final green 
product is proportional to the amount of TNF in the culture medium.  
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2.3. Statistics 
The statistical significance of the results of qPCR, WST-1, ELISA and attached cell area 
analysis by “ImageJ” was assessed by the Student's test (t-test) and the analysis of variance 
(ANOVA test) using the software “GraphPad Prism”. ANOVA test was performed to 
statistically highlight the existence of differences between the means of different treatment 
groups at each time-point and with more than two groups considered. If an ANOVA test 
showed significant differences, t-test (for one time-point experiments) or multiple t-test (for 
multiple time-point experiments) were then applied to compare between two distinct groups. 
Each test was considered as statistically significant when the p-value was below 0.05. 
As classically done, data of the biological replicates of multiple experiments was pooled to get 
more information and increase the power of statistical tests. For qPCR, every biological 
replicate was divided in two technical replicates read by the thermocyler. The average of the 
values of two technical replicates was used as final data for every biological replicate. 
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Chapter 3 HSV-1-infection in human brain cells 
 
3.1. Introduction 
As previously mentioned, Herpes Simplex Encephalitis (HSE) is a rare but fatal disease. It is 
characterised by important lymphocyte infiltration at the brain tissue, activated microglia, 
necrosis and neuronophagia (phagocytosis of neurons by microglia) in some brain areas37, 39. 
Areas affected typically include the temporal lobe, the infero-frontal lobe and the insular 
cortex of cerebral hemispheres in an asymmetrical way. In HSE, necrosis affects multiple 
types of brain cells, including neurons and astrocytes39.  
As described in chapter one, this brain damage is not only the result of HSV-1-induced cell 
death but also of a secondary immune response to the virus. Microglial cells, the brain resident 
macrophages, have been described as having both a protective effect against HSV infection 
and also playing a role in this detrimental immune response. On one hand, they were shown, 
via the functional type I INF pathway, to decrease mouse brain lateral ventricle enlargement 
in an in vivo model of HSE87. Microglial cells, through IL-6 secretion, also induce a rescue of 
neuronal precursor cell number following HSV-1-infection of neural progenitor cells136.  
Conversely, following HSV-1-infection, they were also shown to be detrimental for neurons 
by secreting Reactive Oxygen Species (ROS) following TLR2 activation99. Another study 
showed that the drug corilagin reduced inflammation both in HSV-1-infected mouse brain as 
seen by microscope observations and in HSV-1-infected murine microglia cells as shown by 
the decrease in NO, TNF-α and IL-1β concentrations in microglia cell supernatant137. An 
increase in microglial cell apoptosis following corilagin administration after HSV-1-infection 
was also reported. Altogether, this suggests the beneficial effect of corilagin on reducing 
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mouse brain inflammation, following HSV-1-infection, could be due to the reduction of 
cytokine production and the induction of microglial cell apoptosis. 
In HSE-affected brains, extensive HSV-induced neuronal death is widely observed39. In my 
experiments, Kelly neuroblastoma cells were used to create a model of neuron-like cells. This 
avoids all the issues raised by culture of primary neurons per se, particularly the fact they do 
no divide. These neuroblastoma cells were isolated from a patient and underwent N-MYC 
amplification to correlate with the clinical progression of neuroblastoma.  Subtypes of these 
cells have been studied and it was shown that Kelly neuroblastoma cells, similarly to another 
neuroblastoma cell type SH-SY5Y, consisted of more than 90% neuroblasts and less than 10% 
non-neuronal cells138. More recently, Shipley et al. have differentiated the SH-SY5Y 
neuroblastomas cells in a reductionist model of “HSV-1 vs neurons” interactions139. A few in 
vitro studies have used Kelly neuroblastoma cells including one assessing the gene expression 
level of MYC, C-KIT and VEGFA as these genes could be interesting targets for 
neuroblastoma treatment201. However, to my knowledge, Kelly neuroblastomas have never 
been used in an HSV-1 or brain infection in vitro model.  
Astrocytes play a role in brain tissue homeostasis and provision of nutrients to neurons. A 
cross-talk between microglia and astrocytes was observed in pathological conditions in the 
CNS140. Co-culture with astrocytes was shown to be protective for neurones in a thiamine 
deficiency in vitro model141. In an in vitro model of HSE using monoculture, extensive cell 
death and decrease in cytochrome c oxidase (CO) expression were observed in primary 
astrocytes following HSV-1 infection135. 
There is a lack of data and understanding about the effects of HSV-1 on Kelly neuroblastomas, 
microglia and astrocyte cell types individually. In this chapter, I set up in vitro models of HSE 
using single cultures of these three human brain cell types targeted and eliminated by HSV-1 
and/or potentially contributing to HSE pathogenesis. Hence, in these cells following HSV-1 
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Figure 3.1. Experimental design for Chapter 3 “HSV-1-infection in human brain cells”. 
(A) Brain cell populations used. (B) Techniques performed on brain cells following HSV-1-
infection. (C) Techniques performed on brain cell culture medium following HSV-1-infection. 
 
3.2. Results 
3.2.1. HSV-1-infection of neuroblastoma cells 
3.2.1.1. HSV-1 replicates and is associated with cell death in neuroblastoma cells 
The effects of HSV-1 on neuroblastoma cells were first assessed by light microscopy at 
MOI=0.01. Uninfected neuroblastomas presented with a “fibroblast-like” morphology that 
became less obvious with time. These cells are highly proliferative and quickly became 
confluent (fig 3.2A, C, E).  At 24 h post-infection (pi), the monolayer of infected cells 
exhibited their first signs of infection, which included a loss of attachment of the confluent 
monolayer (with more gaps appearing between cells) and the first appearance of rounded cells 
on the surface of the plate (fig 3.2B). At 48 h and 72 h pi (respectively fig 3.2D and F), all 
infected cells possessed a “rounded” morphology and there were a higher number of gaps 
between them. These combined observations demonstrated the ability of HSV-1 to lead to cell 
death in neuroblastomas. These microscopy pictures together with other replicate experiments 
were analysed by the software “ImageJ” and it was quantitatively shown that HSV-1 was 
associated with a reduction in attached neuroblastoma cell area at 72 h pi (fig 3.3). Using the 
dye calcein-AM, staining live cells in green, there was decrease in neuroblastoma live cell 
staining following HSV-1 infection (MOI=0.01) at 72 h pi (fig 3.4).  
At MOI=0.001, a significant decrease in both (i) RNA yield, following acid nucleic extraction, 
and (ii) cell viability, by cell counting following Trypan blue exclusion staining, was also 
observed in HSV-1-infected neuroblastomas compared to the uninfected cells (data not 
shown). qRT-PCR analysis that targeted the expression of the reference gene DAD-1, as a 
proxy marker of neuroblastomas viability, showed that the presence of HSV-1 was associated 
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with a decrease in DAD-1 gene expression (higher Ct values) from 30 h to 72 h pi (MOI=0.01) 
(fig 3.5). Similarly, WST-1 assay also showed a decrease in cellular activity of dehydrogenases 
(mitochondrial metabolism), another proxy marker of cell viability, in the infected population 
(MOI=0.01), at 48 h and 72 h pi (fig 3.6). Additionally, evidence of viral replication of HSV-
1 in neuroblastomas was demonstrated by an increase in viral load in cell culture medium over 
time from 24 h to 72 h pi (MOI=0.01) (fig 3.7).  
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    Figure 3.2. Representation of HSV-1-infected neuroblastoma cell culture. HSV-1 
infection was done at MOI=0.01. On the left panel, the uninfected neuroblastomas are represen  
ted at 24 h (A), 48 h (C) and 72 h (E) after time of infection for the infected cells. The 
monolayer of these uninfected cells is 100% confluent at all time-points with number of cells 
increasing over time (as cells look smaller at 48 h and 72 h). (B), (D) and (F) represent HSV-
1-infected neuroblastoma cells respectively at 24 h, 48 h and 72 h post-infection (h pi). Infected 
cells start to lose confluence at 24 h pi with gaps in the monolayer and some round cells 
appearing (B). At 48 h pi (D) and 72 h pi (F), the infection has progressed since there are 
bigger gaps between cells and all cells seem round. 10 x magnification. Scale bar: 50 µm.  
A B 
C D 
 
E F 
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Figure 3.3. Percentage of attached cell area in microscopy pictures of HSV-1-infected 
neuroblastoma cells. HSV-1-infection was done at MOI=0.01. Areas of attached 
neuroblastoma cells were measured by the software “ImageJ” from pictures taken at 48 h and 
72 h post-infection of uninfected (circles) or infected (squares) neuroblastoma cells. Data are 
expressed as mean of the area of live cells + 95% CI and were obtained as described in chapter 
2 (Material and methods). At 48 h pi, one picture was used for uninfected and three for HSV-
1-infected. At 72 h pi, nine pictures from three replicates were used for the uninfected cells 
and twenty-four pictures from 3 replicates for the HSV-1-infected ones. (****) p<0.0001 
(multiple t-tests).  
 
 
 
 
 
 
 
 
 
 
 
 
**** 
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Figure 3.4. Live cell pictures by fluorescent microscopy in HSV-1-infected 
neuroblastoma cells. HSV-1 infection was done at MOI=0.01. (A) Uninfected 
neuroblastomas monolayer observed by light microscopy. The cells are “fibroblast-like” and 
the monolayer is 100% confluent. (B) HSV-1-infected neuroblastomas observed 72 h pi by 
light microscopy. There is no monolayer anymore, only few round cells are left. (C) Same 
picture as (A) observed by fluorescence microscopy following staining with the live cell dye 
calcein-AM (0.5 µM; excitation at 495 nm). (D) Same picture as (B) observed by fluorescence 
microscopy following staining with the live cell dye calcein-AM (0.5 µM; excitation at 495 
nm). 10 x magnification. Scale bar: 50 µm. 
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Figure 3.5. DAD-1 gene expression in HSV-1-infected neuroblastoma cells. HSV-1 
infection was done at MOI=0.01. The values represent Ct values after qRT-PCR targeting 
DAD-1 from 1 µg of RNA extracts of uninfected (circles) or HSV-1-infected (squares) 
neuroblastomas at 30, 48, 72 h pi.  Data are expressed as mean + 95% Confidence Interval 
(C.I) of 9 replicates from 3 independent experiments. (*) p<0.05; (***) p<0.005 (multiple t-
tests). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Mitochondrial activity in HSV-1-infected neuroblastoma cells. HSV-1 
infection was done at MOI=0.01. The values represent WST-1 activity (absorbance at 450 nm 
(A450 nm) normalised by subtraction of the background (A650 nm) after addition of WST-1) 
of uninfected neuroblastomas (circles) and HSV-1-infected neuroblastomas (squares) at 
different time-points (0-72 h post-infection). Data are expressed as mean + 95% CI of 30 
replicates from 3 independent experiments. (****) p<0.0001 (multiple t-tests). 
**** 
**** 
* *** 
*** 
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Figure 3.7. HSV DNA abundance in culture medium of HSV-1-infected neuroblastoma 
cells. HSV-1 infection was done at MOI=0.01. The values represent Ct values after HSV DNA 
qPCR from culture medium of HSV-1-infected neuroblastomas at 24, 30, 48 and 72 h pi. Each 
point represents the mean + 95% CI of data from at least 3 independent experiments. 
Triplicates were used for each point-time in each experiment.  
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3.2.1.2. Neuroblastoma cells exhibit an increase in TNF and INF-γ relative gene expression 
following HSV-1 infection  
HSV-1 infection was associated in these cells with a significant increase in relative gene 
expression of the key pro-inflammatory cytokine TNF as early as 30 h pi and still present at 
48 h and 72 h pi (fig 3.8). Interestingly, a single experiment showed that IFN-γ relative gene 
expression was also significantly increased in neuroblastomas following HSV-1 infection at 
39 h pi (data not shown, only experiment and one time point). 
 
 
 
 
 
 
Figure 3.8. TNF relative gene expression in HSV-1-infected neuroblastoma cells. HSV-1 
infection was done at MOI=0.01 in neuroblastoma cells. The data represent TNF relative gene 
expression expressed as mean +/- 95% CI of 2-ΔΔ Ct values at 30 h, 48 h and 72 h post-infection. 
The scale is logarithmic. 2-ΔΔ Ct values were obtained following qRT-PCR of TNF and DAD-1 
genes. DAD-1 gene was used as reference (housekeeping) gene. From qRT-PCR Ct values of 
DAD-1 and TNF, ΔCt values [Ct (TNF)-Ct(DAD-1]) were obtained for both uninfected and 
HSV-1-infected cells. ΔΔ Ct values represented [(ΔCt) HSV - (ΔCt)uninfected]. Data were obtained 
from 3 independent experiments. 
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3.2.1.3. An increase in secreted TNF was not detected in neuroblastoma cell culture medium 
in response to HSV-1  
TNF expression was also assessed at the protein level by ELISA test in the culture medium of 
HSV-1 infected neuroblastomas in T75 flasks, at different time-points (-6 to 72 h pi). 
Following HSV-1 infection, there was no detectable increase in TNF observed at any time 
point in flasks containing 8 mL (fig 3.9A) or 16 mL of culture medium (fig 3.9B). 
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Figure 3.9. TNF protein concentration in culture medium of HSV-1-infected 
neuroblastoma cells. (A) TNF protein concentration in neuroblastoma cell culture 
medium (V= 8 mL). TNF concentration obtained by ELISA in culture medium of uninfected 
(circles) and HSV-1-infected neuroblastoma cells (squares) at 6, -1, 24, 48 and 72 h pi. TNF 
concentration was detected by spectrophotometer at 405 nm with correction at 650 nm. Values 
are expressed as mean of TNF concentration (pg/mL) + 95% CI. Each point is the mean of 4 
replicates, each replicate was read twice by the spectrophotometer. (****) p<0.0001 (multiple 
t-tests). (B) TNF protein concentration in neuroblastoma cell culture medium (V= 16mL). 
TNF concentration obtained by ELISA in culture medium of uninfected (circles) and HSV-1-
infected neuroblastoma cells (squares) at -6, -1, 24, 48 and 72 h pi. TNF concentration was 
detected by ELISA plate reader at 405 nm with correction at 650 nm. Values are expressed as 
mean of TNF concentration (pg/mL) + 95% CI. Each point is the mean of 4 replicates, each 
replicate was read twice by the spectrophotometer. (****) p<0.0001 (multiple t-tests). 
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3.2.2. HSV-1-infection of microglial cells. 
3.2.2.1. HSV-1 replicates and is associated with cell death in microglia 
The effect of HSV-1 on microglial cells was first assessed by light microscopy using three 
different MOI (0.001, 0.01 and 0.1). At 24 h post-infection (pi), the infected cells were 100% 
confluent for all the MOI tested (fig 3.11A; fig3.12A; fig 3.13A). The first signs of infection 
appeared at 24h pi. Some of the cells lost their “ovoid” shape to become rounder, smaller and 
brighter while the uninfected cell monolayer continued to present normal ovoid-shaped 
microglial cells (fig 3.10A). This phenomenon was linked with the viral load as the proportion 
of round cells increased with higher MOI. At 48h pi, in addition to a higher proportion of 
round cells, gaps in the monolayer could be observed for all MOI tested (fig 3.11B; fig 3.12B; 
fig 3.13B) while the uninfected cells were still 100% confluent and “ovoid” (fig 3.10B). These 
gaps indicate HSV-1-induced cell death in microglia. Again, cell of death (gaps) increased 
with MOI. Finally, at 72 h pi, all the infected cells appeared rounded at all MOI. The majority 
of cells had detached from the monolayer at MOI=0.1 (fig 3.13C). At MOI=0.001 (fig 3.11C) 
and 0.01 (fig 3.12C), more round cells were still attached compared to MOI=0.1 but the 
monolayer was still highly altered compared to uninfected (fig 3.10C). These microscopy 
pictures were then analysed by the software “ImageJ” and it was again observed that HSV-1 
induced a reduction in the area of attached microglial cells at MOI=0.01 although the results 
were not statically significant (due to the low number of pictures suitable for “ImageJ” 
analysis) (fig 3.14). 
The decrease in microglial cell viability was linked to higher HSV-1 viral load (MOI). This 
was confirmed by cell counting using Trypan Blue exclusion staining (fig 3.15). The lowest 
number of live cells (fig 3.15A) and the highest percentage of cell death (fig 3.15D) were seen 
at the highest MOI (0.1) at 72 h pi (not statistically significant). At MOI=0.01, HSV-1 was 
associated with a decrease in live cell number at 72 h pi and 96 h pi (fig 3.16A).  The 
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percentage of dead cells was again elevated in presence of HSV-1 at these two time-points (fig 
3.16D). Abundance of DAD-1 (housekeeping gene) was lower at 48 and 72 h pi (fig 3.17). 
Again this indicates reduced live cell number and/or reduced cell viability. A reduction of 
mitochondrial metabolism was also shown by WST-1 assay following HSV-1-infection at 72 
h pi (fig 3.18). HSV viral load continued to increase over time. HSV DNA measured in culture 
medium demonstrated a steadily increase in abundance from 30 to 72 h pi (fig 3.19).  
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Figure 3.10. Microscopy pictures of (uninfected) microglia culture. Microscopy pictures 
of microglial cells at (A) 24 h, (B) 48 h and (C) 72 h after time of infection for the infected 
cells. These uninfected microglia show the same “ovoid” morphology and 100% confluency 
through the 3 time-points. 10 x magnification. Scale bar: 50 µm. 
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Figure 3.11. Microscopy pictures of HSV-1-infected microglia culture at MOI=0.001. (A) 
24 h post-infection (pi). First round cells appear in the middle. (B) 48 h pi. More cells are 
round and the first gaps appear in the monolayer. (C) 72 h pi. All cells seem round and gaps 
are more frequent. 10 x magnification. Scale bar: 50 µm. 
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Figure 3.12. Microscopy pictures of HSV-1-infected microglia culture at MOI=0.01. (A) 
24 h post-infection (pi). Half of the cells seem round. (B) 48 h pi. The proportion of round 
cells increase while frequent gaps in the monolayer appear. (C) 72 h pi. All cells are round 
and there are more gaps in the monolayer. 10 x magnification. Scale bar: 50 µm. 
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Figure 3.13. Microscopy pictures of HSV-1-infected microglia culture at MOI=0.1. (A) 
24 h post-infection (pi). Most cells seem round. (B) 48 h pi. A lot of gaps in the monolayer 
appear. A giant cell, syncytia-like structure appears in the middle. (C) 72 h pi. All cells are 
round and most of cells detached from the surface. 10 x magnification. Scale bar: 50 µm. 
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Figure 3.14. Percentage of attached cell area in microscopy pictures of HSV-1-infected 
microglial cells. HSV-1-infection was done at MOI=0.01. Areas of attached cells were 
measured by the software ImageJ from pictures taken at 72 h post-infection. Two 4 x 
magnification microscope pictures for uninfected and four for infected were analysed. 
Statistical tests were not relevant due to a number of replicates too low. 
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Figure 3.15. Figures 3.15B-C and legend next page. 
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Figure 3.15. Live and dead cell number in HSV-1 infected microglial cells at 72 h pi at 
different MOI. The infection was done at MOI=0.001 (unfilled squares), MOI=0.01 (squares 
half-filled on the left side) or MOI=0.1 (squares half-filled on the right side). Cell counting at 
72 h pi by trypan blue exclusion staining of the number of live cells (A), the number of dead 
cells (B), the total number of cells (C) and the percentage of dead cells (D) in uninfected 
(circles) and HSV-1-infected microglial cells (squares). Data is expressed as the mean of cell 
counting + 95% CI (except for figure (D) that represents mean of percentage of dead cells 
(without 95% CI)). Each condition was assessed in triplicates in only one experiment. 
ANOVA test statistically showed significant differences between the means of the different 
conditions for live cell counting (A) (p<0.005) but not for dead cell counting (B) or total cell 
counting (C) (p>0.05).  (*) p<0.05; (**) p<0.01 (t-tests). 
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Figure 3.16. Legend and figures 3.16C-D next page. 
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Figure 3.16. Live and dead cell number in HSV-1-infected microglia (MOI=0.01) over 
time. Cell counting by trypan blue exclusion staining of the number of live cells (A), the 
number of dead cells (B), the number of total cells (C) and the percentage of dead cells (D) in 
uninfected (circles) and HSV-1-infected (squares) microglia cells (MOI=0.01) at different 
time-points (24 h-96 h pi). Data are expressed as mean of cell counting + 95% CI. Each 
condition was assessed in triplicates in 3 independent experiments. (*) p<0.05; (***) p<0.005; 
(****) p<0.001 (multiple t-tests). 
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Figure 3.17. DAD-1 gene expression in HSV-1-infected microglial cells. HSV-1-infection 
was done at MOI=0.01. The values represent Ct values after qRT-PCR targeting DAD-1 from 
1 µg of RNA extracts of uninfected (circles) or HSV-1-infected (MOI=0.01) (squares) 
microglial cells at 30, 48, 72 h pi.  Data are expressed as the mean + 95% Confidence Interval 
(C.I) of 9 replicates from 3 independent experiments. (**) p<0.005 at 48 h pi and 72 h pi 
(multiple t-tests). 
 
Figure 3.18. Mitochondrial activity in HSV-1-infected microglial cells. HSV-1 infection 
was done at MOI=0.01. The values represent WST-1 activity (Absorbance at 450 nm 
normalised by subtraction of the background (A650 nm) after addition of WST-1) of 
uninfected (circles) and HSV-1-infected microglial cells (squares) at different time-points (0-
72 h pi). Data are expressed as mean + 95% CI of 30 replicates from 3 independent 
experiments. (***) p<0.001 (multiple t-tests). 
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Figure 3.19. HSV DNA abundance in culture medium of HSV-1-infected microglial cells. 
HSV-1 infection was done at MOI=0.01. The values represent Ct values after HSV DNA 
qPCR from culture medium of HSV-1-infected microglia at 24, 30, 48, 72 h pi. Each point 
represents the mean + 95% CI of data from at least 3 independent experiments with triplicates 
used for each point in each experiment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
79 
 
3.2.2.2. TNF and IFN-γ relative gene expression increase in microglia following HSV-1 
infection  
The relative gene expression of TNF was significantly increased in microglial cells at both 48 
h and 72 h pi, while slightly increased at 24 h pi, following HSV-1 challenge (fig 3.20) 
In these same cells after HSV-1 infection, a high increase in IFN-γ relative gene expression, 
was also observed at 48-96 h pi following a decrease at 24h pi (fig 3.21). No drastic change 
was seen for IL-1β or IL-6 relative gene expression at any of these time-points (fig 3.22 and 
3.23). 
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Figure 3.20. TNF relative gene expression in HSV-1-infected microglial cells. HSV-1 
infection was done at MOI=0.01 in microglial cells. The data represent TNF relative gene 
expression expressed as mean +/- 95% CI of 2-ΔΔ Ct values at 30 h, 48 h and 72 h post-infection. 
The scale is logarithmic. 2-ΔΔ Ct values were obtained following qRT-PCR of TNF and DAD-1 
genes. DAD-1 gene was used as reference (housekeeping) gene. From qRT-PCR Ct values of 
DAD-1 and TNF, ΔCt values [Ct (TNF)-Ct(DAD-1]) were obtained for both uninfected and 
HSV-1-infected cells. ΔΔCt values represented [(ΔCt) HSV - (ΔCt)uninfected]. Data were obtained 
from 3 independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21. IFN-γ relative gene expression in HSV-1-infected microglial cells. HSV-1 
infection was done at MOI=0.01 in microglial cells. The data represent INF-γ relative gene 
expression expressed as mean +/- 95% CI of 2-ΔΔ Ct values at 30 h, 48 h and 72 h post-infection. 
2-ΔΔ Ct values were obtained following qRT-PCR of IFN-γ and DAD-1 genes. DAD-1 gene was 
used as reference (housekeeping) gene. From qRT-PCR Ct values of DAD-1 and IFN-γ, ΔCt 
values [Ct (IFN-γ)-Ct(DAD-1]) were obtained for both uninfected and HSV-1-infected cells. 
ΔΔCt values represented [(ΔCt) HSV - (ΔCt)uninfected]. Data were obtained from a single 
experiment. 
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Figure 3.22. IL-6 relative gene expression in HSV-1-infected microglial cells. HSV-1 
infection was done at MOI=0.01 in microglial cells. The data represent IL-6 relative gene 
expression expressed as mean +/- 95% CI of 2-ΔΔ Ct values at 30 h, 48 h and 72 h post-infection. 
2-ΔΔ Ct values were obtained following qRT-PCR of IL-6 and DAD-1 genes. DAD-1 gene was 
used as reference (housekeeping) gene. From qRT-PCR Ct values of DAD-1 and IL-6, ΔCt 
values [Ct (IL-6)-Ct(DAD-1]) were obtained for both uninfected and HSV-1-infected cells. 
ΔΔCt values represented [(ΔCt) HSV - (ΔCt)uninfected]. Data were obtained from a single 
experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23. IL-1B relative gene expression in HSV-1-infected microglial cells. HSV-1 
infection was done at MOI=0.01 in microglial cells. The data represent IL-1B relative gene 
expression expressed as mean +/- 95% CI of 2-ΔΔ Ct values at 30 h, 48 h and 72 h post-infection. 
2-ΔΔ Ct values were obtained following qRT-PCR of IL-1B and DAD-1 genes. DAD-1 gene was 
used as reference (housekeeping) gene. From qRT-PCR Ct values of DAD-1 and IL-1B, ΔCt 
values [Ct (IL-1B)-Ct(DAD-1]) were obtained for both uninfected and HSV-1-infected cells. 
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ΔΔCt values represented [(ΔCt) HSV - (ΔCt)uninfected]. Data were obtained from a single 
experiment. 
 
3.2.2.3. An increase in secreted TNF is not detected by ELISA in microglia cell culture 
medium in response to HSV-1  
Similar to what has been shown in neuroblastomas, there was no increase in TNF protein 
detected by ELISA in culture medium of HSV-1infected microglia compared to that of 
uninfected cells, at any time-points (24 h-96 h pi) (fig 3.24). 
 
 
 
 
 
 
 
 
Figure 3.24. TNF protein concentration in culture medium of HSV-1-infected microglial 
cells. TNF concentration obtained by ELISA in culture medium of uninfected (circles) and 
HSV-1-infected microglia cells (squares) at -6, -1, 24, 48 and 72 h pi. TNF concentration was 
detected by spectrophotometer at 405 nm with correction at 650 nm. Values are expressed as 
mean of TNF concentration (pg/mL) + 95% CI. Each point is the mean of at least 6 replicates, 
from 3 different experiments. No statistical differences at any time-point (t-tests). 
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3.2.3. Comparisons of the dynamics of HSV-1 replication and HSV-1-associated cell viability 
loss in neuroblastoma and microglia cells 
I wanted to compare the dynamics of HSV-1 infection in two different brain cells. Therefore 
I compared changes in viral load and cell viability among neuroblastoma ad microglial cells. 
Viral load was measured by HSV DNA by qPCR. Cell viability was measured using 
mitochondrial activity (via WST-1 assay). Cells were exposed to the same MOI (0.01). 
The figure 3.25A compares two HSV DNA abundance over time from the culture medium of 
infected neuroblastoma (fig 3.7) and microglial cells (fig 3.19). Viral load in infected microglia 
cell culture medium was low at 24 h pi (Ct around 34) but was relatively high by 72 h pi (Ct 
around 23). The profile of HSV replication was different in neuroblastoma culture medium. 
The viral load appeared to plateau between 24 h and 72 h pi with a Ct value around 28 at 24 h 
pi and around 24 at 72 h pi. Hence, from 24 h to 72 h pi, culture medium HSV DNA abundance 
showed a faster rate of increase in infected microglia than neuroblastoma cells at this time-
point (fig 3.25A). During this period, in average, HSV DNA abundance doubled every four 
hours in infected microglia culture medium while more than thirteen hours were needed in that 
of infected neuroblastoma cells (fig 3.25B). However, final viral load (at 72 h pi) was 
comparable between the two brain cell types. 
The figure 3.26A compares the two mitochondrial activity for both infected neuroblastoma 
(fig 3.6) and microglial cells (fig 3.18). A steady decrease of mitochondrial activity among 
neuroblastoma cells can be observed following HSV-1-infection from 24 h to 72 h pi (fig 
3.24A). The mitochondrial activity profile was different in microglial cells following HSV-1 
infection (fig 3.26A). In microglia, there was an increase from 24 h to 48 h pi in WST-1 activity 
followed by a decrease from 48 h to 72 h pi. At 72 h pi, mitochondrial activity was estimated 
as null in infected neuroblastoma cells (fig 3.26A-B). In infected microglial cells, 
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mitochondrial activity had initially risen (48 h pi) and then fallen (72 h pi) to levels observed 
at 24 h pi (fig 3.26A-B). 
During the period 24 to 72 h pi, HSV DNA replicates faster in microglia than in 
neuroblastomas cells. Mitochondrial activity, a proxy marker of cell viability, was steadily 
reduced in infected neuroblastoma cells and was essentially not detected at 72 h pi. Infected 
microglial cells showed a maintenance of mitochondrial activity at 72 h pi. Dynamics of HSV 
replication and cell viability were very different between HSV-1-infected microglia and 
neuroblastoma cells in the in vitro models used. Microglia cells could be described as more 
permissive to HSV-1 infection. They allowed viral replication rate while maintaining cell 
activity. Furthermore, infected neuroblastoma cells exhibited a higher viral load but reduced 
mitochondrial activity compared to infected microglial cells at 24 h pi.  
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Figure 3.25. Comparisons of dynamics of culture medium HSV DNA abundance between 
HSV-1-infected microglial and neuroblastoma cells. HSV-1 infection was done at 
MOI=0.01. A. HSV DNA abundance in culture medium of infected microglial and 
neuroblastoma cells The values represent Ct values after HSV DNA qPCR from culture 
medium of HSV-1-infected microglial (white triangles) or neuroblastoma (black triangles) 
cells at 24, 30, 48, 72 h pi. Each point represents the mean + 95% CI of data from at least 3 
independent experiments with triplicates used for each point in each experiment. These data 
come from the figures 3.7 and 3.20. B. Determination of the dynamics of HSV DNA 
abundance in culture medium of infected microglial and neuroblastoma cells using linear 
trend line and slope. From each curve expressed in the figure 3.26A, a linear trendline was 
determined and a slope associated using the softwate “Excell” (Microsoft). From the slope 
A 
B 
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value, time (h) for HSV DNA abundance to double in cell culture medium from 24 to 72 h pi 
was calculated. 
 
 
 
 
 
 
 
 
 
Figure 3.26. Comparisons of dynamics of mitochondrial activity between HSV-1-infected 
microglial and neuroblastoma cells. HSV-1 infection was done at MOI=0.01. A. 
Mitochondrial activity in infected microglial and neuroblastoma cells The values 
represent mitochondrial activity measured by the WST-1 assay (A450 – A650 nm) in HSV-1-
infected microglial (white triangles) or neuroblastoma (black triangles) cells at 24, 30, 48, 72 
h pi. Data are expressed as mean + 95% CI of 30 replicates from 3 independent experiments. 
These data come from the figures 3.6 and 3.19. B. Determination of the dynamics of 
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mitochondrial activity in infected microglial and neuroblastoma cells using linear trend 
line and slope. From each curve expressed in the figure 3.27A, a linear trendline was 
determined and a slope associated using the softwate “Excell” (Microsoft). From the slope 
value, time (h) for WST-1 activity to be null was estimated. 
3.2.4. HSV-1-infection in primary astrocytes 
HSV-1 was associated with cell death and morphologic changes in primary astrocytes in a 
similar manner to that seen in neuroblastoma cells and microglia. The progression of HSV-1 
infection (MOI=0.01) in primary astrocytes was observed under light microscope (fig 3.27). 
At 24 h post-infection (pi), infected astrocytes became less confluent and appeared more 
isolated (fig 3.27B) compared to the uninfected (fig 3.27A), demonstrating HSV-1-induced 
cell death. At this time-point, some infected astrocytes (but not the control uninfected cells) 
were already losing their normal shape (thin, very long, with occasional star-like ramifications) 
to become rounder, smaller and brighter. These phenomena became more pronounced over 
time. At 48 h pi, a higher proportion of infected cells looked small, round and bright (fig 
3.27D) whereas 24 h later (72h pi), the monolayer of infected cells exhibited more gaps 
between cells, no “normal-shaped” astrocytes left and some giant, potentially multi-nuclei 
cells (syncytia-like structure) (fig 3.27F). There were no changes in the uninfected astrocyte 
monolayer over time (fig 3.27C and E). Cell counting showed that infection with HSV-1 was 
associated with a decrease in live astrocyte number along with an increase in the percentage 
of dead cells at 24 h, 48 h and 72 h pi (fig 3.28). There was also a decrease in DAD-1 gene 
expression in astrocytes following HSV-1 infection (fig 3.29). qRT-PCR targeting TNF in 
infected astrocytes was also performed. However, Ct values for this TNF target were routinely 
beyond the limits of detection of the PCR machine (data not shown), making an accurate 
detection of TNF expression following HSV-1 infection in astrocytes not possible. 
A more in-depth study of HSV-1 infection in primary astrocytes (including an assessment of 
HSV-1 replication and new qRT-PCR targeting DAD-1) is discussed in chapter 7 in the 
context of co-culture with microglia. 
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Figure 3.27. Microscopy pictures of HSV-1-infected primary astrocytes. HSV-1-infection 
was done at MOI=0.01. On the left panel, the uninfected astrocytes are represented at 24 h 
(A), 48 h (C) and 72 h (E) after time of infection for the infected cells. The monolayer of these 
uninfected cells is 100% confluent at all time-points. These uninfected cells exhibit the 
morphology of healthy primary astrocytes: they are thin, very long with some “star-like”-
ramifications. (B), (D) and (F) represent HSV-1-infected astrocytes respectively at 24 h, 48 h 
and 72 h post-infection (h pi). Infected cells start to lose their confluence at 24 h pi with gaps 
in the monolayer and some round cells appearing (B). At 48 h pi (D) and 72 h pi (F), the 
infection has progressed with bigger gaps between cells and almost all cells seem round. At 
72 h pi, a syncitia-like structure can also be observed. 10 x magnification. Scale bar: 50 µm. 
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Figure 3.28. Figures 3.26B-C and legend on the next page. 
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Figure 3.28. Live and dead cell number in HSV-1-infected astrocytes. HSV-1 infection 
was done at MOI=0.01. Cell counting by trypan blue exclusion staining of the number of live 
cells (A), the number of dead cells (B), the total number of cells (C) and the percentage of 
dead cells (D) was performed in uninfected (circles) or HSV-1-infected astrocytes (squares) at 
different time-points (24 h, 48 h, 72 h post-infection (pi)). Data are expressed as the mean of 
cell count + 95% CI.  3 independent experiments. (*) p<0.05; (***) p<0.005 (multiple t-tests). 
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Figure 3.29. DAD-1 gene expression in HSV-1-infected astrocytes. HSV-1 infection was 
done at MOI=0.01.  The values represent Ct values after qRT-PCR targeting DAD-1 from 1 
µg of RNA extracts of uninfected (circles) or HSV-1-infected (squares) astrocytes at 24; 48 
and 72 h post-infection (pi).  Data are expressed as mean + 95% Confidence Interval (C.I) 
from one experiment. DAD-1 Ct values were in triplicate for uninfected. However, among 
infected samples, at every time-point, only one out of three replicates led to Ct values after 
qRT-PCR (missing values for the two others). Each replicate of the experiment was read twice 
by qPCR. (***) p<0.005; (****) p<0.001 (multiple t-tests). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*** **** 
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3.3. Discussion 
In this chapter, HSV-1 infection of three types of cells (neuroblastoma cells, microglia, 
primary astrocytes) have been characterised in terms of cell morphology and viability, viral 
replication and expression of TNF and/or INF-γ. Cell viability has been assessed by the 
analysis of attached cell areas on microscopy pictures by “ImageJ”, cell counting using Trypan 
blue exclusion staining, qRT-PCR targeting the housekeeping gene DAD-1 and WST-1 assay 
measuring cell mitochondrial metabolism. Viral replication was measured by HSV DNA 
qPCR from culture medium of infected brain cells. Finally, TNF and INF-γ gene expression 
was assessed by qRT-PCR TNF protein levels were determined in cell culture medium by 
ELISA. 
At the same MOI (0.01), in microscopy, it has been shown that HSV-1 was associated with 
both live cell loss and changes in morphology of neuroblastoma cells, microglia and primary 
astrocytes (fig3.2, 3.4, 3.12, 3.27). These morphologic changes resulted in a loss of their 
normal shape to a new phenotype of round and small cells. This may be due to the effect of 
HSV-1 on some plasma membrane proteins involved in cell adhesion and cell-cell junctions.  
Attached cell area analysis on microscopy pictures (using “ImageJ”), cell counting by trypan 
blue exclusion, qRT-PCR targeting DAD-1 and WST-1 assay all confirmed quantitatively that 
HSV-1 was associated with a decrease in cell viability/mitochondrial activity in 
neuroblastoma, microglia and primary astrocytes (fig 3.3, 3.5-3.6, 3.14-3.18; 3.28-29). 
Crucially, with these measurement techniques, a decrease in live cells induced by HSV-1 
infection was observed earlier in astrocytes (24 h pi) than in neuroblastomas (30 h-48 h pi) 
and microglia (48 h-72 h pi) suggesting that susceptibility to HSV-1 infection appears brain 
cell type-dependent. My observed decrease in mitochondrial activity (fig 3.6 and 3.18) in 
microglial and neuroblastoma cells following HSV-1-infection could be linked to another 
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study of my group. The latter showed that HSV-1 was linked to early and important selective 
mitochondrial damage in primary astrocytes135.  
HSV-1 was shown to be replicative (viral load increasing) in both neuroblastoma and 
microglial cells (fig 3.7 and fig 3.19). The two brain cell types exhibited different HSV-1 
replication dynamics with a faster increase in microglia compared to neuroblastomas cells 
during the period 24h to 72h pi (fig 3.25). Nonetheless, viral loads at the final time point (72 
h pi) were very similar. From 24 h to 72 h pi, mitochondrial metabolism, proxy marker of cell 
viability, was steadily reduced in infected neuroblastoma but not microglial cells (fig 3.26). 
This suggests that during this period (24-72 h pi), microglia cells were more permissive to 
HSV-1 than neuroblastoma cells, allowing viral replication with maintenance of cell activity. 
Furthermore, neuroblastoma cells were also impacted earlier by HSV-1 than microglia cells. 
At 48h pi, mitochondrial activity was already reduced in neuroblastoma cells (fig 3.6) but not 
in microglia (fig 3.18). Meanwhile, relative viral load was higher in infected neuroblastoma 
than in microglial cells (6 Ct difference) at 24h pi (fig 3.7 and 3.19). Therefore, dynamics of 
HSV-1 replication is different between microglial and neuroblastoma cells. 
HSV DNA qPCR was performed in primary astrocytes in the context of co-culture with 
microglia (chapter 7). Virus load was again shown to increase in this astrocyte model.  
 In an in vitro study of Lokensgard and colleagues, it was shown HSV-1 syn 17+ was highly 
replicative in both neurons and astrocytes with viral titres peaking respectively at 48 h and 72 
h pi as measured by 50% tissue culture infectious dose (TCID50) assay85. However, HSV-1 syn 
17+ was shown to replicate poorly in primary human foetal microglia with viral titres peaking 
only at 24 h pi. This differs to the results presented here for microglia, but could be explained 
by the fact they used primary human foetal microglia, a different HSV-1 strain and a different 
MOI. 
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In cerebrospinal fluid (CSF) samples from HSE, an increase in INF-γ and IL-6 levels were 
detected during the acute phase of illness (1st week) while an increase in TNF-α was observed 
during convalescence (weeks 2-6 of illness)71. Another study showed high CSF values of INF-
γ at the time of admission and a maximum value of CSF IL-6 between 103-104 pg/ml were 
predictors of poor outcome93. Finally, in a mice in vivo model of HSE, valaciclovir combined 
with an anti-TNF was shown to be beneficial with a decrease in both brain inflammation and 
mortality133. Together, this data suggests that targeting TNF-α, INF-γ or IL-6, in combination 
with the standard treatment with aciclovir, may improve the outcome among HSE patients. 
Numerous studies have shown microglia produce extensively pro-inflammatory cytokines 
such as TNF-α, INF-γ and IL-6 in response to HSV-1142, 85, 106. I assessed the gene expression 
of these cytokines in microglia after HSV-1 exposure. While IL-6 and IL-1B gene expression 
was relatively similar between HSV-1 infected and uninfected microglia (fig 3.22-3.23), 
significantly higher levels of TNF and INF-γ relative gene expression were observed for the 
infected cells at 48 h and 72 h pi (fig 3.20-21). TNF-α gene expression has been shown to be 
increased in murine microglia at 5 h pi and higher MOI (above MOI=1)86. TNF relative gene 
expression in HSV-1-infected neuroblastoma cells exhibited similar results, with a significant 
increase following infection at 30, 48 and 72 h pi (fig 3.8).  In a single experiment, an increased 
INF-γ relative gene expression in neuroblastomas following HSV-1 infection was observed 39 
h pi (data not shown).  
No increase in TNF-α protein levels were not detected by ELISA analysis in culture medium 
of infected neuroblastomas or microglia compared to uninfected cells (fig 3.9 and 3.22). This 
is contradictory to another study which reports a drastic increase of TNF-α (up to 400 pg/ml) 
in cell culture medium of HSV-1-infected human foetal microglia compared to uninfected (24-
72 h pi)85. This difference could be due to the use of foetal microglia, a different viral strain 
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and different MOIs or the fact that my HSE model represents the HSE acute phase in which 
viral load is high and CSF TNF protein levels low71, 143.  
My gene expression data indicates TNF transcription is increased following HSV infection. 
However, TNF ELISA did not detect an increase in “free” TNF in the cell culture medium. 
TNF protein production could still have increased inside the cells or at the cell membrane after 
HSV-1 challenge. As I saw an increase in TNF transcription, it was important to assess the 
impact of anti-TNF treatments in my HSE models. Hence, in chapter 6, the effect of the 
administration of a TNF inhibitor together with aciclovir in HSV-1-infected neuroblastoma 
and microglial cells is discussed. 
The primary astrocytes I used exhibited a really low multiplication rate (2-3 weeks to become 
confluent after a 1/3 cell culture passage) and replication slowed further after ten passages. 
Subsequently, I did not have sufficient cells to do experiments such as ELISA test, qRT-PCR 
targeting INF-γ or WST-1 assay on them. Previous work from my research group indicates 
that HSV-1 was also associated with an increased TNF gene expression in primary astrocytes 
(unpublished data). 
To summarise this chapter, I set up in vitro models of HSE using single culture of 3 different 
types of human brain cells infected by HSV-1. Interestingly, among them, I used Kelly 
neuroblastoma cells that had never been characterised following HSV-1 infection before this 
PhD. In this chapter, I showed that HSV-1 17+ was able to replicate and was associated with 
cell death and morphologic changes in this neuroblastoma cell model, and also in 
(transformed) microglia and primary astrocytes. A significant decrease in mitochondrial 
activity was observed in neuroblastoma and microglial cells following HSV-1-infection. 
Interestingly, I also showed that the expression of the pro-inflammatory genes TNF and INF-
γ was increased following HSV-1 in both microglial and neuroblastoma cells. No change in 
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TNF protein levels in culture medium of these cells was observed. However, the ELISA tests 
I performed did not measure TNF production in cells.  
In the next chapter (4), the effect of the antiviral drug aciclovir was assessed in these same 
HSV-1-infected brain cells. 
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Chapter 4 The effect of aciclovir on HSV-1-infection in human brain 
cells 
4.1. Introduction 
Before the advent of aciclovir as gold standard therapy used for HSE treatment, 70% of HSE 
(untreated) patients died while 97% of survivors did not return to normal function49. Aciclovir 
is an antiviral drug, converted by the enzyme thymidine kinase (TK) into a competitive 
inhibitor of DNA polymerase as a result blocking HSV genome replication. For HSE 
treatment, this drug is usually administrated at 10 mg/kg intravenously, every 8 h, for 2-3 
weeks49. The administration of aciclovir in HSE patients has been shown to decrease both 
mortality and morbidity. In a Swedish prospective clinical study, among HSE patients treated 
by aciclovir, it was shown that 19% died and 56% returned to normal life 6 months after the 
onset of the disease202. In comparison, among HSE patients treated with vidarabine, another 
drug inhibiting HSV replication, 50% died and only 13% could return to normal life at the 6 
months follow-up. Another study confirmed that aciclovir was a more efficient drug for HSE 
treatment than vidarabine125. Indeed, a reduced mortality (aciclovir:28% versus vidarabine: 
54%) and an increase in the percentage of patients functioning normally at 6 months (aciclovir: 
38% versus vidarabine: 14%) were observed again in HSE patients treated with aciclovir 
compared to the ones treated with vidarabine. Crucially, delays in aciclovir administration 
(beyond 48 h after hospital admission) were associated with worse prognosis124. Of note, a 
higher dose of aciclovir (15 mg/kg) was not associated with better outcome144. 
As previously discussed, in HSE patients treated with aciclovir, neurological sequelae are still 
very frequent. A study of long-term sequelae among HSE patients treated by aciclovir showed 
that 12% died within one month, 2% lived in a vegetative state, 17% experienced a severe 
disability, 21% a moderate disability and 48% a good recovery53. Among the long-term 
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survivors, 69% lived with memory impairment, and 20-35% experienced severe anxiety, 
impaired concentration, insomnia, irritability, fatigue, poor motivation, or emotional lability. 
This emphasizes the fact that although almost one in two patients have a good recovery, the 
majority of HSE patients experience long-term neurological sequelae. Interestingly, in mice 
affected by HSE, it was shown that aciclovir led to a reduction of the nervous system viral 
titres to undetectable levels. However, aciclovir had no effect on either brain inflammation or 
mortality69. Although aciclovir improves the outcome of HSE patients, this therapy exhibits 
important limitations. Around 10-20% of HSE patients treated with aciclovir still die and the 
majority exhibits long-term neurological sequelae. These limitations could be due to the fact 
that HSE pathogenesis seems to be due to direct viral damage and secondary damage due to 
the host immune responses to the virus131, 91, 133, 93. Aciclovir only targets HSV replication and 
has no direct effect on inflammation. 
There is a lack of knowledge concerning the impact of aciclovir on HSV-1 infection of specific 
human brain cell types such as microglia or neurons/neuroblastoma cells. In this chapter, I 
studied the effect of aciclovir on HSV-1-infection of both microglial and neuroblastoma cells 
in separate sets of experiments. A standard concentration of 20 µM was used in all experiments 
with aciclovir treatment. This concentration was chosen following the data obtained from 
pharmokinetics studies on intravenous aciclovir.  In a clinical study on postherpetic neuralgia 
treatment, after administering 10 mg/kg of aciclovir, the mean peak in plasma was 66.2 µM145. 
In a prospective study, it was shown that the average maximum plasma concentration of 
aciclovir was  8.2 mg/L in control (healthy) patients following intravenous administration of 
aciclovir at 5 mg/kg 146. Hence, for a 10 mg/kg intravenous administration, we can suppose a 
plasma concentration of aciclovir around 16.2 mg/L that represents 72.8 µM. Hence, a 
maximum plasma concentration of aciclovir of 66.2-72.8 µM can be considered. In an article 
of King et al about aciclovir., it was stated that” 30% to 35% of the serum concentration of the 
drug is found in the brain humans”147. Therefore, the maximum brain aciclovir concentration 
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in HSE patients treated three time a day by 10 mg/kg of intravenous aciclovir should be around 
19.9-25.5 µM. This is in adequacy with the concentration of 20 µM I used in my experiments. 
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Figure 4.1. Experimental design for Chapter 4 “The effect of Aciclovir (ACV) on HSV-
1-infection in human brain cells”. (A) Brain cell populations used. (B) Techniques 
performed on brain cells following HSV-1-infection. (C) Techniques performed on brain 
cell culture medium following HSV-1-infection. 
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4.2. Results 
4.2.1. The effect of Aciclovir on HSV-1-infection of neuroblastoma cells 
4.2.1.1. Aciclovir is associated with a decrease in viral load and an increase in cell survival in 
HSV-1-infected neuroblastoma cells 
In the previous chapter, it was shown that HSV-1 was replicative and led to morphological 
changes and extensive cell death in neuroblastoma cells. In this chapter, I have assessed if 
aciclovir, the antiviral drug, used clinically in HSE, could impact on cell viability and viral 
load in HSV-1-infected neuroblastoma cells. The treatment with aciclovir (20 µM) was done 
24 h post-infection (pi).  
Firstly, in light microscopy, an increase in cell survival could be observed in HSV-1-infected 
neuroblastomas treated with aciclovir compared to the infected untreated cells (fig 4.2-4.3). A 
lower proportion of gaps in the monolayer of infected cells treated with aciclovir was seen 
compared to the infected untreated cells both at 48 h and 72 h pi at 4 x-10 x magnification (fig 
4.2C-E and fig 4.3C-E). No gaps were seen in uninfected neuroblastoma monolayers (fig 
4.2A-B and fig 4.3A-B). By analysing 10 x magnification microscopy pictures using the 
software “ImageJ”, a significant increase in the attached cell area could be observed in HSV-
1-infected neuroblastomas following administration of aciclovir (20 µM) (fig 4.4). 
The WST-1 assay measuring the mitochondrial metabolism at 48 h and 72 h pi (fig 4.6) 
quantitatively confirmed that aciclovir increased cell viability of HSV-1-infected 
neuroblastoma cells. However, no change in DAD-1 gene expression as measured by qRT-
PCR in infected neuroblastoma cells was observed (fig 4.5).  
Surprisingly, HSV DNA qPCR on culture medium of infected neuroblastomas showed no 
differences in HSV-1 load detection with or without aciclovir treatment (fig. 4.7). Next, the 
culture medium of infected neuroblastoma cells, untreated or treated with aciclovir, was used 
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to infect Vero cells. Following 24 h of Vero cell infection, a HSV DNA qPCR on Vero cell 
culture medium was performed (as explained by fig 4.1C). This qPCR showed a significant 
decrease in HSV DNA abundance (higher Ct values) in culture medium of Vero cells infected 
by the medium of HSV-1 infected neuroblastomas treated with aciclovir compared to the one 
infected by the medium of infected neuroblastomas untreated (fig 4.8). This suggests that 
aciclovir decreases the load of infective (active) viruses in culture medium. However, total 
load of HSV DNA (from active and inactive viral particles) remains the same during the in 
vitro infection of neuroblastoma cells following aciclovir administration. 
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Figure 4.2. Microscopy pictures of HSV-1-infected neuroblastoma cells treated with 
aciclovir (10 x magnification). HSV-1 infection was performed at MOI=0.01. The treatment 
with aciclovir (20 µM) was done 24 h post-infection. The uninfected neuroblastoma cells are 
represented at 48 h (A) and 72 h (B) after infection of the HSV-1 infected counterparts. (C) 
and (D) show HSV-1-infected neuroblastoma cells (untreated) respectively at 48 h and 72 h 
pi. (E) and (F) show infected neuroblastoma cells treated with aciclovir at 48 h and 72 h pi 
respectively. By comparing (C) vs (E) and (D) vs (F), a lower proportion of gaps in the 
monolayer, signs of HSV-1-induced cell death, could be seen when infected cells are treated 
with aciclovir and at both time-points (E and F). These pictures are representative of at least 
3 experiments. 10 x magnification. Scale bar: 50 µm. 
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Figure 4.3. Microscopy pictures of HSV-1-infected neuroblastoma cells treated with 
aciclovir (4 x magnification). HSV-1 infection was performed at MOI=0.01. The treatment 
with aciclovir (20 µM) was done 24 h post-infection. The uninfected neuroblastoma cells are 
represented at 48 h (A) and 72 h (B) after infection of the HSV-1 infected counterparts. (C) 
and (D) show HSV-1-infected neuroblastoma cells (untreated) respectively at 48 h and 72 h 
pi. (E) and (F) show infected neuroblastoma cells treated with aciclovir at 48 h and 72 h pi 
respectively. By comparing (C) vs (E) and (D) vs (F), a lower proportion of gaps in the 
monolayer, signs of HSV-1-induced cell death, could be seen when infected cells are treated 
with aciclovir and at both time-points (E and F). 4 x magnification. Scale bar: 50 µm. 
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Figure 4.4. Influence of aciclovir treatment on the percentage of attached cell area in 
microscopy pictures of HSV-1-infected neuroblastoma cells. HSV-1-infection was done at 
MOI=0.01. Areas of attached neuroblastoma cells were measured by the software “ImageJ” 
from pictures taken at 48 h and 72 h post-infection of uninfected (circles) or infected (white 
squares) or aciclovir-treated infected (squares half-filled in black) neuroblastoma cells. Data 
are expressed as mean of the area of live cells + 95% CI and were obtained as described in the 
chapter 2 (Material and methods). At 48 h pi (24 h post-treatment), one picture for uninfected 
cells, three for infected untreated cells and three for infected cells treated with aciclovir (20 
µM) were analysed. At 72 h pi (48 h post-treatment), nine pictures for uninfected cells, twenty-
four for infected untreated cells and twenty-two pictures for infected cells treated with 
aciclovir were analysed. The pictures were representative of 3 independent experiments. 
ANOVA test statistically showed significant differences between the means of the different 
conditions at 72 h pi (p<0.0001). It could not be performed at 48 h pi as one group only 
includes one value. (*) p<0.05; (**) p<0.01; (****) p<0.0001 (multiple t-tests) 
**** 
* 
** 
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Figure 4.5. Influence of aciclovir on DAD-1 gene expression in HSV-1-infected 
neuroblastoma cells. HSV-1 infection was done at MOI=0.01. The treatment with aciclovir 
(20 µM) was done at 24 h pi. The values represent Ct values after qRT-PCR targeting DAD-1 
from 1 µg of RNA extracts of uninfected (circles) or untreated infected (white squares) or 
aciclovir-treated infected (black half-filled squares) neuroblastoma cells at 30, 48, 72 h pi.  
Data are expressed as mean + 95% Confidence Interval (C.I) of 9 replicates from 3 
independent experiments. ANOVA test statistically showed significant differences between 
the means of the different conditions at 48 h pi (p<0.001); 72 h pi (p<0.0001) but not at 30 h 
pi (p>0.05). (*) p<0.05; (**) p<0.01; (***) p<0.005 (multiple t-tests). 
 
 
 
 
Figure 4.6. Influence of aciclovir on mitochondrial activity in HSV-1-infected 
neuroblastoma cells. HSV-1 infection was done at MOI=0.01. The treatment with aciclovir 
(20 µM) was done at 24 h pi. The values represent WST-1 activity (values of absorbance at 
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450 nm (A 450nm) normalised by subtraction of the background (A 650nm) after addition of 
WST-1). WST-1 assay has been performed in uninfected (circles), untreated infected (white 
squares) and aciclovir-treated infected (black half-filled squares) neuroblastomas at different 
time-points (0, 24, 30, 48, 72 h pi). Data are expressed as mean + 95% CI of 30 replicates from 
3 independent experiments. ANOVA test statistically showed significant differences between 
the means of the different conditions at 48 h pi (p<0.001); 72 h pi (p<0.0001) but not at 30h 
pi (p>0.05). (****) p<0.0001 (multiple t-tests). 
 
Figure 4.7. Influence of aciclovir on HSV DNA abundance in HSV-1-infected 
neuroblastoma cell culture medium. HSV-1 infection was done at MOI=0.01. The treatment 
with aciclovir (20 µM) was done at 24 h pi. The values represent Ct values after HSV DNA 
qPCR from culture medium HSV-1-infected (white squares) or aciclovir-treated infected 
(black half-filled squares) neuroblastoma cells at 24 (just before the treatment), 30, 48 and 72 
h pi. Each point represents the mean + 95% CI of data from at least 3 independent experiments. 
Triplicates were used for each point-time in each experiment. Multiple t-tests were performed 
(no statistical difference (p<0.05) at any time-point). 
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Figure 4.8. Influence of aciclovir on the viral load of active HSV-1 particles released in 
the culture medium of (infected) neuroblastoma cells. HSV-1 infection and treatment with 
aciclovir (20 µM) in neuroblastoma cells were done as described previously (i.e. figure 4.7). 
Then, the culture medium of infected untreated (white squares) or infected neuroblastoma cells 
treated with aciclovir (black half-filled squares) was taken off at 72 h pi and used to 
secondarily infect Vero cells. 24 h post-infection of Vero cells with neuroblastoma cell culture 
medium, a qPCR targeting HSV DNA was performed on Vero cell culture medium. The values 
represent Ct values after HSV DNA qPCR from Vero cell culture medium. Each point 
represents the mean + 95% CI of data from 2 independent experiments. Triplicates were used 
for each point-time in each experiment. (****) p<0.0001 (t-tests). 
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4.2.1.2. Aciclovir is associated with an increase in TNF relative gene expression in HSV-1-
infected neuroblastoma cells 
In the previous chapter, an increase in TNF relative gene expression had been observed in 
neuroblastoma cells following HSV-1-infection. Here, I assessed the impact of the drug 
aciclovir (20 µM), added at 24 h pi, on TNF relative gene expression. There was still an 
increase in TNF relative gene expression in HSV-1-infected neuroblastoma cells treated with 
aciclovir compared to the uninfected counterparts since all values of infected cells treated with 
aciclovir were still significantly superior to 1 (at least 30-40 times higher than uninfected for 
all time-points) (fig 4.9). Furthermore, the increase in TNF relative gene expression was 
significantly more elevated in HSV-1-infected-neuroblastoma cells treated with aciclovir 
compared to the infected untreated at 72 h pi.  
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Figure 4.9. Influence of aciclovir on TNF relative gene expression in HSV-1-infected 
neuroblastoma cells. HSV-1 infection was done at MOI=0.01 in neuroblastoma cells. 
Aciclovir treatment (20 µM) was added at 24h pi. The data represent TNF relative gene 
expression expressed as mean +/- 95% CI of 2-ΔΔ Ct values at 30 h, 48 h and 72 h post-infection 
(respectively 6h, 24h and 48h post-treatment). The scale is logarithmic. 2-ΔΔ Ct values were 
obtained following qRT-PCR of TNF and DAD-1 genes. DAD-1 gene was used as reference 
(housekeeping) gene. From qRT-PCR Ct values of DAD-1 and TNF, ΔCt values [Ct (TNF)-
Ct(DAD-1]) were obtained for both uninfected and HSV-1-infected cells. ΔΔCt values 
represented [(ΔCt) HSV - (ΔCt)uninfected]. Data were obtained from 3 independent 
experiments.(***): p<0,001 (multiple t-tests). 
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4.2.2. The effect of aciclovir on HSV-1-infection of microglial cells 
4.2.2.1. Aciclovir is associated with an increase in cell survival and a decrease in viral 
replication in HSV-1-infected microglial cells 
In the previous chapter, it was shown that HSV-1 was replicative and led to both morphologic 
changes and a decrease in cell viability in microglial cells. In this present chapter, I assessed 
if the antiviral drug aciclovir could influence both cell viability and viral load in HSV-1-
infected microglial cells. Treatment with aciclovir (20 µM) in infected microglia was done at 
24 h post-infection (h pi). An increase in microglial cell survival following HSV-1 infection 
was noticed, by visualisation using light microscopy, for infected cells treated with aciclovir 
compared to the infected untreated (fig 4.10). Indeed, infected microglial cells treated with 
aciclovir presented a lower proportion of gaps in the monolayer compared to the infected 
untreated cells both at 48 h and 72 h pi (fig 4.10 C-F). No signs of infection, such as gaps in 
the monolayer of cells, were seen for uninfected microglia cells (fig 4.10 A-B). By analysing 
10 x magnification microscopy pictures using the software “ImageJ”, an increase in the 
attached cell area could also be observed in HSV-1-infected microglial cells following 
administration of aciclovir (20 µM) (fig 4.11). Finally, both qRT-PCR targeting DAD-1 at 48 
h and 72 h pi (fig 4.12) and WST-1 assay measuring the mitochondrial metabolism at 72 h pi 
(fig 4.13) quantitatively confirmed that aciclovir increased microglia cell mitochondrial 
activity during HSV infection. 
At 48 h and 72 h pi, viral genome detection was significantly lower in culture medium of 
infected cells treated with aciclovir than in culture medium of infected untreated microglia 
cells (fig 4.14). This shows aciclovir inhibits HSV-1 replication in microglial cells 
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Figure 4.10. Microscopy pictures of HSV-1-infected microglial cells treated with 
aciclovir. HSV-1 infection was done at MOI=0.01. Treatment with aciclovir (20 µM) was 
done 24 h post-infection. The uninfected microglia cells are represented at 48 h (A) and 72 h 
(B) after infection of the HSV-1 infected counterparts. (C) and (D) show HSV-1-infected 
microglial cells (untreated) respectively at 48 h and 72 h pi. (E) and (F) show infected 
microglial treated with aciclovir at 48 h and 72 h pi respectively. By comparing (C) vs (E) and 
(D) vs (F), a lower proportion of gaps in the monolayer, signs of HSV-1-induced cell death, 
could be seen when infected cells are treated with aciclovir and at both time-points (E and F). 
These pictures are representative of 3 experiments. 10 x magnification. Scale bar: 50 µm. 
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Figure 4.11. Influence of aciclovir on the percentage of attached cell area in microscopy 
pictures of HSV-1-infected microglial cells. HSV-1-infection was done at MOI=0.01. The 
treatment with aciclovir (20 µM) was done 24 h pi. Areas of live cells were measured by the 
software “ImageJ” from pictures taken at 72 h post-infection. HSV-1: HSV-1-infected 
microglial cells; HSV-1+ACV: HSV-1-infected microglial cells treated with aciclovir (20 
µM). Two 4 x magnification microscope pictures for uninfected, four for HSV-1-infected and 
two for HSV-1-infected cells treated with aciclovir were analysed. Statistical analysis were 
not relevant due to a really low number of replicates. 
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Figure 4.12. Influence of aciclovir on DAD-1 gene expression in HSV-1-infected 
microglial cells. HSV-1 infection was done at MOI=0.01. The treatment with aciclovir (20 
µM) was done at 24 h pi. The values represent Ct values after qRT-PCR targeting DAD-1 from 
1 µg of RNA extracts of uninfected (circles) or untreated infected (white squares) or aciclovir-
treated infected (black half-filled squares) microglial cells at 30, 48, 72 h pi.  Data are 
expressed as mean + 95% Confidence Interval (C.I) of 9 replicates from 3 independent 
experiments. ANOVA test statistically showed significant differences between the means of 
the different conditions at 72 h pi (p<0.005) but not at 30 h pi (p>0.05) or at 48h pi (p>0.05). 
(*) p<0.05; (***) p<0.005 (multiple t-tests). 
Figure 4.13. Influence of aciclovir on mitochondrial activity in HSV-1-infected microglia. 
HSV-1 infection was done at MOI=0.01. Treatment with aciclovir (20 µM) was done at 24 h 
pi. The values represent values of WST-1 activity (absorbance at 450 nm (A450 nm) 
normalised by subtraction of the background (A650 nm) after WST-1 addition). WST-1 assay 
was performed in uninfected (circles), untreated infected (white squares) and aciclovir-treated 
infected (black half-filled squares) microglia at different time-points (0, 24, 30, 48, 72 h pi). 
* 
*** 
*** 
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Data are expressed as mean + 95% CI of 30 replicates from 3 independent experiments. 
ANOVA test statistically showed significant differences between the means of the different 
conditions at 72 h pi (p<0.005) but not at 30 h pi or at 48h pi. (***) p<0.005 (multiple t-tests). 
 
 
 
Figure 4.14. Influence of aciclovir on HSV DNA abundance in HSV-1-infected microglia 
culture medium. HSV-1 infection was done at MOI=0.01. Treatment with aciclovir (20 µM) 
was done at 24 h pi. The values represent Ct values after HSV DNA qPCR from culture 
medium of HSV-1-infected (white squares) or aciclovir-treated infected (black half-filled 
squares) microglia at 24 h (just before treatment), 30 h, 48 h and 72 h pi.. Each point represents 
the mean + 95% CI of data from at least 3 independent experiments. Triplicates were used for 
each point-time in each experiment. (*) p<0.05; (****) p<0.0001 (multiple t-tests). 
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4.2.2.2. Aciclovir is associated with a decrease in TNF relative gene expression following 
HSV-1 infection of microglial cells 
In the previous chapter, HSV-1 was shown to induce an increase in TNF relative gene 
expression in microglial cells. Here, I assessed the effect of the drug aciclovir (20 µM), added 
at 24 h pi, on TNF relative gene expression in HSV-1-infected microglial cells. Interestingly, 
HSV-1 was still associated with a large increase in TNF relative gene expression in microglia 
at 48h and 72h pi in spite of the presence of aciclovir as observed with values much higher 
than one (fig 4.15). However, this increase was markedly lower in infected microglia cells 
treated with aciclovir compared to HSV-1-infected cells untreated, at 72 h pi (fig 4.15).  
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Figure 4.15. Influence of aciclovir on TNF relative gene expression in HSV-1-infected 
microglial cells. HSV-1 infection was done at MOI=0.01 in microglial cells. Aciclovir 
treatment (20 µM) was added at 24h pi. The data represent TNF relative gene expression 
expressed as mean +/- 95% CI of 2-ΔΔCt values at 30 h, 48 h and 72 h post-infection 
(respectively 6 h, 24 h and 48 h post-treatment). The scale is logarithmic. 2-ΔΔCt values were 
obtained following qRT-PCR of TNF and DAD-1 genes. DAD-1 gene was used as reference 
(housekeeping) gene. From qRT-PCR Ct values of DAD-1 and TNF, ΔCt values [Ct (TNF)-
Ct(DAD-1]) were obtained for both uninfected and HSV-1-infected cells. ΔΔCt values 
represented [(ΔCt) HSV - (ΔCt)uninfected]. Data were obtained from 3 independent 
experiments.(***): p<0,001 (multiple t-tests). 
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4.3. Discussion 
Aciclovir is the gold standard therapy used for HSE treatment, acting to inhibit HSV 
replication. It has significantly improved patient outcome and survival since it began to be 
clinically used for HSE in the 1980’s 34, 107. It has also been shown to be much more efficient 
than other antiviral drugs such as vidarabin125, 202. However, aciclovir is not an optimal therapy 
as 10-20% of patients treated with aciclovir die, and the majority of survivors experience long-
term neurological sequelae53, 34, 110.  
Although the beneficial effect of aciclovir has been shown in HSE patients, less is known 
about the effect of aciclovir on specific human brain cell types, such as microglial cells or 
neurons, infected with HSV. In this chapter, I studied the effect of aciclovir on HSV-1-infected 
microglial cells and neuron-like cells (neuroblastomas). Cell survival, viral load in cell culture 
medium and TNF gene expression were assessed.  
In HSV-1-infected neuroblastomas, aciclovir was associated with an increase in cell 
survival/mitochondrial metabolism as seen by (i) light microscopy and the analysis of attached 
cell area by the software “ImageJ” (fig 4.2-4.-4) and (ii) the WST-1 assay (fig 4.6) from 48 h 
to 72 h pi. Of note, aciclovir increased cell viability/mitochondrial metabolism following 
HSV-1-infection of neuroblastomas but not up to the levels of the uninfected cells. There were 
no differences in Ct values following qRT-PCR targeting DAD-1 between infected untreated 
and infected aciclovir-treated neuroblastomas (fig 4.5). This is not surprising as in qPCR a 
difference of only one cycle threshold, in the same conditions, means a two-fold change 
between them. As a result, slight differences in cell viability (below 2-fold change, for 
example, an increase or decrease in 10-80%) are not likely to be seen by comparing Ct values 
issued from qRT-PCR targeting DAD-1. Direct qPCR from culture medium of infected 
neuroblastoma cells did not show any differences in viral load between cells treated with 
aciclovir or untreated (fig 4.7). qPCR only detects HSV DNA, some of which may be partially 
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degraded, in some (damaged) viral particles, although detected by qPCR. Hence, it does not 
perfectly assess the ability of HSV-1 particles to be infective. The culture medium of infected 
neuroblastoma cells treated with aciclovir or untreated was then used to infect Vero cells. A 
second HSV DNA qPCR showed a decrease in viral load in culture medium of Vero cells 
infected by the culture medium of HSV-1 infected neuroblastoma cells treated with aciclovir 
compared to the ones infected by the culture medium of infected neuroblastoma cells untreated 
(fig 4.8). Hence, aciclovir was associated with a reduction of active HSV-1 viral load in 
infected neuroblastoma cells.  
In HSV-1-infected microglia, aciclovir was also associated with an increase in cell 
survival/mitochondrial metabolism as seen by light microscopy followed by the analysis of 
attached cell areas by “ImageJ" (fig 4.10-11), WST-1 assay (fig 4.13) and qRT-PCR targeting 
DAD-1 (fig 4.12) at 48-72 h pi. Aciclovir was also associated with increased cell viability 
following HSV-1-infection of microglial cells. Unlike for neuroblastoma cells, direct HSV 
DNA qPCR from culture medium of infected microglia showed a significant decrease in HSV 
DNA abundance at 48 h and 72 h pi in cells treated with aciclovir (compared to untreated 
infected) (fig 4.14). Hence, aciclovir is responsible for HSV-1 load decrease in microglia.  
Altogether, aciclovir has been shown to decrease viral load and increase cell survival in both 
HSV-1-infected neuroblastoma and microglial cells. This is in agreement with the fact that 
aciclovir is the antiviral therapy used for HSE treatment125, 124, 202. 
Interestingly, TNF relative gene expression was still increased in HSV-1-infected microglial 
and neuroblastoma cells compared to their uninfected counterparts (fig 4.9 and fig 4.15). 
However, the comparison of TNF relative gene expression between infected cells untreated 
and infected cells treated with aciclovir revealed differences between brain cell types. In 
neuroblastoma cells, aciclovir was associated with a significant increase in TNF relative gene 
expression in infected cells at 72h pi whereas in infected microglial cells, a decrease following 
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aciclovir treatment was observed at this same time-point. Aciclovir was associated with an 
increase in cell viability of both HSV-1-infected neuroblastoma and microglial cells. However, 
this was not associated with the same effect on TNF relative gene expression among these 
infected cells. This suggests TNF relative gene expression is not strongly associated with 
HSV-1-infected brain cell viability. 
Of note, some of the techniques used appeared to have some limitations such as the qRT-PCR 
targeting DAD-1 as a proxy marker of cell viability and the direct HSV DNA qPCR on culture 
medium of infected brain cells to measure the impact of a drug on HSV replication. The qRT-
PCR targeting DAD-1 was sensitive enough to detect differences in cell viability between 
uninfected and infected brain cells (chapter 3). However, for smaller differences requiring a 
higher sensitivity, like between two groups of infected cells (one treated with aciclovir, one 
untreated), it seems to be less precise. Thus, the qRT-PCR targeting DAD-1 was not sensitive 
enough to detect differences in cell viability between the untreated and aciclovir-treated HSV-
1-infected neuroblastomas. Nevertheless WST-1 assay measuring mitochondrial activity, used 
by other researchers as a very accurate technic for cell viability149 quantification was able to 
detect a difference also seen by attached cell area determination on microscopy pictures using 
the software “ImageJ”. In the next chapters, WST-1 will be used as our selected method for 
cell viability measurement. Assessing HSV-1 load by direct HSV DNA qPCR from culture 
medium of brain cells showed significant differences between infected and uninfected cells 
(negative control) in the previous chapter. Nonetheless, comparing two groups of infected 
brain cells (one treated with aciclovir, one untreated) by the same technique was also less 
useful. Indeed, no differences were seen in this first direct qPCR on neuroblastoma cell culture 
medium between the untreated and the aciclovir-treated infected groups. But a second HSV 
DNA qPCR from Vero cell culture medium after infection of Vero cells using culture medium 
of infected neuroblastomas untreated or treated with aciclovir showed that aciclovir was also 
associated with a reduction of viral load of active HSV-1-particles in in neuroblastoma cells. 
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In the next chapters, this second infection in Vero cells followed by the secondary HSV DNA 
qPCR will also be performed when the first direct qPCR on culture medium of infected brain 
cells did not show significant differences between the different “infected” groups. 
As discussed previously, aciclovir is a suboptimal treatment for HSE only targeting HSV 
replication. There is a growing body of evidence demonstrating HSE is the result of both HSV 
infection and detrimental immune responses69, 71, 94, 93. In this chapter, using a single dose of 
aciclovir, at 20 µM, markedly increased cell viability, but not as the same levels as seen in 
uninfected cells. Using anti-inflammatory drugs as adjunctive therapies to aciclovir for 
treatment of HSV-1-infected neuroblastomas and microglial cells may help to increase cell 
viability further. In the next chapter (chapter 5), I examined the effect of aciclovir combined 
with the anti-inflammatory drug dexamethasone on HSV-1-infected microglial and 
neuroblastoma cells. 
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Chapter 5 The effect of Dexamethasone on HSV-1 infection in 
human brain cells 
5.1. Introduction  
Dexamethasone and other glucocorticoids are drugs clinically used to treat a wide range of 
inflammatory conditions such as allergies, rheumatoid arthritis, ulcerative colitis and several 
skin diseases including psoriasis. Among CNS infections, glucocorticoids have been widely 
assessed in addition to antimicrobial therapy (cefotaxime) for treatment of patients with 
bacterial meningitis. Interestingly, adding dexamethasone early (first administration before or 
within the first hour following antimicrobial therapy administration; 10 mg every 6 h; at least 
4 days) in addition to antibiotics has been associated with favourable outcome in an elderly 
population of patients suffering from acute bacterial meningitis and presenting high levels of 
immunosuppressive co-morbidity (including alcoholism, malignancy, diabetes mellitus, 
asplenia, HIV infection (positive status:1%))150. In an European clinical trial, a similar 
administration of early dexamethasone in adults with bacterial meningitis also led to more 
favourable outcome (higher Glasgow Coma Score) and a reduction in mortality at discharge 
but not one month or one year later (HIV status unknown)151. During the 1990’s, 
administration of dexamethasone, 15 to 20 minutes prior to antimicrobial therapy in children 
with bacterial meningitis, quickly induced an improvement of cerebral perfusion pressure, a 
reduction in meningeal inflammation, and an overall better clinical condition and prognostic 
score (HIV status unknown)152. During the follow-up of this trial in Costa-Rica, a decrease in 
neurologic and audiologic sequelae in the population of children co-treated with 
dexamethasone was observed. However, a meta-analysis of individual data from five clinical 
trials stated that early administration of adjunctive dexamethasone in bacterial meningitis did 
not lead to a decrease in mortality or neurological disability but just to a slight reduction in 
hearing loss among survivors153.  Of note, in this meta-analysis, the HIV positive status was 
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just above 40% among patients enrolled in both “steroid” and “placebo” groups. A randomised 
clinical trial on dexamethasone as adjunctive treatment in childhood bacterial meningitis in 
Malawi, showed that the administration of this steroid influenced neither mortality nor 
sequelae at final outcome154. In the latter study, HIV status was positive for 24% of patients in 
the “steroid” group and for 29% in the “placebo” group, and around 23-24% of patients in 
both groups were not HIV-tested. Finally, a systematic review of twenty-five clinical studies 
focusing on the impact of corticosteroids for acute bacterial meningitis concluded overall that 
corticosteroids significantly reduced hearing loss and neurological sequelae in high-income 
countries but not mortality rate in both low and high-income countries155. Nonetheless, 
corticosteroids seemed to induce a reduced mortality in patients affected by meningitis 
specifically caused by Steptococcus pneumoniae (but not by Haemophilus influenza or 
Neisseria meningitis). Hence, despite a large amount of clinical data, the beneficial impact of 
adjunctive steroids (mainly dexamethasone) in bacterial meningitis is still uncertain and 
remains an area for discussion. Nevertheless, these clinical studies revealed that (i) steroids 
never worsened the clinical state of patients, (ii) the beneficial impact could be dependent on 
the causative microbial agent and (iii) the positive effects of steroids in bacterial meningitis 
seem to be optimal during early administration (just before or until 1 h after antimicrobial 
therapy) in both adults and children. Furthermore, HIV status could affect the beneficial 
impact of adjunctive dexamethasone or corticosteroids on bacterial meningitis, thus HIV 
negative patients seem to benefit more from this treatment. In vitro, in a brain cell co-culture 
consisting of both astrocytes and microglia, lipopolysaccharide (LPS) challenge has been 
shown to induce an increase in microglia activation and a loss of astrocyte properties156. 
Crucially, in this experimental bacterial meningitis model, dexamethasone induced both a 
decrease in microglial activation and a restoration of astrocyte properties. 
Herpes Simplex Encephalitis (HSE) pathogenesis is the result of both HSV infection and 
detrimental immune response as previously discussed71, 94, 93, 131, 91, 133. However, the gold 
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standard therapy to treat HSE is the intravenous administration of aciclovir targeting only viral 
replication124. Therefore, the use of anti-inflammatory drugs such as dexamethasone or other 
glucocorticoids as an adjuvant therapy to aciclovir in HSE could be a relevant approach to 
decrease both the detrimental immune response and overcome the current limitations of the 
antiviral therapy157. Nevertheless, only a few studies have assessed the effect of 
dexamethasone or other glucocorticoids to treat HSE. 
In an in vivo model of HSE, it was shown that aciclovir combined to another glucorticoid drug, 
methylprednisolone, compared to the administration of aciclovir alone, reduced long-term 
Magnetic Resonance Imaging (MRI) abnormalities in the brains of mice131.  
In HSE patients, the administration of dexamethasone has been assessed combined with 
aciclovir in only a few small clinical studies. In one retrospective clinical study, a multiple 
logistic regression analysis revealed that the administration of glucocorticoids (initiation, dose 
and duration of treatment at the discretion of each clinician), used as adjuvant therapy to 
aciclovir, was one predictor of good outcome in HSE patients158. Another study on several 
HSE patients treated with aciclovir suggested that treatment with dexamethasone could induce 
a decrease in temporal lobe and total oedema volumes132. In a small retrospective study on 
children affected by HSE and all treated by aciclovir, the supplementary administration of 
glucocorticoids (prednisone or methylprednisolone; 2 mg/kg/day per oral; 2 weeks) started at 
the same time as acyclovir also led to better cognition, motor function and seizure control129. 
Finally, a case report also described the positive impact of short high-dose intravenous steroid 
therapy (1g of methylprednisolone per m2 for 3 days) for a 16-month-old girl presenting HSE 
with clinical and radiologic deterioration despite aciclovir treatment128. 
Altogether, several small clinical and animal studies have shown a beneficial impact of the 
administration of glucocorticoids as adjuvant therapy to HSE158, 132, 128, 129, 131. However, despite 
these promising results, there is still a lack of clinical data to confirm glucocorticoids are 
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beneficient adjuvant therapies to aciclovir for HSE treatment. Unfortunately, one clinical trial 
which started in Germany in 2008, assessing the effect of dexamethasone as adjuvant therapy 
in HSE, stopped prematurately159. The trial seems to have ended because of poor recruitment, 
possibly due to clinical concerns of dexamethasone promoting HSV replication. A similar 
clinical trial, is currently led in the United-Kingdom (DexEnceph) and France (clinical trial 
references: ISRCTN11774734 and NCT03084783). The effect of Dexamethasone combined 
to aciclovir has been poorly assessed in in vitro models of HSE using HSV-1-infected human 
brain cells. To my knowledge, only one in vitro study assessed the impact of dexamethasone 
following HSV-1-infection in brain cells, using murine BV2 microglial cells137. This work 
showed that dexamethasone induced a reduction in protein secretion of the pro-inflammatory 
cytokines TNF-α and NO in these infected murine microglia cells, but the authors did not study 
the effect of this drug on viral replication, cell viability or cytokine gene expression level. In 
this chapter 5, I assessed the effect of dexamethasone in a human microglial cell line and Kelly 
neuroblastomas following HSV-1-infection at the level of cell viability, HSV-1 replication and 
TNF gene expression. The main aim was to see if the positive impact of dexamethasone as 
adjuvant therapy for HSE treatment seen in the few in vivo and small clinical studies, 
potentially partially due to oedema reduction, could also been observed in individual human 
brain cell lines infected by HSV-1.  
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-microglia 
Uninfected 
HSV-1-infected 
Untreated 
Treated with 
Dex, ACV or 
Dex+ACV 
  
A 
B 
Figure 5.1. Experimental design for assessing the effect of sub-toxic doses of 
dexamethasone (dex) on HSV-1-infection in human brain cells. (A) Brain cell 
populations used. (B) Techniques performed on brain cells following HSV-1-infection. (C) 
Techniques performed on brain cell culture medium following HSV-1-infection. 
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5.2. Results 
5.2.1. Toxic doses of dexamethasone in brain cells 
5.2.1.1. Toxic doses of dexamethasone in neuroblastoma cells 
Firstly, dexamethasone was shown to be toxic for (uninfected) neuroblastoma cells 24 h post-
treatment at 500 µM (0.5 mM) as shown by a significant decrease in live cell counting by 
Trypan blue exclusion staining (fig 5.2). High dexamethasone concentrations (100-500 µM) 
were also associated with a decrease in live cell number in HSV-1-infected-neuroblastoma 
cells although not statistically significant (p>0.05).  
 
Figure 5.2. Live cell number in uninfected and HSV-1-infected neuroblastoma cells 
following treatment with high doses of dexamethasone. Uninfected neuroblastoma cells are 
represented by circles while HSV-1-infected ones are represented by squares. HSV-1 infection 
was done at MOI=0.001. (Dex) means Dexamethasone treatment has been done 24 h post-
infection (h pi) at the concentration of 10, 100 or 500 µM as indicated. At 48 h pi (24 h post-
treatment), live cells were counted using Trypan Blue exclusion staining. Data represent mean 
+ 95% Confidence Interval (CI) of 6 replicates from 2 independent experiments. ANOVA test 
** 
**** 
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statistically showed significant differences between the means of the different conditions 
(p<0.0001). (**) p<0.01, (**) p<0.0001 (t-tests). 
5.2.1.2. Toxic doses of dexamethasone in microglial cells 
Dexamethasone toxicity was also assessed in uninfected human microglia by observations in 
light microscopy (fig 5.3-5.5). As soon as 2 h post-treatment, 5 mM of dexamethasone induced 
visible toxicity characterized by extensive live cell loss as witnessed by an incomplete 
microglia cell monolayer (fig 5.3D). At this time, this toxic concentration also led to an 
obvious change in microglial cell morphology making “surviving” cells lose their normal 
shape (ovoid with ramifications) to become smaller, rounder and brighter. Pictures of 
microglia cells 24 h (fig 5.4D) and 48 h post-treatment (pt) (fig 5.5D) with 5 mM of 
dexamethasone also showed apparent changes in cell morphology and extensive decrease in 
live cell number with most cell debris seen at 48 h pt. Dexamethasone was also toxic in 
microgliam cells at 1 mM (fig 5.4C and 5.5C) but not at 0.5 mM (fig 5.4B and 5.5B) at 24 h 
and 48 h post-treatment as seen by the same HSV-1-induced cell damage (cell death and 
change in morphology). LD50, known as Lethal Dose 50%, is the dose for which a chemical 
induces 50% of cell death in a tissue. As demonstrated in figure 5.4, more than half of 
microglia cells were killed by 1 mM of dexamethasone (fig 5.4C) while no toxic effect on the 
cell monolayer could be seen with a concentration of 0.5 mM at 24 h post-treatment (fig 5.4B). 
This was similar at 48 h pt (fig 5.5). This suggests an LD50 of dexamethasone around 0.5-1 
mM to consider in my experiments in microglial cells (48 h pt being the last time-point used 
in all my experiments). The dose of dexamethasone used in HSE clinical studies is around 40 
mg/day159. This matches with a concentration of 2 x 10-2 mM in the bloodstream. 
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Figure 5.3. Microscopy pictures of HSV-1-infected microglial cells 2 h after high doses of 
dexamethasone. (A) Culture of (untreated) microglial cells 2 h after treatment of the 
dexamethasone-treated cells. Most of the cells had the classic morphologic features of 
microglial cells with ovoid or fibroblast-like shape and ramifications. The confluence was 
around 70-80% and a few small round cells could be observed. (B) Culture of microglial 
cells 2 h after treatment with 0.5 mM of Dexamethasone. The picture is very similar to the 
untreated cells (A). (C) Culture of microglia cells 2 h after treatment with 1 mM of 
Dexamethasone. The picture is very similar to the untreated cells (A). (D) Culture of 
microglial cells 2 h after treatment with 5 mM of Dexamethasone. This treatment induced 
extensive live cell loss 2 h post-treatment as shown by the spaces between cells (20-30% 
confluence). Cells lost their classic microglia shape, almost all of them looked small and 
round. 10 x magnification. Scale bar: 50 µm.  
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Figure 5.4. Microscopy pictures of HSV-1-infected microglial cells 24 h after high doses 
of dexamethasone. (A) Culture of (untreated) microglial cells 24 h after treatment of the 
treated ones. Most of the cells had the classic morphologic features of microglial cells with 
ovoid or fibroblast-like shape and ramifications. The confluence was around 80% and a few 
small round cells could be observed. (B) Culture of microglial cells 24 h after treatment 
with 0.5 mM of Dexamethasone. The picture is very similar to the untreated cells (A). (C) 
Culture of microglial cells 24 h after treatment with 1 mM of Dexamethasone. This 
treatment induced extensive live cell loss as shown by the spaces between cells (20% 
confluence). Cells lost their classic microglia shape, almost all them looked small and round 
and formed clusters. (D) Culture of microglia cells 24 h after treatment with 5 mM of 
Dexamethasone. This treatment induced extensive live cell loss as shown by the spaces 
between cells (10-20% confluence). Cells lost their classic microglia shape, almost all of them 
looked small and round. 10 x magnification. Scale bar: 50 µm.  
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Figure 5.5. Microscopy pictures of HSV-1-infected microglial cells 48 h after high doses 
of dexamethasone. (A) Culture of (untreated) microglial cells 48 h after treatment of the 
treated ones. Most of the cells had the classic morphologic features of microglial cells with 
ovoid or fibroblast-like shape and ramifications. The confluency was around 80-90% and a 
few small round cells could be observed. (B) Culture of microglial cells 48 h after treatment 
with 0.5 mM of Dexamethasone. The picture is very similar to the untreated cells (A). (C) 
Culture of microglial cells 48 h after treatment with 1 mM of Dexamethasone. This 
treatment induced extensive live cell loss as shown by the spaces between cells (10% 
confluence). Cells lost their classic microglia shape, almost all of them looked small and 
round. There were a lot of cells floating and forming clusters. (D) Culture of microglial cells 
48 h after treatment with 5 mM of Dexamethasone. The monolayer was completely 
different with only few cells attached compared to the one made by untreated (A). All cells 
lost their classic microglia shape, they all looked small and round. A lot of floating cells and 
debris could be observed.10 x magnification. Scale bar: 50 µm. 
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5.2.1.3. Toxic doses of dexamethasone in primary astrocytes 
Dexamethasone toxicity was finally studied in (uninfected) primary astrocytes using light 
microscopy as well (fig 5.6-5.8). Similar to what was observed in microglial cells, at 2 h post-
treatment (pt), 5 mM of dexamethasone was also toxic for astrocytes since it was associated 
with both an extensive decrease in live cells with big spaces between cells and a big proportion 
of cells losing their astrocyte classic morphology (“star-like” shape, thin, long with 
ramifications) to become smaller, rounder and brighter cells in light microscopy (fig 5.6D). At 
24 h and 48 h pt, all astrocytes treated with 5 mM looked round and small with big spaces 
between cells indicating cell death (fig 5.7D and 5.8D). 1 mM but not 0.5 mM of 
dexamethasone was also toxic for astrocytes at 24 h and 48 h pt as witnessed by a visible 
decrease in live cells and morphologic changes in the cells (fig 5.7B-C and 5.8B-C). Crucially, 
more than half of the primary astrocytes were killed by 1 mM of Dexamethasone (fig 5.8C) 
while no toxic effect on the cell monolayer could be seen with a concentration of 0.5 mM at 
48 h post-treatment (fig 5.8B). This also suggests a LD50 of dexamethasone around 0.5-1 mM 
to consider in my experiments in primary astrocytes (48h pt being the last time-point used for 
all my experiments). 
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Figure 5.6. Microscopy pictures of HSV-1-infected astrocytes 2 h after high doses of 
dexamethasone. (A) Culture of (untreated) astrocytes 2 h after treatment of the treated 
ones. Most of the cells had the classic morphologic features of astrocytes: thin, long with a 
“star”-like shape and ramifications. The confluence was close to 100%. (B) Culture of 
astrocytes 2 h after treatment with 0.5 mM of Dexamethasone. The picture was very 
similar to the untreated cells (A). (C) Culture of astrocytes cells 2 h after treatment with 1 
mM of Dexamethasone. The picture was very similar to the untreated cells (A). (D) Culture 
of astrocytes 2 h after treatment with 5 mM of Dexamethasone. This treatment induced 
extensive live cell loss as shown by the spaces between cells (30-40% confluency). Many cells 
lost their classic astrocyte shape, almost all of them looking small, round and bright in light 
microscopy. 10 x magnification. Scale bar: 50 µm. 
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Figure 5.7. Microscopy pictures of HSV-1-infected astrocytes 24 h after high doses of 
dexamethasone. (A) Culture of (untreated) astrocytes 24 h after treatment of the treated 
ones. Most of the cells had the classic morphologic features of astrocytes: thin, long with a 
“star”-like shape and ramifications. The confluency was close to 100%. (B) Culture of 
astrocytes 24 h after treatment with 0.5 mM of Dexamethasone. The picture was very 
similar to the untreated cells (A). (C) Culture of astrocytes 24 h after treatment with 1 mM 
of Dexamethasone. This treatment induced live cell loss as shown by gaps in the monolayer 
(60-70% confluence). A big proportion of the cells started to lose their astrocyte shape to 
become round and small. (D) Culture of astrocytes 24 h after treatment with 5 mM of 
Dexamethasone. This treatment induced extensive live cell loss as shown by the spaces 
between cells (around 40-50% confluency). Almost all cells looked small and round. 10 x 
magnification. Scale bar: 50 µm. 
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Figure 5.8. Microscopy pictures of HSV-1-infected astrocytes 48 h after high doses of 
dexamethasone. (A) Culture of (untreated) astrocytes 48 h after treatment of the treated 
ones. Most of the cells had classic morphologic features of astrocytes: thin, long with a “star”-
like shape and ramifications. The confluence was close to 100%. (B) Culture of astrocytes 
48 h after treatment with 0.5 mM of Dexamethasone. The picture was very similar to the 
untreated cells (A). (C) Culture of astrocytes 48 h after treatment with 1 mM of 
Dexamethasone. This treatment induced extensive live cell loss as shown by gaps in the 
monolayer (around 30% confluency). A big proportion of the cells lost their astrocyte shape 
to become round and small but there were still some astrocytes with classic morphology. (D) 
Culture of astrocytes 48 h after treatment with 5 mM of Dexamethasone. This treatment 
induced extensive live cell loss as shown by the spaces between cells (around 30% 
confluence). All cells looked small and round. 10 x magnification. Scale bar: 50 µm. 
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5.2.2. The effect of sub-toxic doses of dexamethasone combined to aciclovir on HSV-1-
infection of neuroblastoma cells and microglia cells 
5.2.2.1. Determination of the dose of dexamethasone to assess 
As mentioned in previous sections above, in light microscopy, acute toxicity was seen in 
(uninfected) microglia and primary astrocytes from dexamethasone concentrations of 1 mM 
(but not 0.5 mM) and it was therefore concluded that the LD50 for dexamethasone should be 
in the range of 0.5-1 mM for both brain cell types. The same trend was also observed for HSV-
1-infected-neuroblastoma cells. Indeed, by live cell counting, 0.5 mM (500 µM) 
dexamethasone was associated with a decrease slightly below 50% in live (uninfected) 
neuroblastoma number. Hence, the LD50 of dexamethasone in neuroblastomas is also higher 
than 0.5 mM and should also be around 0.5-1 mM. Interestingly, in the brain of patients 
suffering from glioblastomas and treated by dexamethasone, it was shown that the brain tissue 
concentration of dexamethasone which acts to potentially reduce oedema in this disease, is 
around one thousand times lower than the cytotoxic concentration determined in cell culture156. 
This suggests that it could be interesting to assess the biological effect of dexamethasone on 
HSV-1-infected brain cells combined with aciclovir using concentrations of dexamethasone 
around one thousand times lower than the previously determined LD50 (0.5-1 mM). 
Therefore, concentrations of around 0.5-1 µM were chosen. This is in agreement with the 
concentration used (0.5 µM) to demonstrate that dexamethasone administration was beneficial 
for microglia and astrocyte following LPS challenge in an in vitro model of bacterial 
meningitis156. As a result, the main concentration of dexamethasone assessed in the following 
experiments was 0.5 µM. The dose of dexamethasone used in HSE clinical studies is around 
40 mg/day159. This matches with a concentration of 20 µM in the bloodstream (depending on 
the blood brain barrier permeability, only proportion of this 20 µM of dexamethasone will 
penetrate the brain parenchyma). 
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5.2.2.2. The effect of sub-toxic doses of dexamethasone combined with aciclovir in HSV-1-
infected neuroblastoma cells 
5.2.2.2.1. The effect of sub-toxic doses of dexamethasone combined with aciclovir on cell 
viability and viral replication in HSV-1-infected neuroblastoma cells 
The effect of dexamethasone (0.5 µM), alone and combined with aciclovir (20 µM), was 
assessed on HSV-1-infected neuroblastoma cell viability. The cell viability levels were 
determined by light microscopy followed by analysis of microscopy pictures using the 
software “ImageJ”, live cell counting after Trypan blue staining, WST-1 assay (measuring 
mitochondrial activity) and qRT-PCR targeting the housekeeping gene DAD-1. The treatment 
with dexamethasone and/or aciclovir was performed 24 h post-infection (pi).  
In light microscopy, at 48 h post-treatment (pt) (72 h pi), more signs of infection (including 
live cell loss and debris) could be observed in infected cells untreated or treated with 
dexamethasone alone compared to infected neuroblastomas treated with aciclovir alone or 
combined with dexamethasone (fig 5.10). At 24 h pt, such a difference was not detectable 
since, at this earlier time-point, HSV-1 had only started to induce cell death sporadically and 
the monolayers of infected cells were all more than 90% confluent, independently of the 
treatment given (fig 5.9).  
Analysing multiple microscope pictures at 4 x magnification using the software “ImageJ” also 
showed that the area of attached neuroblastomas was significantly bigger in HSV-1-infected 
neuroblastoma cells treated by aciclovir alone or combined with dexamethasone than in 
infected cells untreated at 48 h pt (fig 5.11) (p<0.05). The area of attached infected cells treated 
with dexamethasone alone was similar to that of infected cells untreated. 
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qRT-PCR targeting the housekeeping gene DAD-1 was sensitive enough to show differences 
in Ct values between uninfected and infected cells but not between infected neuroblastoma 
untreated, treated with dexamethasone, aciclovir or both (fig 5.12).  
At 24 h and 48 h pt (48 h and 72 h pi), aciclovir alone or combined with dexamethasone, but 
not dexamethasone alone, was associated with an increase in mitochondrial activity in HSV-
1-infected neuroblastoma cells as detected by the WST-1 assay (fig 5.13). However, dual 
therapy with aciclovir and dexamethasone did not lead to higher levels of mitochondrial 
activity than the administration of aciclovir alone. Of note, mitochondrial activity was also 
similar at 24 h and 48 h pt between infected neuroblastomas untreated and treated with 
dexamethasone emphasizing that dexamethasone was not detrimental for mitochondrial 
activity and cell viability in HSV-1-infected neuroblastoma cells. 
Finally, a direct qPCR on HSV DNA from culture medium of infected neuroblastomas, did 
not show any differences in viral load between infected cells untreated or treated with 
aciclovir, dexamethasone or both (fig 5.14). As stated before, this technique does not perfectly 
reflect the amount of viruses remaining active or functional in culture medium. As a result, the 
culture medium of infected neuroblastomas untreated or treated with aciclovir, dexamethasone 
or both, was then used to infect Vero cells; at 24h after Vero cell infection, an HSV DNA 
qPCR on Vero cell culture medium was performed (fig 5.15). This secondary qPCR showed a 
decrease in HSV DNA abundance (higher Ct values) in culture medium of Vero cells infected 
by the medium of HSV-1 infected neuroblastoma cells treated with aciclovir alone or 
combined to dexamethasone, compared to those infected by the medium of infected 
neuroblastoma cells untreated or treated by dexamethasone alone (fig 5.15). As seen in the 
previous chapter, this confirms that aciclovir decreases viral load in HSV-1-infected 
neuroblastoma cells, but here it also shows that it is still the case in presence of dexamethasone.  
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Altogether, this shows dexamethasone (0.5 µM) has no positive effect on cell viability or viral 
load in HSV-1-infected neuroblastomas and suggests that the positive impact of aciclovir 
therapy combined to dexamethasone, very similar to the one caused by aciclovir alone, is only 
due to the inhibition of viral load by aciclovir. However, these experiments show that adding 
dexamethasone (0.5 µM) does not have a negative impact either, since it does not lead to an 
increase in live cell loss or higher viral load in HSV-1-infected neuroblastomas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9. Microscopy pictures of HSV-1-infected neuroblastoma cells 48 h post-
infection with a sub-toxic dose of dexamethasone (0.5 µM) alone or combined with 
aciclovir. HSV-1-infection was done at MOI=0.01. Treatment was done with dexamethasone 
(0.5 µM) and/or aciclovir (20 µM) at 24 h post-infection (pi). Pictures were taken at 48 h pi 
(24 h post-treatment). (A) Uninfected neuroblastoma cells. Most of the cells have classic 
morphologic features of neuroblastomas with a fibroblast-like shape. The confluence is around 
100%. (B) HSV-1-infected neuroblastoma cells untreated. A round gap, a sign of viral-
induced cell death, can be observed. Cells look also rounder and smaller than uninfected (A) 
(C) HSV-1-infected neuroblastoma cells treated with Dexamethasone. The picture is very 
similar to the one of infected untreated cells (B). Indeed, a gap in the monolayer and a change 
of cell morphology can also be observed. (D) HSV-1-infected-neuroblastoma cells treated 
with aciclovir. The picture is very similar to the one of uninfected cells (A). (E) HSV-1-
infected-neuroblastoma cells treated with aciclovir and dexamethasone. The picture is 
very similar to the one of uninfected cells (A). 10 x magnification. Scale bar: 50 µm. 
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magnification. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Microscopy pictures of HSV-1-infected neuroblastoma cells 72 h post-
infection with a sub-toxic dose of dexamethasone (0.5 µM) alone or combined with 
aciclovir. HSV-1-infection was done at MOI=0.01. Treatment was done with dexamethasone 
(0.5 µM) and/or aciclovir (20 µM) at 24h post-infection (pi). Pictures were taken at 72 h pi 
(48 h post-treatment). (A) Uninfected neuroblastoma cells. Most of the cells look round now 
as they are overconfluent. (B) HSV-1-infected neuroblastoma cells untreated. There are big 
gaps in the monolayer now and, the confluence seems around 50%. (C) HSV-1-infected 
neuroblastoma cells treated with dexamethasone. The picture is very similar to the one of 
infected untreated cells (B). Indeed, a lot of cells are detached from the monolayer as we can 
see with the big gap (around 50% confluency). (D) HSV-1-infected-neuroblastoma cells 
treated with aciclovir. The monolayer presents signs of live cell loss with a central gap and 
more space between cells. However, the infection with aciclovir has induced less damage than 
for cells untreated (B) or treated with dexamethasone (C). Indeed, around 70-80% of cells are 
still present. (E) HSV-1-infected-neuroblastoma cells treated with aciclovir and 
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dexamethasone. The monolayer is still almost complete (around 90% confluent). 10 x 
magnification. Scale bar: 50 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11. The effect of dexamethasone alone (0.5 µM) or combined with aciclovir on 
the attached cell area of microscopy pictures of HSV-1-infected neuroblastoma cells 72 
h post-infection. HSV-1-infection was done at MOI=0.01. Treatment was done with 
dexamethasone (0.5 µM) and/or aciclovir (20 µM) 24 h post-infection (pi). Areas of attached 
cells were measured by the software “ImageJ” from pictures taken at 72 h post-infection (48 
h post-treatment) of neuroblastoma cells uninfected (circles), infected untreated (white 
squares), infected treated with aciclovir (squares half-filled in black on the left side), infected 
treated with dexamethasone (squares half-filled in black on the right side) or infected treated 
with the combination “aciclovir+dexamethasone” (black squares). Data are expressed as mean 
of the area of live cells +95% CI and were obtained as described in the chapter 2. At 72 h pi 
(48 h post-treatment), nine pictures for uninfected cells, twenty-four for infected untreated 
cells, twenty-two pictures for infected cells treated with aciclovir, fourteen for infected cells 
treated with dexamethasone and thirteen for infected cells treated both aciclovir and 
dexamethasone were analysed. The pictures were representative of 3 independent experiments. 
ANOVA test statistically showed significant differences between the means of the different 
conditions (p<0.0001).  (*) p<0.05; p=0.01; (****) p<0.0001 (t-tests). 
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Figure 5.12. The effect of dexamethasone (0.5 µM) alone or combined with aciclovir on 
DAD-1 gene expression in HSV-1-infected neuroblastoma cells. HSV-1 infection was 
performed at MOI=0.01. The treatments with aciclovir (20 µM) and/or dexamethasone (0.5 
µM) were done at 24 h pi. The values represent Ct values after qRT-PCR targeting DAD-1. 
qRT-PCR was performed using 1 µg of RNA extracts of uninfected (circles) or untreated 
infected (unfilled squares) or aciclovir-treated infected (squares half-filled in black on the left 
side) or dexamethasone-treated infected (squares half-filled in black on the right side) or 
“dexamethasone+aciclovir”-treated infected (black squares) neuroblastoma cells at 30, 48, 72 
h pi.  ANOVA test statistically showed significant differences between the means of the 
different conditions at 48 h pi (p<0.0001) and 72 h pi (p<0.0001) but not at 30 h pi (p>0.05). 
Data are expressed as mean + 95% Confidence Interval (C.I) of 9 replicates from 3 
independent experiments. (*) p<0.05; (***) p<0.005 (multiple t-tests). 
 
 
          
                                    
 
Figure 5.13. The effect of dexamethasone (0.5 µM) alone or combined with aciclovir on 
mitochondrial activity in HSV-1-infected neuroblastoma cells. HSV-1 infection was done 
* *** 
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at MOI=0.01. The treatment with aciclovir (20 µM) and/or dexamethasone (0.5 µM) was done 
at 24 h pi. The values represent values of WST-1 activity (absorbance at 450 nm (A450nm) 
normalised by subtraction of the background (A650 nm)). WST-1 assay has been performed 
in uninfected (circles), untreated infected (unfilled squares) or aciclovir-treated infected 
(squares half-filled in black on the left side) or dexamethasone-treated infected (squares half-
filled in black on the right side) or “dexamethasone+aciclovir”-treated infected (black squares) 
neuroblastoma cells at different time-points (0, 24, 30, 48, 72 h pi). Data are expressed as mean 
+ 95% CI of 30 replicates from 3 independent experiments. ANOVA test showed statistical 
differences between the means of the different conditions for all time-points tested: 30 h, 48 h 
and 72 h pi (p<0.0001).  (***): p<0.005; X= (****) p<0.0001 (multiple t-tests). 
 
 
 
Figure 5.14. The effect of dexamethasone (0.5 µM) alone or combined with aciclovir on 
HSV DNA abundance in culture medium of HSV-1-infected neuroblastoma cells. HSV-
1-infection was done at MOI=0.01.  The treatments with aciclovir (20 µM) and/or 
dexamethasone (0.5 µM) were done at 24 h pi. The values represent Ct values after HSV DNA 
qPCR from culture medium of HSV-1-infected neuroblastoma cells: untreated (white), 
aciclovir-treated (half-filled in black on the left side), dexamethasone-treated (half-filled in 
black on the right side) or “dexamethasone+aciclovir”-treated (in black) at 24 (just before the 
treatment), 30, 48 h and 72 h pi. Each point represents the mean + 95% CI of data from at least 
3 independent experiments. Triplicates were used for each point-time in each experiment. 
ANOVA test showed no statistical differences between the means of the different conditions 
at any time point. 
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Figure 5.15. The effect of dexamethasone (0.5 µM) alone or combined with aciclovir on 
the viral load of active HSV-1 particles in the culture medium of infected neuroblastoma 
cells. HSV-1 infection was done at MOI=0.01 and treatment with aciclovir (20 µM) and/or 
dexamethasone (0.5 µM) in neuroblastoma cells were done as described previously (figure 
5.14). Then, the culture medium of neuroblastoma cells infected untreated (white), treated with 
aciclovir (black squares half-filled on the left side), treated with dexamethasone (black squares 
half-filled on the right side) or treated with both aciclovir and dexamethasone (black squares) 
was taken at 72 h pi and used to secondarily infect Vero cells. 24 h post-infection of Vero cells 
with neuroblastoma culture medium, a qPCR targeting HSV DNA was performed on Vero cell 
culture medium. The values represent Ct values after HSV DNA qPCR from Vero cell culture 
medium. Each point represents the mean + 95% CI of data from 2 independent experiments. 
Triplicates were used for each point-time in each experiment. ANOVA test showed statistical 
differences between the means of the different conditions (p<0.0001). (****) p<0.0001 (t-
tests).  
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5.2.2.2.2. The effect of sub-toxic doses of dexamethasone combined to aciclovir on TNF gene 
expression in HSV-1-infected neuroblastoma cells 
 
In chapter 3, an increase in TNF relative gene expression was observed in neuroblastoma cells 
following HSV-1-infection. Furthermore, in chapter 4, treatment with aciclovir (20 µM) led 
to a further increase in TNF relative gene expression in infected neuroblastoma cells at 72nh 
pi. Here, I assessed the impact of the drug dexamethasone (0.5 µM), alone or combined with 
aciclovir (20 µM), on TNF relative gene expression in HSV-1-infected neuroblastoma cells. 
There was still a significant increase in TNF relative gene expression in HSV-1-infected 
neuroblastoma cells treated with dexamethasone co-treated with aciclovir or alone, compared 
to the uninfected counterparts as observed with all the values much higher than one (30-72 h 
pi) (fig 5.16). At 72 h pi, the infected cells untreated, treated with dexamethasone alone or 
combined with aciclovir presented similar TNF relative gene expression. Interestingly, 
aciclovir alone induced a more elevated TNF relative gene expression than all these other 
treatments. 
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Figure 5.16. The effect of dexamethasone (0.5 µM) alone or combined with aciclovir on 
TNF relative gene expression in HSV-1-infected neuroblastoma cells. HSV-1 infection 
was done at MOI=0.01 in neuroblastoma cells. The treatments with aciclovir (20 µM); 
dexamethasone (0,5 µM) or both were added at 24 h pi. The data represent TNF relative gene 
expression expressed as mean +/- 95% CI of 2-ΔΔCt values at 30 h, 48 h and 72 h post-infection 
(respectively 6 h, 24 h and 48 h post-treatment). The scale is logarithmic. 2-ΔΔCt values were 
obtained following qRT-PCR of TNF and DAD-1 genes. DAD-1 gene was used as reference 
(housekeeping) gene. From qRT-PCR Ct values of DAD-1 and TNF, ΔCt values [Ct (TNF)-
Ct(DAD-1]) were obtained for both uninfected and HSV-1-infected cells (untreated, treated 
with aciclovir, dexamethasone or both). For each condition (untreated, aciclovir, 
dexamethasone or both), ΔΔCt values represented [(ΔCt) HSV+/-treatment - (ΔCt)uninfected]. Data 
were obtained from 3 independent experiments. ANOVA test showed statistical differences 
between the means of the different conditions at 30 h (p<0.05) and 72 h pi (p<0.001) but not 
at 48 h pi (p>0.05). (*): p<0,05 (multiple t-tests). 
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5.2.2.3. The effect of sub-toxic doses of dexamethasone combined with aciclovir in HSV-1-
infected microglial cells 
5.2.2.3.1. The effect of sub-toxic doses of dexamethasone combined with aciclovir on cell 
viability and viral replication in HSV-1-infected microglia 
The effect of 0.5 µM dexamethasone, alone and combined with aciclovir (20 µM) on cell 
viability of HSV-1-infected microglia cells by light microscopy, live cell counting, WST-1 
assay measuring mitochondrial metabolism and qRT-PCR targeting the housekeeping gene 
DAD-1 was also assessed. Once again, the treatment with dexamethasone and/or aciclovir was 
done 24 h post-infection (pi).  
By light microscopy (10 x magnification), 48h post-infection (pi) (24 h pt), no important 
differences in microglia cell viability and morphology could be seen between infected cells 
untreated or treated with aciclovir, dexamethasone or both (fig 5.17). However, at 72 h pi (48 
h pt), at lower magnification (4 x), it was clear that aciclovir alone or combined with 
dexamethasone was similarly and significantly increasing HSV-1-infected microglia cell 
viability (fig 5.18). Despite a less clear effect, dexamethasone alone seemed to increase 
infected microglia cell viability at 48 h pt (72 h pi) (fig 5.18). 
By qRT-PCR, at 48h post-treatment (72 h pi), it was shown that DAD-1 gene expression was 
more elevated in samples from infected microglial cells treated with aciclovir combined or not 
with dexamethasone than in untreated infected cells (p=0.55) (fig 5.19). The administration of 
aciclovir alone or combined to dexamethasone led to similar levels of DAD-1 gene expression. 
Furthermore, at this time, DAD-1 gene expression was not different between samples from 
infected microglial cells treated with dexamethasone alone or untreated.  
The WST-1 assay, measuring mitochondrial metabolic activity, showed a similar profile at 72 
h post-infection (48 h post-treatment) (fig 5.20). At this time point, the treatment with aciclovir 
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alone or combined with dexamethasone but not the administration of dexamethasone alone 
was associated with an increase in mitochondrial activity of microglial cells that was reduced 
following HSV-1-infection (fig 5.20). The levels of mitochondrial activity were very similar 
between infected cells treated with aciclovir alone or combined with dexamethasone. Of note, 
mitochondrial activity was also similar at this time-point between infected microglia cells 
untreated and treated with dexamethasone suggesting that dexamethasone was not detrimental 
for mitochondrial activity in HSV-1-infected microglila cells. 
At the viral replication level, direct qPCR targeting HSV DNA on culture medium of infected 
microglial cells also presented the same dichotomy between cells treated with aciclovir or not 
(fig 5.21). Indeed, there was a significant and similar reduction of culture medium HSV DNA 
abundance among microglia cells infected and treated with aciclovir alone or combined with 
dexamethasone compared to the infected untreated or treated only by dexamethasone (fig 
5.21). 
Altogether, this shows that dexamethasone (0.5 µM) has no positive effect on cell viability or 
viral load in HSV-1-infected microglia cells. These data also suggest that the beneficial effects 
of aciclovir combined to dexamethasone in HSV-1-infected microglial cells on cell viability 
and viral load (decrease in viral load) observed during light microscopy, WST-1 assay, DAD-
1 qRT-PCR and HSV-1 DNA qPCR, similar to the ones due to aciclovir alone, are due to the 
inhibition of HSV-1 replication by aciclovir. However, these experiments showed that the 
administration of dexamethasone (0.5 µM) does not have a negative impact since it does not 
lead to an increase in cell death or higher viral load in HSV-1-infected microglial cells.  
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Figure 5.17. Microscopy pictures of HSV-1-infected microglial cells treated with a sub-
toxic dose of dexamethasone (0.5 µM) alone or combined with aciclovir 48 h post-
infection (24 h post-treatment). HSV-1-infection was done at MOI=0.01. Treatment was 
done with dexamethasone (0.5 µM) and/or aciclovir (20 µM) 24 h post-infection (pi). (A) 
Uninfected microglial cells. Most of the cells have the classic morphological features of 
microglial cells with ovoid or fibroblast-like shape and small ramifications. The confluency is 
around 90-100%. (B) HSV-1-infected microglial cells untreated. Big gaps, evidence of 
HSV-1-associated cell death, can be observed between cells (confluency around 60-70%) and 
a lot of cells are now round. (C) HSV-1-infected microglial cells treated with 
dexamethasone. The cell density is very similar to the one of infected untreated cells (B). (D) 
HSV-1-infected-microglial cells treated with aciclovir. The cell density is very similar to 
the one of infected untreated cells (B). (E) HSV-1-infected-microglial cells treated with 
aciclovir and dexamethasone. The cell density is very similar to the one of infected untreated 
cells (B). 10 x magnification. 
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Figure 5.18. Microscopy pictures of HSV-1-infected microglia treated with a sub-toxic 
dose of dexamethasone (0.5 µM) alone or combined with aciclovir 72 h post-infection (48 
h post-treatment). HSV-1-infection was done at MOI=0.01. Treatment was done with 
dexamethasone (0.5 µM) and/or aciclovir (20 µM) 24h post-infection (pi). (A) Uninfected 
microglia. The confluency is still around 90-100%. (B) HSV-1-infected microglial cells 
untreated. Many gaps have appeared between the cells, the confluency is now approximately 
40-50%. (C) HSV-1-infected microglial cells treated with Dexamethasone. The confluency 
seems higher (60-70%) than in the picture (C). (D) HSV-1-infected-microglia cells treated 
with aciclovir. Only few gaps between cells can be seen (confluency seems around 80-90%). 
(E) HSV-1-infected-microglial cells treated with aciclovir and dexamethasone. The 
picture is similar to the one with aciclovir alone (D), with probably even less gaps between 
cells and slightly higher confluency. 4 x magnification. Scale bar: 125 µm. 
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Figure 5.19. The effect of dexamethasone (0.5 µM) combined with aciclovir on DAD-1 
gene expression in HSV-1-infected microglial cells. HSV-1 infection was done at 
MOI=0.01. The treatment with aciclovir (20 µM) and/or dexamethasone (0.5 µM) was done 
at 24 h pi. The values represent Ct values after qRT-PCR targeting DAD-1. qRT-PCR was 
performed from 1 µg of RNA extracts of uninfected (circles) or untreated infected (unfilled 
squares) or aciclovir-treated infected (squares half-filled in black on the left side) or 
dexamethasone-treated infected (squares half-filled in black on the right side) or 
“dexamethasone+aciclovir”-treated infected microglial cells at 30, 48, 72 h pi.  Data are 
expressed as mean + 95% Confidence Interval (C.I) of 9 replicates from 3 independent 
experiments. ANOVA test showed statistical differences between the means of the different 
conditions at 48 h pi and 72 h pi (p<0.005) but not at 30 h pi (p>0.05). (*): p<0,05; (***) 
p<0.005 (multiple t-tests). 
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Figure 5.20. The effect of dexamethasone (0.5 µM) combined with aciclovir on 
mitochondrial activity in HSV-1-infected microglial cells. HSV-1-infection was done at 
MOI=0.01. The treatment with aciclovir (20 µM) and/or dexamethasone (0.5µM) was done at 
24 h pi. The values represent values of WST-1 activity (absorbance at 450 nm (A450 nm) 
normalised by subtraction of the background (A650 nm)). WST-1 assay has been performed 
in uninfected (circles), untreated infected (unfilled squares) or aciclovir-treated infected 
(squares half-filled in black on the left side) or dexamethasone-treated infected (squares half-
filled in black on the right side) or “dexamethasone+aciclovir”-treated infected (black squares) 
microglial cells at different time-points (0, 24, 30, 48 and 72h pi). Data are expressed as mean 
+ 95% CI of 30 replicates from 3 independent experiments. ANOVA test showed statistical 
differences between the means of the different conditions at 30 h and 72 h pi (p<0.001) but 
not at 48 h pi (p>0.05). (*) p<0.05, (***) p<0.005, (****) p<0.0001 (multiple t-tests).  
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Figure 5.21. The effect of dexamethasone (0.5 µM) combined with aciclovir on HSV DNA 
abundance in culture medium of HSV-1-infected microglial cells. HSV-1-infection was 
done at MOI=0.01. The treatment with aciclovir (20uM) and/or dexamethasone was done at 
24 h pi. The values represent Ct values after HSV DNA qPCR from culture medium of HSV-
1-infected (white) or aciclovir-treated infected (squares half-filled in black on the left side) or 
dexamethasone-treated infected (squares half-filled in black on the right side) or 
“dexamethasone+aciclovir”-treated infected (black squares) microglial cells at 24 (just before 
the treatment), 30, 48 and 72 h pi. Each point represents the mean + 95% CI of data from at 
least 3 independent experiments. Triplicates were used for each point-time in each experiment. 
ANOVA test showed statistical differences between the means of the different conditions at 
30 h (p<0.05), 48 h (p<0.0001) and 72 h pi (p<0.0001) but not at 24 h pi (p>0.05). (*): p<0.05; 
(****): p<0.0001 (multiple t-tests). 
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5.2.2.3.2. The effect of sub-toxic doses of dexamethasone combined with aciclovir on TNF 
relative gene expression in HSV-1-infected microglia cells 
 
In chapter 3, an increase in TNF relative gene expression was observed in microglial cells 
following HSV-1-infection and in chapter 4, I could see that the treatment with aciclovir (20 
µM) decreased TNF relative gene expression in infected microglia at 72 h pi. Here, I assessed 
the impact of the drug dexamethasone (0.5 µM) alone or combined with aciclovir (20uM) on 
TNF relative gene expression in these HSV-1-infected microglial cells.  
At 48 h-72 h pi (24 h-48h post-treatment), there was still an increase in TNF relative gene 
expression in HSV-1-infected microglia treated with dexamethasone co-treated or not with 
aciclovir compared to the uninfected counterparts as observed with all the values much higher 
than one (fig 5.22). At 72 h pi, a significant decrease in TNF relative gene expression could 
be observed in HSV-1-infected microglial cells when treated with aciclovir alone or combined 
with dexamethasone compared to untreated. This was not the case for dexamethasone alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
156 
 
 
 
Figure 5.22. The effect of dexamethasone (0.5 µM) combined with aciclovir on TNF 
relative gene expression in HSV-1-infected microglial cells. HSV-1 infection was done at 
MOI=0.01 in microglial cells. The treatments with aciclovir (20 µM); dexamethasone (0,5 
µM) or both were added at 24 h pi. The data represent TNF relative gene expression expressed 
as mean +/- 95% CI of 2-ΔΔCt values at 30 h, 48 h and 72 h post-infection (respectively 6 h, 24 
h and 48 h post-treatment). The scale is logarithmic. 2-ΔΔCt values were obtained following 
qRT-PCR of TNF and DAD-1 genes. DAD-1 gene was used as reference (housekeeping) gene. 
From qRT-PCR Ct values of DAD-1 and TNF, ΔCt values [Ct (TNF)-Ct(DAD-1]) were 
obtained for both uninfected and HSV-1-infected cells (untreated, treated with aciclovir, 
dexamethasone or both). For each condition (untreated, aciclovir, dexamethasone or both), 
ΔΔCt values represented [(ΔCt) HSV+/-treatment - (ΔCt)uninfected]. Data were obtained from 3 
independent experiments. ANOVA test showed statistical differences at 72h pi (p<0.0001) but 
not at 30 h (p>0.05) and 48 h pi (p>0.05) between the means of the different conditions. (***): 
p<0,001 (multiple t-tests). 
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5.3. Discussion 
Herpes Simplex Encephalitis (HSE) pathogenesis is due to both HSV replication and 
subsequent detrimental immune responses71, 94, 93, 131, 91, 133. However, the therapy that is 
clinically used is the antiviral aciclovir. Hence, combining an anti-inflammatory drug with 
aciclovir may improve HSE patient outcome. Several clinical studies on HSE patients have 
already shown that some immunosuppressive drugs belonging to the glucocorticoids, 
including dexamethasone, were predictors of good outcome and reduced oedema in adults and 
decreased morbidity in children158, 132, 160.  However, more data especially from bigger clinical 
studies, are needed to validate the positive impact of dexamethasone as HSE adjuvant therapy. 
Before this PhD project, there were no in vitro data detailing the effect of dexamethasone on 
specific HSV-1-infected-human brain cell type such as human neuron-like cells 
(neuroblastomas) or microglia cells. Therefore, it was of main interest to assess the effect of 
dexamethasone combined to aciclovir on cell survival and viral load in HSV-1-infected 
neuroblastoma and microglial cells.  
Firstly, dexamethasone toxicity was studied by light microscopy and the LD50, Lethal Dose 
50% (dose for which a chemical induces 50% of cell death in a tissue) was valued at 0.5-1 mM 
in neuroblastoma cells, microglia and primary astrocytes (fig 5.2-5.8). Hence, below 0.5 mM, 
dexamethasone was not seen as toxic for these brain cells. One study has concluded that the 
brain tissue concentration of dexamethasone used to effectively treat patients suffering from 
glioblastomas was one thousand time lower than the LD50 from in vitro studies161. Another 
study investigating an in vitro model of bacterial meningitis, showed that a concentration of 
dexamethasone of 0.5 µM had a beneficial effect on a LPS-challenged co-culture of microglia 
and astrocytes156. Altogether, a 0.5 µM concentration of dexamethasone appeared to be the 
most relevant dose to use for assessing the effect of this drug, combined with aciclovir, in 
HSV-1-infected brain neuroblastoma and microglial cells. The dose of dexamethasone used in 
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HSE clinical studies is around 40 mg/day159. This matches with a concentration of 20 µM in 
the bloodstream (depending on the blood brain barrier permeability, only proportion of this 20 
µM of dexamethasone will penetrate the brain parenchyma). 
In light microscopy, an apparent increase in infected neuroblastoma (at 48 h and 72 h pi) and 
microglial cell (at 72 h pi) viability could be observed after treatment with aciclovir alone or 
combined with dexamethasone (0.5 µM) (but not with dexamethasone alone) (fig 5.9-10 and 
fig 5.18). Crucially, dexamethasone alone (0.5 µM) was not detrimental and did not induce 
more visible cell damage in infected microglial (at 72 h pi) and neuroblastoma cells (at 48 h 
and 72h pi) (fig 5.9-10 and fig 5.18).  
Dexamethasone (0.5 µM) alone had no impact in mitochondrial activity, proxy marker of cell 
viability, following HSV-1-infection, both in neuroblastoma and microglial cells as observed 
using WST-1-assays (fig 5.13 and fig 5.20). Nevertheless, dexamethasone (0.5 µM) combined 
with aciclovir (20 µM) was associated with an increase in mitochondrial metabolism similar 
to that induced by aciclovir alone both in HSV-1-infected neuroblastomas at 48 h and 72 h 
post-infection (pi) (24 h and 48 h pt) and in infected microglia cells at 72 h pi (48 h pt) 
(p<0.0001).  
In HSV-1-infected neuroblastoma cells, these WST-1 results were confirmed by another 
quantitative technique assessing cell viability at 72 h pi (48 h pt) using the software “ImageJ” 
to measure the area of attached cells from microscopy pictures (fig 5.11). Indeed, bigger 
attached cell areas were significantly measured at 72 h pi (48 h pt) for infected neuroblastoma 
cells treated with aciclovir alone or combined to dexamethasone but not for infected cells 
untreated or treated with dexamethasone alone (p<0.05). The issue of sensibility of qRT-PCR 
targeting DAD-1 had already been raised in the previous chapter and here again, no differences 
could be seen in DAD-1 Ct values between HSV-1-infected neuroblastoma cells untreated or 
treated with dexamethasone, aciclovir or both (fig 5.12).  
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In HSV-1-infected microglial cells, the WST-1 results showing a microglia cell viability 
increase due to the treatments “aciclovir/dexamethasone” or aciclovir alone 72 h after HSV-
1-infection (48 h pt) was confirmed by qRT-PCR targeting DAD-1 (p=0.055) despite the low 
sensitivity of this technique (fig 5.19). Unfortunately, there were not enough 4 x magnification 
microscope pictures of quality to use the software “ImageJ” for quantification of attached 
microglia cell areas. 
In an in vivo mice model of HSE, a decrease in brain inflammation was observed following 
dexamethasone administration137. Another mice in vivo study showed a decrease in MRI brain 
abnormalities of HSE affected mice with the dual treatment aciclovir and the glucocorticoid 
methylprednisolone compared to aciclovir therapy alone131. Moreover, few small clinical and 
animal studies reported a beneficial impact of the administration of glucocorticoids as adjuvant 
therapy to HSE158, 132, 128, 129, 131. The administration of the glucocorticoid dexamethasone in 
my in vitro models of HSE in single culture did not show such beneficial effects on brain cell 
viability although not detrimental either. More complex HSE in vitro models associating 
different brain cells, a longer time of infection (using lower MOI) would be interesting to be 
closer to in vivo conditions and reassess dexamethasone effect. 
Following HSV-1-infection in primary astrocytes, changes in mitochondrial activity coded by 
mitochondrial genes have been shown early and prior to nuclear gene expression-coded 
modifications and cell death63. In astrocytes, this may suggest overall that HSV-1 firstly leads 
to changes in mitochondria activity that could be detected by WST-1 assay and afterwards 
other metabolic changes causing cell death that can be detected by microscopy or qRT-PCR 
targeting DAD-1. This may also be the case for neuroblastoma cells as WST-1 assay 
demonstrated an increase in neuroblastoma mitochondrial activity as early as 48 h pi (24 h pt) 
while cell viability loss could not be properly seen before 72 h pi (48 h pt) by light microscopy 
analysis. 
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At the level of HSV load, it was also shown that aciclovir and aciclovir combined with 
dexamethasone but not dexamethasone alone were associated with a decrease in viral load in 
HSV-1-infected neuroblastoma and microglial cells (fig 5.15 and 5.21 respectively). This 
suggests that the combination aciclovir/dexamethasone has an inhibitory effect on HSV-1 load 
only driven by the action of aciclovir. Crucially, dexamethasone alone did not induce any 
exacerbation of HSV-1 load either brain cell types. This is in agreement with a study of 
Thompson et al., demonstrating that dexamethasone did not exacerbate HSV-1 replication and 
dissemination in HSE-affected rat (infection into the cervical vagus nerve with 105 plaque-
forming units (pfu)) brain both when administered alone or combined with aciclovir162. 
Altogether, the results of this chapter revealed that (i) the combination 
aciclovir/dexamethasone had a positive impact on cell survival of HSV-1-infected 
neuroblastoma and microglial cells probably only due to the inhibitory effect of aciclovir on 
viral load and that (ii) the addition of dexamethasone did not lead to any negative impact on 
either brain cell viability or viral load in these models. The latter point is clinically interesting 
as the addition of dexamethasone or other anti-inflammatory drugs for treatment of viruses-
infected brain cells is quite controversial. Indeed, there is a fear by some clinicians that the 
administration of such anti-inflammatory drugs would exacerbate viral replication and hence 
brain cell damage.  
Interestingly, it has also been shown that dexamethasone alone, or combined with aciclovir, 
maintained high levels of TNF relative gene expression in HSV-1-infected microglia and 
neuoblastoma cells compared to the basal level in uninfected (untreated) cells (fig 5.16 and fig 
5.22). However, the comparison of TNF relative gene expression between infected cells 
untreated and infected cells treated with dexamethasone, aciclovir or both revealed differences 
between brain cell types.  
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In HSV-1-infected neuroblastoma cells, dexamethasone alone, or combined with aciclovir did 
not lead to any significant difference in TNF relative gene expression compared to the 
(infected) untreated at 48-72 h pi (24-48 h pt) (fig 5.16). However, aciclovir alone was 
associated, at 72 h pi (48 h post-treatment), with a significant increase in TNF relative gene 
expression in infected neuroblastoma cells. Both aciclovir and aciclovir combined to 
dexamethasone increased cell viability, and in a similar way, following HSV-1 infection. 
However, they differently influenced TNF relative gene expression. This suggests that TNF 
relative gene expression does not seem to be a useful predictor of HSV-1-infected 
neuroblastoma cell viability/death in my in vitro model.  
In microglial cells, aciclovir alone and combined to dexamethasone was associated with a 
decrease in TNF relative gene expression in infected cells compared to infected cells untreated 
at 72 h pi (fig 5.22). At this same time-point, dexamethasone alone seemed to induce a slight 
but not significant increase in TNF relative gene expression in infected microglia cells. Of 
note, another in vitro study using HSV-1-infected murine microglial cells showed that 
dexamethasone induced a decrease in TNF-α protein release in HSV-1-infected BV2 microglia 
cell supernatant137. This difference with my results may be explained either by the fact human 
microglial cells were not used in this study or because a decrease in protein release could lead 
to a feedback-loop increasing TNF gene expression.  
To conclude, dexamethasone has no additive benefit with aciclovir in my model. Crucially, it 
is not harmful in either HSV-1-infected neuroblastoma or microglial cells both in terms of cell 
viability and HSV-1 load. The latter point may be another argument for clinicians to be less 
worried about administrating dexamethasone in combination with aciclovir in HSE patients. 
However, its action has still to be tested in more complex systems, closer to in vivo conditions 
of brains affected by HSE. Such systems could consist of several HSV-1-infected brain cells 
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simultaneously and include peripheral immune cells such as peripheral macrophages and T-
cell.  
In the next chapter, another candidate as adjuvant therapy to aciclovir in HSE, the anti-TNF 
Infliximab, was assessed in HSV-1-infected neuroblastoma and microglial cells. 
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Chapter 6 The effect of Infliximab on HSV-1 infection in human 
brain cells 
6.1. Introduction  
Herpes Simplex Encephalitis (HSE) is a lethal disease characterised by brain inflammation 
due to both HSV-induce damage and subsequent detrimental immune responses71, 94, 131, 93, 130. 
The gold standard therapy is the antiviral drug aciclovir. Aciclovir only targets viral replication 
and has limitations as a treatment as demonstrated by the fatal outcome in 8-20% of HSE 
patients and a high percentage of neurological sequelae among survivors163, 127, 53, 39. A few 
small clinical studies and in vivo/in vitro works have suggested that the use of anti-
inflammatory drugs, especially glucocorticoids, as adjuvant therapy to aciclovir in HSE could 
be potentially beneficial for patients132, 115, 130, 131, 133. This effect could possibly be due to their 
inhibitory action on this detrimental immune response132, 115, 130, 131, 133. However, this effect 
has not been confirmed in clinical trials or verified in in vitro models of HSE using different 
human brain cell types such as neuroblastoma or microglial cells. In the previous chapter, I 
have assessed the effect of the glucocorticoid drug dexamethasone combined with aciclovir 
on cell viability, viral replication, TNF gene expression and mitochondrial activity in these 
HSV-1-infected brain cells. I found that adding dexamethasone to aciclovir did not have any 
impact on cell survival, mitochondrial activity or viral replication in both HSV-1-infected 
neuroblastoma and microglial cells.  
TNF-α protein levels have been found to be elevated in the cerebrospinal fluid (CSF) of HSE 
patients71. High CSF TNF levels are observed during the convalescence stage of illness. These 
findings suggest a detrimental immune response may persist after the acute phase and 
contributes to neurological sequelae. Furthermore, in chapter 3, I saw a significant increase in 
TNF relative gene expression but not in TNF protein extra-cellular production at 24 h-72 h 
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post-infection (pi) in human microglial and neuroblastoma cells following HSV-1 infection at 
MOI=0.01. However, an in vitro study of Lokensgard et al. using a higher MOI (MOI=1) 
showed that a high concentration of TNF proteins was released by purified human foetal 
microglia, but not by astrocytes or neurons 24 h-72 h after HSV-1-infection85. In this same 
study, HSV-1 was also associated with a significant increase in TNF mRNA expression 
(observed by RNase protein assay) in human foetal microglia from 3 to 24 h post-infection 
(pi) and peaking and 8 h pi. Lokensgard et al. also showed, in another study, by real-time 
qPCR a 600-fold increase in TNF gene expression following HSV-1 infection in murine 
microglia cells at 5 h pi and at MOI=286.  These two studies used different microglial cells 
(murine and human foetal), a higher MOI and earlier time-points than the ones I have used in 
my experiments making direct comparisons difficult. However, in common, with my 
experiments, they all showed an increase in TNF gene expression following HSV-1-infection 
of microglial cells. Altogether, TNF expression could be associated with a HSV-1-induced 
pro-inflammatory response especially in microglia. It may represent a target for an adjuvant 
therapy to use combined with aciclovir to improve HSE treatment. Crucially, a murine in vivo 
study showed that combining the antiviral valacyclovir and the anti-TNF etanercept, 
significantly increased mice survival after HSV-1 infection compared to untreated 
counterparts or mice treated with only one of these two drugs 133.  
TNF combined with aciclovir has never been studied in clinical or in vitro studies using human 
brain cells. In this new chapter, an anti-inflammatory drug from the TNF inhibitors family, 
infliximab, was assessed as adjuvant therapy to aciclovir in in vitro models of HSE. TNF 
inhibitors such as infliximab (but also etanercept, adalimumab and certolizumab) are used to 
treat a wide range of inflammatory conditions. These inflammatory conditions include 
rheumatoid arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis etc. 
Of note, a few clinical case reports have suggested HSE could sometimes be induced by TNF 
inhibitor treatments in patients suffering from rheumatologic disorders164 165. This may be due 
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to a potential effect of TNF inhibitors on reactivating HSV from latency within nerves. 
However, using TNF inhibitors to treat HSE once inflammation has already affected the brain 
could result in different observations and may be beneficial. 
Infliximab targets not only soluble TNFα but also transmembrane TNFα. As a result, 
transmembrane TNF, which was not measured by the ELISA tests performed in the chapter 3, 
may be increased within the membrane of neuroblastoma and microglial cells following HSV-
1-infection..  
The main goal of chapter 6 is to determine if infliximab alone or combined with aciclovir has 
an impact on cell survival, mitochondrial metabolism, viral load and TNF gene expression in 
both HSV-1-infected-microglial and neuroblastoma cells compared to infected cells treated by 
aciclovir alone or untreated. 
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Figure 6.1. Experimental design for assessing the effect of Infliximab (IFX) alone or 
combined to aciclovir (ACV) in HSV-1-infected human neuroblastoma and microglial 
cells. (A) Brain cell populations used. (B) Techniques performed on brain cells following 
HSV-1-infection. (C) Technique performed on brain cell culture medium following HSV-1-
infection. 
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6.2. Results 
6.2.1. Effect of infliximab combined to aciclovir in HSV-1-infected neuroblastoma cells 
6.2.1.1. Infliximab alone (from 0.5 mg/ml) partially rescues HSV-1-infected neuroblastoma 
cells  
Firstly, the effect of infliximab alone at a wide range of concentrations (0.01 to 1 mg/ml) was 
assessed in HSV-1-infected neuroblastoma cells by light microscopy. From 0.01 mg/ml (data 
not shown) to 0.1 mg/ml (fig 6.2C), there was no improvement in infected cell survival in 
comparison to infected cells untreated at 48 h post-treatment (48 h pt). However, infliximab 
at 0.5 mg/ml (fig 6.2D) and 1 mg/ml (fig 6.2E) was associated with a rise of HSV-1-infected-
neuroblastoma viability as shown by the visible increase in the proportion of live cell still 
attached at this same time-point. Since similar beneficial effects were seen for infliximab at 
both concentrations, it was decided to continue experiments using the lowest concentration 
(0.5 mg/ml). In uninfected cells, no signs of toxicity could be observed at any concentrations 
of infliximab tested (up to 1 mg/ml) (data not shown).  
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Figure 6.2. Microscopy observations of HSV-1-infected neuroblastoma cells treated with 
various doses of infliximab at 72 h post-infection (48 h post-treatment). HSV-1-infection 
was done at MOI=0.01. Treatment with infliximab was performed at different concentrations 
(0.05-1 mg/ml) 24 h post-infection (pi). Pictures were taken at 72 h pi (48 h pt) and are 
representative of multiple replicates for each condition. (A) HSV-1-infected neuroblastoma 
cells untreated. Extensive live cell loss has happened, only few live cells are still attached 
(around 10%). (B) HSV-1-infected neuroblastoma cells treated with infliximab at 0.05 
mg/ml. Extensive live cell loss has happened, only few live cells are still attached (around 
10%). (C) HSV-1-infected neuroblastoma cells treated with infliximab at 0.1 mg/ml. 
Extensive live cell loss has happened, only few live cells are still attached (around 10%). (D) 
HSV-1-infected neuroblastoma cells treated with infliximab at 0.5 mg/ml. More cells 
survived (around 40%) compared to those in pictures (A-C). (E) HSV-1-infected 
neuroblastoma cells treated with infliximab at 1 mg/ml. More cells survived (around 50%) 
compared to those in pictures (A-C). 4 x magnification. Scale bar: 125 µm. 
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6.2.1.2. Effect of infliximab alone and combined with aciclovir on TNF gene expression in 
HSV-1-infected neuroblastoma cells 
In chapter 3, an increase in TNF relative gene expression was observed in neuroblastoma cells 
following HSV-1-infection. In chapter 4, treatment with aciclovir (20 µM) increased TNF 
relative gene expression in infected neuroblastoma cells beyond that seen in HSV-1-infected 
cells alone (72 h pi). Here, I have assessed the impact of the anti-TNF drug infliximab (0.5 
mg/ml) alone or combined with aciclovir (20 µM) on TNF relative gene expression in HSV-
1-infected neuroblastoma cells. TNF relative gene expression is based on the TNF absolute 
gene expression (data non shown) normalised by DAD-1 absolute gene expression (fig 6.3). 
Of note, there was still an increase in TNF relative gene expression in HSV-1-infected 
neuroblastoma cells treated with infliximab co-treated or not with aciclovir compared to the 
uninfected counterparts as observed with all the values much higher than one (30-72 h pi) (fig 
6.4).  
This increase in TNF relative gene expression compared to uninfected was quite similar 
between HSV-1-infected neuroblastoma cells untreated, treated with infliximab, aciclovir or 
both at 30 h pi (6 h pt) and 48 h pi (24 h pt). At 72 h pi, in infected neuroblastoma cells, 
aciclovir led to a higher increase in TNF relative gene expression compared to the other 
treatments (p<0.05). 
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Figure 6.3. The effect of infliximab alone and combined with aciclovir on DAD-1 absolute 
gene expression in HSV-1-infected neuroblastoma cells. HSV-1 infection was done at 
MOI=0.01. Treatment with aciclovir (20 µM) and/or infliximab (0.5 mg/ml) was done at 24 h 
pi. Absolute DAD-1 gene expression in uninfected (circles) or infected untreated (unfilled 
squares) or aciclovir-treated infected (squares half-filled in black on the left side) or 
infliximab-treated infected (squares half-filled in black on the right side) or 
“infliximab+aciclovir”-treated infected (black squares) neuroblastoma cells at 30, 48 and 72 h 
pi. Data are expressed as the mean of qRT-PCR DAD-1 Ct values + 95% CI and were obtained 
from 3 independent experiments, each condition being assessed in triplicate. ANOVA test 
statistically showed differences between the means of the different conditions at 48h 
(p<0.0001) and 72h pi (p<0.0001) but not at 30 h (p>0.05). (*) p<0.05; (***) p<0.005 
(multiple t-tests).  
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Figure 6.4. The effect of infliximab (0.5 mg/ml) alone or combined with aciclovir on TNF 
relative gene expression in HSV-1-infected neuroblastoma cells. HSV-1 infection was done 
at MOI=0.01 in neuroblastoma cells. The treatments with aciclovir (20 µM); infliximab (0,5 
mg/ml) or both were added at 24 h pi. The data represent TNF relative gene expression 
expressed as mean +/- 95% CI of 2-ΔΔCt values at 30 h, 48 h and 72 h post-infection 
(respectively 6 h, 24 h and 48 h post-treatment). The scale is logarithmic. 2-ΔΔCt values were 
obtained following qRT-PCR of TNF and DAD-1 genes. DAD-1 gene was used as reference 
(housekeeping) gene. From qRT-PCR Ct values of DAD-1 and TNF, ΔCt values [Ct (TNF)-
Ct(DAD-1]) were obtained for both uninfected and HSV-1-infected cells (untreated, treated 
with aciclovir, infliximab or both). For each condition (untreated, aciclovir, infliximab or 
both), ΔΔCt values represented [(ΔCt) HSV+/-treatment - (ΔCt)uninfected]. ANOVA test statistically 
showed significant differences between the means of the different conditions at 72 h pi 
(p<0.005) but not at 30 h (p>0.05) and 48 h pi (p>0.05). Data were obtained from 3 
independent experiments. (*): p<0,05 (multiple t-tests). 
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6.2.1.3. Effect of infliximab alone and combined with aciclovir on cell viability, mitochondrial 
metabolism and viral replication in HSV-1-infected neuroblastoma cells 
Microscopy studies confirmed that infliximab at 0.5 mg/ml alone led to an increased cell 
survival of HSV-1-infected neuroblastoma cells both at 48 h and 72 h post-infection (24 h and 
48 h post-treatment (pt)) (fig 6.5 and 6.6). The same beneficial effect was also noticed with 
aciclovir (20 µM) alone at both time-points confirming the results of the chapter 4. However, 
at 72 h pi, treatment with aciclovir increased infected cell survival at a higher level than 
infliximab therapy alone (fig 6.6). Following HSV-1-infection, a higher proportion of cells 
with uninfected neuroblastoma cell features, such as fibroblast-like morphology, could be 
observed in presence of infliximab and/or aciclovir but not in the untreated infected 
populations at 48 h pi (fig 6.5).  Finally, the impact of infliximab combined with aciclovir on 
HSV-1-infected neuroblastoma cells appeared similar to that of aciclovir alone. Co-treatment 
led to (i) an increase in infected neuroblastoma viability similar to that observed after aciclovir 
monotherapy at 48 h and 72 h pi; and (ii) a partial preservation of fibroblast-like morphology 
in the infected cells at 48 h pi (fig 6.5 and 6.6). 
Analysing multiple microscopy pictures at 4 x magnification using the software “ImageJ” also 
showed that the attached cell area was significantly bigger in infected cells treated by aciclovir, 
infliximab or both than in infected cells untreated at 48 h pi (fig 6.7) (p<0.05 or p<0.01). At 
72 h pi, only HSV-1-infected neuroblastomas treated with aciclovir alone or combined with 
infliximab, but not infected cells treated with infliximab alone (although the same trend was 
also observed), presented significantly bigger areas of attached cells compared to infected 
untreated cells following statistical analysis (fig6.7) (p<0.05).  
At 48-72 h pi, treatment with aciclovir, infliximab or combination of both, was shown to 
significantly increase mitochondrial activity of HSV-1-infected neuroblastoma cells, as 
demonstrated by the WST-1 assay (fig 6.8). However, this was much more significant with 
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aciclovir alone or combined with infliximab than with infliximab monotherapy (p<0.0001). 
Furthermore, dual therapy did not lead to a higher WST-1 activity than aciclovir alone, but a 
similar one.   
Surprisingly, a direct HSV DNA qPCR from culture medium of infected neuroblastoma cells 
showed that infliximab alone or combined to aciclovir but not aciclovir alone was associated 
with a significant decrease in HSV DNA abundance (6-48 h pt) (fig 6.9) (p<0.001 or 
p<0.0001). The decrease in viral load was similar between cells treated with infliximab alone 
or combined with aciclovir.  
Altogether, this suggests that infliximab increases cell viability and mitochondrial metabolism 
following HSV-1-infection, possibly by reducing viral load. However, although its antiviral 
effect seems to be more rapid than aciclovir in this brain cell type, aciclovir led to a much 
higher levels of mitochondrial activity and to a higher survival of HSV-1-infected 
neuroblastoma cells compared to the effect of infliximab alone. Finally, the combination 
“aciclovir/infliximab” led to similar effects than aciclovir alone on cell survival and 
mitochondrial metabolism (fig 6.5-6.8). 
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Figure 6.5. Microscopy pictures of HSV-1-infected neuroblastoma cells treated with 
infliximab (0.5 mg/ml) alone or combined with aciclovir at 48 h post-infection (24 h post-
treatment). HSV-1-infection was done at MOI=0.01. Treatment was done with infliximab 
(0.5 mg/ml), aciclovir (20 µM) and infliximab combined with aciclovir 24 h post-infection 
(pi). Pictures were taken 48 h pi (24 h post-treatment). (A) HSV-1-infected neuroblastoma 
cells untreated. Big gaps have appeared in the monolayer (around 60% confluent) and all 
cells look round. (B) HSV-1-infected neuroblastoma cells treated with infliximab. Only a 
few small gaps have appeared (around 80% confluent) and a lot of the cells still have typical 
neuroblastoma morphologic features. (C) HSV-1-infected neuroblastoma cells treated with 
aciclovir. Similar to picture (B). (D) HSV-1-infected neuroblastoma cells treated with 
infliximab and aciclovir Similar to pictures (B-C). 10 x magnification. Scale bar: 50 µm. 
A B 
C D 
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Figure 6.6. Microscopy pictures of HSV-1-infected neuroblastoma cells treated with 
infliximab (0.5 mg/ml) alone or combined with aciclovir at 72 h post-infection (48 h post-
treatment). HSV-1-infection was done at MOI=0.01. Treatment was done with infliximab 
(0.5 mg/ml), aciclovir (20 µM) and infliximab combined with aciclovir 24 h post-infection 
(pi). Pictures were taken 72 h post-infection (48 h post-treatment). (A) HSV-1-infected 
neuroblastoma cells untreated. The majority of cells have died and detached (around 20-
30% confluency). All cells look round. (B) HSV-1-infected neuroblastoma cells treated 
with infliximab. More cells survived compared to those in picture (A) (around 50-60% 
confluency). All cells look round. (C) HSV-1-infected neuroblastoma cells treated with 
aciclovir. All cells look round but the majority of cells are still alive (around 90% confluency). 
(D) HSV-1-infected neuroblastoma cells treated with infliximab and aciclovir. All cells 
look round but the majority of cells are still alive (around 80% confluency). 4 x magnification. 
Scale bar: 50 µm. 
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Figure 6.7. The effect of infliximab alone (0.5mg/ml) or combined with aciclovir on 
attached cell area of HSV-1-infected neuroblastoma cell microscopy pictures at 72 h post-
infection (48 h post-treatment). HSV-1-infection was done at MOI=0.01. Treatment was 
done with infliximab (0.5 mg/ml), aciclovir (20 µM) and infliximab combined with aciclovir 
24h post-infection (pi). Areas of attached cells were measured by the software ImageJ from 
pictures taken at 48 h and 72 h post-infection (24 h and 48 h pt respectively) of neuroblastoma 
cells uninfected (circles), infected untreated (white squares), infected treated with aciclovir 
(squares half-filled in black on the left side), infected treated with infliximab (squares half-
filled in black on the right side) or infected treated with the combination 
“aciclovir+infliximab” (black squares). Data are expressed as mean of the area of live cells 
+95% CI and were obtained as described in the chapter 2 (Materials and Methods). At 48 h pi 
(24 h post-treatment), one picture for uninfected cells, three for infected untreated cells, three 
for infected cells treated with aciclovir, three for infected cells treated with infliximab and 
three for infected cells treated with both aciclovir and infliximab were analysed. At 72 h pi (48 
h post-treatment), nine pictures for uninfected cells, twenty-four for infected untreated cells, 
twenty-two pictures for infected cells treated with aciclovir, twenty-one pictures for infected 
cells treated with infliximab and nineteen pictures for infected cells treated with both aciclovir 
and infliximab were analysed. The pictures were representative of 3 independent experiments. 
ANOVA test statistically showed significant differences between the means of the different 
conditions at 72 h pi (48 h pt)(p<0.001). (*) p<0.05; (**) p<0.01, (***) p<0.005, (****) 
p<0.0001 (multiple t-tests).  
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Figure 6.8. The effect of infliximab (0.5 mg/ml) alone and combined with aciclovir on the 
mitochondrial metabolism (WST-1 assay) of HSV-1-infected neuroblastoma cells. HSV-
1 infection was done at MOI=0.01. The treatment with aciclovir (20 µM), infliximab (0.5 
mg/ml) or both was done at 24 h pi. The values represent WST-1 activity (absorbance at 450 
nm (A450 nm) normalised by subtraction of the background (A650 nm) after WST-1 addition). 
WST-1 assay has been performed in uninfected (circles), untreated infected (unfilled squares) 
or aciclovir-treated infected (squares half-filled in black on the left side) or infliximab-treated 
infected (squares half-filled in black on the right side) or “infliximab+aciclovir”-treated 
infected (black squares) neuroblastoma cells at different time-points (0, 24, 30, 48, 72 h pi). 
Data are expressed as the mean + 95% CI of 30 replicates from 3 independent experiments. 
ANOVA test showed statistical differences between the means of the different conditions for 
all time-points tested: 30 h, 48 h and 72 h pi (p<0.0001). X= (***) p<0.005; (****) p<0.001 
(multiple t-tests).  
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Figure 6.9. The effect of infliximab (0.5 mg/ml) alone and combined with aciclovir on 
HSV DNA abundance in HSV-1-infected neuroblastoma cell culture medium. HSV-1-
infection was done at MOI=0.01. The treatment with aciclovir (20 µM), infliximab (0.5 
mg/ml) or both was done at 24 h pi. The values represent Ct values after HSV DNA qPCR 
from culture medium of HSV-1-infected (white) or aciclovir-treated infected (squares half-
filled in black on the left side) or infliximab-treated infected (squares half-filled in black on 
the right side) or “infliximab+aciclovir”-treated infected neuroblastoma cells at 24 (just before 
the treatment), 30, 48 and 72 h pi (0, 6, 24 and 48 h post-treatment respectively). Each point 
represents the mean + 95% CI of data from at least 3 independent experiments. Triplicates 
were used for each time-point in each experiment. ANOVA test showed statistical differences 
between the means of the different conditions at 30 h (p<0,0001), 48 h pi (p<0,0001) and 72 
h pi (p<0.005) but not at 24 h pi (p>0.05). (*) p<0.05, (***) p<0.005, (****) p<0.0001 
(multiple t-tests). 
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6.2.2. Effect of infliximab combined to aciclovir in HSV-1-infected microglial cells 
 6.2.2.1. Effect of infliximab alone and combined with aciclovir on TNF gene expression in 
HSV-1-infected microglial cells 
In chapter 3, an increase in TNF relative gene expression was observed in microglial cells 
following HSV-1-infection and in chapter 4, I could observe that treatment with aciclovir (20 
µM) decreased TNF relative gene expression in infected microglia at 72 h pi. Here, I assessed 
the impact of the drug infliximab (0.5 mg/ml) alone or combined with aciclovir (20 µM) on 
TNF relative gene expression in HSV-1-infected microglial cells. TNF relative gene 
expression is based on TNF absolute gene expression (data non shown) normalised by DAD-
1 absolute gene expression (fig 6.10) 
At 48 h and 72 h pi, there was an increase in TNF relative gene expression in HSV-1-infected 
microglial cells treated with aciclovir, infliximab alone, or combined with aciclovir compared 
to the uninfected counterparts as observed with all the values superior to one (fig 6.11). At 72 
h pi (48 h pt), aciclovir alone (p<0.005) and combined with infliximab (p<0.005) were 
associated with a reduced TNF relative gene expression in infected cells while infliximab 
alone was associated with a slight but not significant increase (fig 6.11).  
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Figure 6.10. The effect of infliximab alone (0.5 mg/ml) and combined with aciclovir on 
DAD-1 absolute gene expression in HSV-1-infected microglial cells. HSV-1 infection was 
done at MOI=0.01. Treatment with aciclovir (20 µM) and/or infliximab (0.5 mg/ml) was done 
at 24 h pi. Absolute DAD-1 gene expression in uninfected (circles) or infected untreated 
(unfilled squares) or aciclovir-treated infected (squares half-filled in black on the left side) or 
infliximab-treated infected (squares half-filled in black on the right side) or 
“infliximab+aciclovir”-treated infected (black squares) microglial cells at 30, 48 and 72 h pi. 
Data are expressed as the mean of qRT-PCR DAD-1 Ct values + 95% CI and were obtained 
from 3 independent experiments, each condition being assessed in triplicate. ANOVA test 
statistically showed significant differences between the means of the different conditions at 48 
h and 72 h pi (p<0.005) but not at 30 h (p>0.05). (***) p<0.005 (multiple t-tests).  
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Figure 6.11. The effect of infliximab (0.5 mg/ml) alone and combined with aciclovir on 
TNF relative gene expression in HSV-1-infected microglial cells. HSV-1 infection was 
done at MOI=0.01 in microglial cells. The treatments with aciclovir (20 µM); infliximab (0,5 
mg/ml) or both were added at 24 h pi. The data represent TNF relative gene expression 
expressed as mean +/- 95% CI of 2-ΔΔCt values at 30 h, 48 h and 72 h post-infection 
(respectively 6 h, 24 h and 48 h post-treatment). The scale is logarithmic. 2-ΔΔCt values were 
obtained following qRT-PCR of TNF and DAD-1 genes. DAD-1 gene was used as reference 
(housekeeping) gene. From qRT-PCR Ct values of DAD-1 and TNF, ΔCt values [Ct (TNF)-
Ct(DAD-1]) were obtained for both uninfected and HSV-1-infected cells (untreated, treated 
with aciclovir, infliximab or both). For each condition (untreated, aciclovir, infliximab or 
both), ΔΔCt values represented [(ΔCt) HSV+/-treatment - (ΔCt)uninfected]. ANOVA test showed 
statistical differences at 72h pi (p<0.0001) but not at 30 h (p>0.05) and 48 h pi (p>0.05) 
between the means of the different conditions. Data were obtained from 3 independent 
experiments. (*): p<0.05;(**): p<0.005; (***): p<0.0001 (multiple t-tests). 
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6.2.2.2. Effect of infliximab alone or combined with aciclovir on cell viability, mitochondrial 
activity and viral replication in HSV-1-infected microglial cells 
The dose of infliximab used to treat HSV-1 infected microglial cells was 0.5 mg/ml as done 
in neuroblastoma cells. By light microscopy, like for neuroblastoma cells, it was shown that 
infliximab, aciclovir (20 µM) and infliximab combined with aciclovir increased HSV-1-
infected microglial cell viability at both 48 and 72 h post-infection (pi) (24 and 48 h post-
treatment (pt)) (fig 6.12-13). Indeed, all these treatments led to more live infected cells 
attached to the plate compared to the infected cells untreated. This trend was confirmed by the 
analysis of attached cell area performed by using the software “ImageJ” on several 4 x 
magnification microscopy pictures for each conditions (fig 6.14). It was shown that the area 
of live microglia cells per picture was approximately 84.5% for uninfected, 52.6% for infected 
untreated, 78.7% for infected cells treated with aciclovir, 66.2% for infected cells treated with 
infliximab and 78.2% for infected cells treated with both infliximab and aciclovir.  
WST-1 assays demonstrated that the decrease in mitochondrial activity in microglia cells 
following HSV-1 infection and observed at 72 h post-infection (48 h post treatment) could be 
significantly increased by aciclovir (p<0.005) and infliximab (p<0.05) (fig 6.15). The same 
trend was observed with the combination of both therapies, but this was not statistically 
significant (p=0.076) (fig 6.15).  
Direct HSV DNA qPCR from culture medium of HSV-1-infected microglial cells untreated 
or treated showed that infliximab alone or combined to aciclovir but not aciclovir alone was 
associated with a significant decrease in viral genome detection at 30 h post-infection (pi) (6h 
post-treatment (pt)) (fig6.16) (p<0.0001). At 48 h and 72 h pi, the administration of infliximab, 
aciclovir and both led to a decrease in HSV-1 DNA abundance compared to infected cells 
untreated (p<0.0001). Interestingly, at 48 h and 72 h pi (24 h and 48 h pt) the most important 
decrease in viral load was observed for the co-treatment infliximab/aciclovir (p<0.005 or 
  
 
183 
 
p<0.0001). Of note, at 72 h pi (48 h pt), viral load was lower in culture medium of infected 
microglia cells treated with aciclovir alone compared to that in culture medium of cells treated 
with infliximab alone (p<0.0001). This suggests that the potential antiviral effect of infliximab 
in microglial cells is faster to act, but shorter-lived than that due to aciclovir.  
As in the case for neuroblastoma  cells, infliximab alone has been shown to increase both cell 
survival and mitochondrial metabolism and decrease culture medium viral load following 
HSV-1-infection of microglia cells. However, the effect of infliximab combined with aciclovir 
was not superior to the effect of aciclovir alone at the level of cell survival and mitochondrial 
metabolism in HSV-1-infected microglial cells. 
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Figure 6.12. Microscopy pictures of HSV-1-infected microglial cells treated with 
infliximab (0.5 mg/ml) alone or combined with aciclovir at 48 h post-infection (24 h post-
treatment). HSV-1-infection was done at MOI=0.01. Treatment was done with infliximab 
(0.5 mg/ml), aciclovir (20 µM) and infliximab combined to aciclovir 24 h post-infection (pi). 
Pictures were taken 48 h post-infection (24 h post-treatment). (A) HSV-1-infected microglial 
cells untreated. One big gap has appeared in the monolayer and all cells look round. (B) HSV-
1-infected microglial cells treated with infliximab. No big gaps can be observed but most 
of the cells have become round. (C) HSV-1-infected microglial cells treated with aciclovir. 
Cells look similar to picture (B). (D) HSV-1-infected microglial cells treated with 
infliximab and aciclovir.  Cells look similar to pictures (B-C). 10 x magnification. Scale bar: 
50 µm. 
A B 
C D 
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Figure 6.13. Microscopy pictures of HSV-1-infected microglial cells treated with 
infliximab (0.5 mg/ml) alone or combined with aciclovir at 72 h post-infection (48 h post-
treatment). HSV-1-infection was done at MOI=0.01. Treatment was done with infliximab 
(0.5 mg/ml), aciclovir (20uM) and infliximab combined with aciclovir 24 h post-infection (pi). 
Pictures were taken 72 h pi (48 h post-treatment). (A) HSV-1-infected microglial cells 
untreated. Big gaps have appeared in the monolayer (around 30-40% confluent) and all cells 
look round. (B) HSV-1-infected microglial cells treated with infliximab. All cells look 
round but no extensive cell death could be observed (around 80-90% confluent). (C) HSV-1-
infected microglial cells treated with aciclovir. Similar to picture (B). (D) HSV-1-infected 
microglial cells treated with infliximab and aciclovir. Almost all cells are still attached. 
There are still an important proportion of cells with microglia cell morphologic features. 10 x 
magnification. Scale bar: 50 µm. 
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Figure 6.14. The effect of infliximab alone (0.5 mg/ml) or combined with aciclovir on 
attached cell area of HSV-1-infected microglial cells microscopy pictures at 72h post-
infection (48h post-treatment). HSV-1-infection was done at MOI=0.01. Treatment was 
done with infliximab (0.5 mg/ml), aciclovir (20 µM) and infliximab combined with aciclovir 
24 h post-infection (pi). Areas of attached cells were measured by the software “ImageJ” from 
pictures taken at 72 h post-infection (48 h post-treatment). Two 4 x magnification pictures for 
uninfected, four for HSV-1 infected, two for HSV-1-infected cells treated with aciclovir, four 
for HSV-1-infected cells treated with infliximab and two for HSV-1-infected cells treated with 
infliximab and aciclovir were analysed. Statistical analysis were not performed due to too few 
replicates. 
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Figure 6.15. The effect of infliximab alone (0.5 mg/ml) and combined with aciclovir on 
the mitochondrial metabolism of HSV-1-infected microglial cells at 72 h post-infection 
(48 h pt). HSV-1 infection was done at MOI=0.01. Treatment with aciclovir (20 µM), 
infliximab (0.5 mg/ml) or both was done at 24h pi. Values represent absorbance measurements 
at 450 nm (A450 nm) normalised by subtraction of the background (A650 nm). The WST-1 
assay was performed in uninfected (circles), untreated infected (unfilled squares) or aciclovir-
treated infected (squares half-filled in black on the left side) or infliximab-treated infected 
(squares half-filled in black on the right side) or “infliximab+aciclovir”-treated infected (black 
squares) microglial cells at different time-points (0, 24, 30, 48 and 72 h pi). Data are expressed 
as the mean + 95% CI of 30 replicates from 3 independent experiments. ANOVA test showed 
statistical differences between the means of the different conditions at 30 h (p<0.0001) and 72 
h pi (p<0.005) but not at 48h pi (p>0.05). X=0.076, (*) p=0.05, (***) p<0.005; (****) p<0.001 
(multiple t-tests performed at all time points but 0 h pi). 
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Figure 6.16. The effect of infliximab (0.5 mg/ml) alone and combined with aciclovir on 
HSV DNA abundance in HSV-1-infected microglial culture medium. HSV-1-infection 
was done at MOI=0.01. Treatment with aciclovir (20 µM), infliximab (0.5 mg/ml) or both was 
done at 24 h pi. The values represent Ct values after HSV DNA qPCR was performed on 
culture medium of HSV-1-infected (white) or aciclovir-treated infected (squares half-filled in 
black on the left side) or infliximab-treated infected (squares half-filled in black on the right 
side) or “infliximab+aciclovir”-treated infected microglial cells at 24 (just before the 
treatment), 30, 48 and 72 h pi (0, 6, 24 and 48 h post-treatment respectively). Each point 
represents the mean + 95% CI of data from at least 3 independent experiments. Triplicates 
were used for each point-time in each experiment. ANOVA test showed statistical differences 
between the means of the different conditions at 30 h, 48 h and 72 h pi (p<0.001) but not at 24 
h pi. (*) p<0.01, (***) p<0.005 X=(****) p<0.0001 (multiple t-tests). 
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6.3. Discussion 
The limitations of aciclovir for treatment of HSE patients clearly emphasize the need of 
discovering new adjunctive therapies. In chapter 4, aciclovir (20 µM) limitations were noticed 
in vitro during treatment of both HSV-1-infected neuroblastoma and microglial cells as this 
antiviral only partially rescued cell viability and mitochondrial activity both dampened by 
HSV-1. As previously mentioned for HSE clinical and in vivo studies, it is thought that this 
suboptimal therapeutic action of aciclovir is the consequence of its limited activity. Indeed, it 
only targets HSV replication but the not immune response. As a result, using an adjunctive 
therapy targeting the pro-inflammatory response to HSV-1 could improve treatment 
efficiency.  
Interestingly, in chapter 3, in both infected microglial and neuroblastoma cells, HSV-1 led to 
a significant increase in expression of the pro-inflammatory gene TNF as observed at 24 h-72 
h pi (confirmed by other studies as discussed previously). Furthermore, an increase in CSF 
TNF levels during HSE convalescence stage was clinically observed by Aurelius et al.71. In an 
in vivo study, an improvement of the outcome of HSE mice treated with valacyclovir (oral 
acyclovir) was observed following the administration of the anti-TNF etanercept133. Hence, 
the hypothesis of this chapter was that infliximab, TNF inhibitor, as adjuvant therapy to 
aciclovir could improve cell viability in HSV-1-infected neuroblastoma and microglial cells 
by its anti-inflammatory action on TNF.  
Microscopy study showed that the concentration of 0.5 mg/ml was the most suitable to use for 
treatment of HSV-1-infected neuroblastomas (fig 6.2). This concentration was used in all other 
experiments in this chapter. As in previous chapters, the concentration of aciclovir used in all 
the experiments was 20 µM. 
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Firstly, in my experiments, infliximab alone was shown to increase cell survival and 
mitochondrial metabolism in HSV-1-infected neuroblastomas and microglia cells as observed 
by the analysis of attached cell area performed with the software “imageJ” on microscopy 
pictures and by WST-1 assay at 48 h and/or 72 h post-infection (h pi) (24 h and 48 h post-
treatment (h pt)) (fig 6.7- 6.8 and fig 6.14-6.15). Surprisingly, viral load was quickly and 
drastically decreased by infliximab alone in both infected microglia cell and neuroblastomas 
culture medium as early as 6 h pt (30 h pi) (fig 6.9 and 6.16). Viral load was still significantly 
lower in infected neuroblastoma and microglial cells treated with infliximab than in the 
untreated cells at 48 h and 72 h pi (24 h and 48 h pt). Interestingly, in both infected brain cell 
types, at 30 h pi (6 h pt), infliximab but not aciclovir was associated with a reduced viral load 
whereas at 72 h pi (48 h pt), aciclovir led to a similar (in neuroblastoma cells) or higher (in 
microglial cells) decrease in HSV DNA abundance compared to infliximab. This may suggest 
that infliximab (0.5 mg/ml) has an anti-HSV-1 effect, potentially shorter than aciclovir (20 
µM) treatment.  
Crucially, this is the first time that infliximab has been associated with an anti-HSV-1 action. 
Interestingly, another anti-TNF, etanercept, used alone, was already shown to act as an 
antiviral against Japanese encephalitis virus in brain cells134. In this latter study, etanercept 
alone was shown to lead to a decrease in mouse mortality and brain inflammation.  
In culture medium of both infected microglial and neuroblastoma cells, the combination of 
both drugs was the treatment with the lowest viral DNA load at 48 h and 72 h pi (24 h and 48 
h pt) (fig 6.16, fig 6.9). However, the combined treatment of infliximab and aciclovir did not 
appear to lead to a better outcome than aciclovir alone in HSV-1-infected neuroblastoma and 
microglial cells; both drugs induced similar cell survival and mitochondrial activity profiles 
(fig 6.7-6.8 and fig 6.14-6.15). Interestingly, before increasing mitochondrial activity at 48 h 
and/or 72 h pi (24 h and/or 72 h pt) in HSV-1-infected neuroblastoma and microglial cells, it 
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seems infliximab was associated with an initial decrease in mitochondrial activity observed at 
6 h pt (30 h pi). Several papers have reported that infliximab is able to induce apoptosis in 
several cell types such as immune cells (i.e macrophages and monocytes)166, 167. Therefore, 
perhaps infliximab induces early apoptosis in a proportion of cells before its antiviral effects 
manifests in HSV-1-infected cells. 
Infliximab alone or combined with aciclovir influenced TNF relative gene expression in HSV-
1-infected brain cells in a different way in the different cell types. Overall, TNF relative gene 
expression is still higher in infected neuroblastoma and microglial cells regardless of the 
treatment (infliximab, aciclovir or both) than in their uninfected counterparts (fig 6.4 and 
6.11). In infected neuroblastoma cells, TNF relative gene expression was even more increased 
by aciclovir alone than by any other treatments (p<0.05) at 72 h pi (48 h pt) (fig 6.4). The gene 
expression profile was different in HSV-1-infected microglia at 72 h pi; with a slight but not 
significant increase in TNF relative gene expression after treatment with infliximab alone, but 
a significant decrease with aciclovir alone or combined to infliximab (fig 6.11). Similarly to 
the conclusions of the chapter 5, TNF relative gene expression does not correlate with survival 
of HSV-1-infected neuroblastomas or microglial cells. 
Altogether this suggests that infliximab alone is (0.5 mg/ml) similar to aciclovir (20 µM) in 
infected microglial and neuroblastoma cells works as an anti-HSV-1 agent, maintaining cell 
survival and mitochondrial activity while reducing viral load. However, infliximab does not 
lead to higher levels of cell survival and mitochondrial activity than aciclovir in HSV-1 
infected neuroblastoma and microglial cells. The combination aciclovir/infliximab does not 
even induce a significant increase in mitochondrial activity in HSV-1-infected microglia cells. 
(compared to untreated infected cells) Hence, one dose of infliximab does not seem to be a 
good adjuvant therapy in individual culture of these HSV-1-infected brain cells as its 
combination with aciclovir does not lead to significant improvement of cell survival or 
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mitochondrial metabolism compared to aciclovir alone. Nonetheless, the dual therapy 
aciclovir/infliximab were associated with lower viral load than aciclovir alone in both 
microglial and neuroblastoma cells. Hence, administering repeated doses of infliximab (0.5 
mg/ml) in these models may be interesting to improve its efficiency, as its inhibitory effect on 
HSV-1 replication appears to be quick and weaken over time compared to aciclovir. 
Infliximab is commonly used as an anti-inflammatory drug. For example, it is to treat 
Inflammatory Bowel Disease (I.B.D), reducing disease activity and improving patient quality 
of life. The biological action of infliximab in I.B.D. has been recently reviewed and shown to 
be involved in: (i) downregulating inflammatory cytokines, (ii) inducing apoptosis of activated 
lymphocytes, (iii) downregulating Th1, (iv) inducing Treg and regulatory macrophages, (v) 
inhibiting NF-kB and (vi) promoting MAPK signalling168. In an in vivo model of HSE, 
combining another TNF inhibitor, etanercept, to the antiviral therapy valaciclovir induced an 
increased life expectancy in mice, together with a reduced brain inflammation compared to 
valaciclovir alone 133. Crucially, there were no significant differences in brain viral load 
between HSV-1-infected-mice treated with valaciclovir alone or combined to etanercept. This 
suggested that the life expectancy of infected mice treated with both valaciclovir and 
etanercept was higher than that of infected mice treated by the valacyclovir alone because of 
the anti-inflammatory action of this anti-TNF etanercept.  
My in vitro models do not exceed 3 days. They may be a representation of acute HSE in which 
viral load is high and CSF TNF levels are not yet elevated143, 71. Hence, the increase in cell 
survival and mitochondrial metabolism observed following administration of infliximab alone 
(24 h-48 h post-treatment) in infected neuroblastoma and microglial cells could also be the 
result of an inhibitory action of infliximab on other pro-inflammatory cytokines or just the 
consequence of its quick anti-HSV-1 action. More studies are needed for a better 
understanding of the effect of infliximab in HSV-1-infected brain cells. 
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Finally, infliximab is usually administrated to patients suffering from inflammatory diseases. 
The human host is complex, and infliximab likely impacts, at the cellular level on a wide range 
of host cells simultaneously, including various immune cells. In this chapter, I have studied its 
impact only in one brain cell type at the time. In the next chapter, I have optimised new in 
vitro HSE models using a co-culture of human brain cells to begin to more closely model the 
in vivo response. 
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Chapter 7 Co-culture of HSV-1-infected human brain cells  
7.1. Introduction  
In the previous chapters, the effects of administering aciclovir (chapter 4), dexamethasone 
alone and combined to aciclovir (chapter 5), infliximab alone and combined with aciclovir 
(chapter 6) have been studied in HSV-1-infected neuroblastoma and microglial cells 
separately. These effects have been assessed at the level of cell viability, TNF gene expression 
and viral load. The data obtained offered a better understanding of HSV-1 infection in each 
human brain cell type. They also provided insight into the relevance of anti-inflammatory 
drugs as adjunctive therapies in combination with aciclovir in human brain cells following 
HSV-1infection.  
HSV Encephalitis (HSE) is the result of HSV-1 infection and subsequent immune response in 
the brain tissue that contains multiple cell types, such as neurons, microglia cells, astrocytes, 
oligodendrocytes45, 49, 169, 37, 85 ,170. Each brain cell type leads to a specific response to the virus 
and these brain cell types also interact with each other adding another degree of complexity140, 
171, 90, 68.  
In HSE, microglia cells, resident brain macrophages, are a key cell type involved in HSV-1 
brain infection, although their role is still not completely clear. Activated microglia and gliosis 
are histopathological features in HSE brain tissue35, 143. Some studies showed microglial cells 
to be protective in HSE136, 87. Chucair-Elliott et al. demonstrated in vitro with murine cells that 
microglia protected neuronal loss following HSV-1-infection of neural progenitor cells 
(NPC)136. In a HSE mouse model, microglia were shown essential to counter HSV-1-induced 
brain lateral ventricle enlargement and encephalitis87. However, another study demonstrated 
that the presence of microglia was associated with neural oxidative damage and toxicity via 
TLR2 activation99. Hence, there is a need to better understand the role of microglia cells and 
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their interaction with other brain cell types during HSV-1 infection. To study such interactions, 
I developed more complex HSV-1-infection in vitro models using microglia in co-culture.  
Several studies have used brain cell co-cultures. In an in vitro model of bacterial meningitis, 
astrocytes (95%) and microglia cells (5%) were co-cultured together in the same compartment 
before LPS challenge156. Another mixed co-culture of astrocytes/microglia cells was used to 
assess the effect of astrocytes on microglia cell activation172. Co-cultures of astrocytes/neurons 
and microglia/neurons were also performed using coverslips in a thiamine deficiency study141. 
Only two studies, previously mentioned, using co-cultures in in vitro models of HSE have 
been published, both used murine cells. In the first one, 30,000 neural progenitor cells (NPC) 
were co-cultured with 200,000 microglia cells in the same well and microglia cells were shown 
to prevent neuronal loss upon differentiation following HSV-1 infection of NPC136. In the 
second one, microglia co-cultured at the ratios 1/5 or 1/10 with mixed neural cultures (85-90% 
neurons, 10-15% astrocytes and less than 2% of microglia cells) were demonstrated to cause 
oxidative stress and neuronal damage99. To my knowledge, there are no studies of HSV-1-
infection using a co-culture of human microglia with another human brain cell type. Further 
in vitro studies using human brain cells need to investigate the role of microglia on HSV-1 
infection of other brain cells.  
In this chapter, two new HSV-1-infection in vitro systems using human brain cells co-cultured 
with microglia have been set up and preliminary works have been performed in them. To 
assess the remote effect of microglia, cell types were cultured in different compartments 
separated via pore-containing inserts. These inserts allowed exchange of fluid, small 
molecules and viruses through the pores (diameter: 0.4 µm) (description in chapter 2 “Material 
and Methods”). In the first model, the co-culture consisted of HSV-1-infected neuroblastomas 
in the bottom compartment and microglia in the top one. In the second model, HSV-1-infected 
primary astrocytes were in the bottom compartment and microglia in the top. In each model, 
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HSV-1-infection was performed at MOI=0.01 in neuroblastoma cells or astrocytes. The effects 
of the microglia co-culture on HSV-1-infected neuroblastoma cells or astrocytes were 
observed at 24, 48 and 72h pi. 
The goals of this chapter were to set up these co-culture models and study the remote influence 
of microglia co-culture (assuming soluble factors are released by microglia in my model), on 
HSV-1-infection of primary astrocytes or neuroblastomas by observing cell viability and viral 
load.  
 
 
 
 
 
 
 
 
 
 
 
  
 
197 
 
Bottom 
compartment: 
neuroblastomas 
(or) astrocytes 
Uninfected 
HSV-1-infected 
Top compartment: 
-microglia 
 
  
Figure 7.1. Experimental design for assessing the effect of microglia on HSV-1-infection 
of neuroblastoma cells and primary astrocytes. (A) Brain cell populations used. (B) 
Techniques performed on brain cells following HSV-1-infection. (C) Techniques performed 
on brain cell culture medium following HSV-1-infection. 
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7.2. Results 
7.2.1. HSV-1-infection of neuroblastoma cells co-cultured with microglial cells 
Here, I assessed the effect of microglia on HSV-1-infected neuroblastoma cells. By light 
microscopy, an increase in live neuroblastoma cell density could be observed when 
neuroblastomas were co-cultured with microglial cells at multiple time-points (fig 7.2-4). The 
increase in infected neuroblastoma cell density when co-cultured with microglia was 
consistently observed in several 10 x magnification microscope pictures at both 48 h and 72 h 
pi (fig 7.3-4). Further examples of the higher cell density due to microglia co-culture are shown 
in the figures 7.5 and 6. The analysis of attached cell area via the software “ImageJ” was only 
performed using 4 x magnification microscope pictures for technical reasons involving picture 
brightness. At 72 h pi, 4 x magnification microscope pictures also showed an increase in 
infected neuroblastoma cell survival when co-cultured with microglial cells (fig 7.7). Although 
showing the same trend, the analysis of attached neuroblastoma cell area by “ImageJ” was 
done with too few pictures at 4 x magnification for statistical significance (fig 7.8).  
At 72 h pi, DAD-1 gene abundance was significantly higher among infected neuroblastoma 
cells co-cultured with microglia compared to the neuroblastoma cells cultured alone (fig 7.9A). 
The analysis of DAD-1 ΔCt values ((DAD-1 Ct) infected – (DAD-1 Ct) uninfected) also 
showed that DAD-1 gene expression was higher during HSV-1-infection of neuroblastoma 
cells when co-cultured with microglial cells (lower ΔCt value) (fig 7.9B).  
The co-culture with microglial cells did not induce any change in HSV DNA abundance in 
neuroblastoma cell culture medium (24 h-72 h pi) (fig 7.10). However, the presence of 
microglia induced a significant decrease in HSV DNA abundance within neuroblastoma cells 
at 72 h pi (fig 7.11).  
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HSV DNA qPCR in microglia cell culture medium (insert-top compartment) showed an 
increase in HSV DNA abundance over time (6-72 h pi) when co-cultured with HSV-1-infected 
neuroblastoma cells (fig 7.12). Finally, qPCR from nucleic extract of microglia cells co-
cultured with infected neuroblastoma cells showed very low levels of HSV DNA amplification 
(72h pi) (data not shown).  
Overall, under these experimental conditions, the presence of microglial cells in co-culture 
appears to protect HSV-1-infected neuroblastoma cells. 
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Figure 7.2. Microscopy pictures of HSV-1-infected neuroblastoma cells co-cultured with 
microglia at 24h post-infection. HSV-1-infection was done in neuroblastoma cells at 
MOI=0.01. Pictures of neuroblastoma cells were taken 24 h pi by light microscopy. A. 
Uninfected neuroblastoma cells. Cells are 100% confluent, big and exhibit fibroblast-like 
morphology. B. HSV-1-infected neuroblastoma cells. There are more spaces between cells 
and few round cells can be observed. C. Uninfected neuroblastoma cells co-cultured with 
300,00 microglia cells. Cells are 100% confluent but they look smaller and rounder than in 
(C). D. HSV-1-infected neuroblastoma cells co-cultured with 300,000 microglial cells. The 
picture is similar as the one in C. 10 x magnification. Scale bar: 50 µm. 
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Figure 7.3. Microscopy pictures of HSV-1-infected neuroblastoma cells co-cultured with 
microglia at 48h post-infection. HSV-1-infection was done in neuroblastoma cells at 
MOI=0.01. Pictures of neuroblastoma cells were taken 48h pi by light microscopy. A. 
Uninfected neuroblastoma cells. Cells are around 90% confluent. B. HSV-1-infected 
neuroblastoma cells. There are big spaces and gaps between cells (around 50% confluent). C. 
Uninfected neuroblastoma cells co-cultured with 300,000 microglia cells. Cells are 100% 
confluent, darker and more numerous than in (C). D. HSV-1-infected neuroblastoma cells co-
cultured with 3x105 microglia cells. Gaps have appeared in the monolayer (around 80% 
confluent). 10x magnification. Scale bar: 50 µm. 
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Figure 7.4. Microscopy pictures of HSV-1-infected neuroblastoma cells co-cultured with 
microglia at 72 h post-infection. HSV-1-infection was done in neuroblastoma cells at 
MOI=0.01. Pictures of neuroblastoma cells were taken 72h pi by light microscopy. A. 
Uninfected neuroblastoma cells. Few small gaps in the monolayer can be observed (around 
90% confluent). In some parts, cell density seems really important with cells on top of each 
other B. HSV-1-infected neuroblastoma cells. Only few cells are still attached (around 15-
20% confluent). C. Uninfected neuroblastoma cells co-cultured with 300,000 microglial cells. 
The picture is similar to picture (A). D. HSV-1-infected neuroblastoma cells co-cultured with 
300,000 microglial cells. Cell density has dropped with a confluency around 30-40%. 10 x 
magnification. Scale bar: 50 µm. 
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Figure 7.5. Supplementary microscopy pictures of HSV-1-infected neuroblastoma cells 
co-cultured with microglia at 48 h post-infection. HSV-1-infection was done in 
neuroblastoma cells at MOI=0.01. Pictures of neuroblastoma cells were taken 48h pi by light 
microscopy. A, C, E. HSV-1-infected neuroblastoma cells. There are big spaces and gaps 
between cells (around 50% confluent). B, D, F. HSV-1-infected neuroblastoma cells co-
cultured with 3x105 microglial cells. Gaps have appeared in the monolayer (around 80% 
confluent) but the monolayers are more dense than that of infected cells cultured alone. 10 x 
magnification. Scale bar: 50 µm. 
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Figure 7.6. Supplementary microscopy pictures of HSV-1-infected neuroblastoma cells 
co-cultured with microglia at 72 h post-infection. HSV-1-infection was done in 
neuroblastoma cells at MOI=0.01. Pictures of neuroblastoma cells were taken 72 h pi by light 
microscopy. A, C, E. HSV-1-infected neuroblastoma cells. Only few cells are still attached 
(around 20% confluent) and a lot of cell debris are floating. B, D, F. HSV-1-infected 
neuroblastoma cells co-cultured with 300,000 microglia cells. Cell density has dropped with a 
confluency around 30-40%. 10 x magnification. Scale bar: 50 µm. 
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Figure 7.7. Microscopy pictures of HSV-1-infected neuroblastoma cells co-cultured with 
microglia at 72h post-infection (4x magnification). HSV-1-infection was done in 
neuroblastoma cells at MOI=0.01. Pictures of neuroblastoma cells were taken 72h pi by light 
microscopy. A. Uninfected neuroblastoma cells. Few small gaps in the monolayer can be 
observed (around 90% confluent). B. HSV-1-infected neuroblastoma cells. Only few cells are 
still attached (around 15-20% confluent). C. Uninfected neuroblastoma cells co-cultured with 
300,000 microglial cells. Cell density seem even higher than in (A). D. HSV-1-infected 
neuroblastoma cells co-cultured with 300,000 microglial cells. Cell density has dropped with 
a confluency around 50%. 4 x magnification. Scale bar: 50 µm. 
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Figure 7.8. The effect of microglia culture on attached cell area on microscopy pictures 
of HSV-1-infected neuroblastoma cells at 72 h post-infection. NI NB: Uninfected 
neuroblastoma cells; NI NB+MG: Uninfected neuroblastoma cells co-cultured with microglia; 
HSV-1 NB: HSV-1-infected neuroblastoma cells; HSV-1 NB+MG: HSV-1-infected 
neuroblastoma cells co-cultured with microglia. HSV-1-infection was done at MOI=0.01 in 
neuroblastomas. Areas of live neuroblastoma cells were measured by the software “ImageJ” 
from 4 x magnification pictures taken at 72 h post-infection. Data are expressed as mean of 
the area of live cells +95% CI and were obtained as described in the chapter 2 (Materials and 
Methods). Three pictures for NI NB, two pictures for NI NB+MG, five for HSV-1 NB and 
three for HSV-1 NB+MG were analysed. These pictures come from a single experiment. 
ANOVA statistically showed significant differences between the means of the different 
conditions (p<0.005). (**) p<0.005 (t-test).  
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Figure 7.9. The effect of microglia co-culture on DAD-1 gene expression in HSV-1-
infected neuroblastoma cells. A. DAD-1 gene expression in neuroblastoma cells (Ct values) 
co-cultured or not with microglial cells. HSV-1-infection was done in neuroblastoma cells at 
MOI=0.01 and DAD-1 gene expression was measured at 72h pi. The values represent Ct 
values after qRT-PCR targeting DAD-1 in uninfected (circle) or HSV-1-infected (squares) 
neuroblastoma cells co-cultured with microglial cells (filled in black) or not (filled in white). 
Each point represents the mean + 95% CI of data from one experiment. Triplicates were used 
for each point-time. ANOVA statistically showed significant differences between the means 
of the different conditions (p<0.0001). (**) p<0.005 (t-test).  (***) p<0.005 (multiple t-tests). 
B. DAD-1 ΔCt values in infected neuroblastomas co-cultured or not with microglial cells. NB: 
Infected Neuroblastoma cells cultured alone; NB+MG: Infected Neuroblastoma cells co-
cultured with microglial cells. The data in this table represents the delta Ct values of the gene 
DAD-1 in Infected neuroblastoma cells culture alone (NB) and in infected neuroblastoma cells 
co-cultured with microglia. The results were obtained by calculating “DAD-1 Ct (infected) - 
DAD Ct (uninfected)” from the figure A for both conditions. 
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Figure 7.10. Influence of microglia co-culture on HSV DNA abundance in neuroblastoma 
cell culture medium following HSV-1 infection in neuroblastoma cells. HSV-1-infection 
was done in neuroblastomas at MOI=0.01. HSV DNA abundance was measured in 
neuroblastoma culture medium at 6, 24, 48, and 72 h pi. The values represent Ct values after 
HSV DNA qPCR from culture medium of HSV-1-infected neuroblastomas co-cultured with 
microglia (filled in black) or not (in white). Each point represents the mean + 95% CI of data 
from one experiment. Triplicates were used for each time-point. Multiple t-tests were 
performed (no statistical difference at any time-point). 
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Figure 7.11. Influence of microglia co-culture on HSV DNA abundance within 
neuroblastoma cells following HSV-1-infection in neuroblastoma cells. HSV NB: HSV-1-
infected neuroblastomas, HSV NB + MG: HSV-1-infected neuroblastomas co-cultured with 
microglia. HSV-1-infection was done in neuroblastomas at MOI=0.01. HSV DNA abundance 
was measured within neuroblastomas at 72 h pi following nucleic acid extraction. The values 
represent Ct values after HSV DNA qPCR following nucleic extraction from HSV-1-infected 
neuroblastomas, co-cultured with microglia (in black) or not (in white). Each point represents 
the mean + 95% CI of data from one experiment. Triplicates were used for each point-time in 
each experiment. (*) p<0.05 (t-test).  
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Figure 7.12. HSV DNA abundance in culture medium of microglia co-cultured with 
HSV-1-infected neuroblastoma cells. HSV-1 infection was done in neuroblastoma cellss at 
MOI=0.01. HSV DNA abundance was measured in culture medium of microglial cells at 6, 
24, 48, and 72 h pi (top compartment-insert). The values represent Ct values after HSV DNA 
qPCR from culture medium of microglia cells co-cultured with HSV-1-infected 
neuroblastomas (bottom compartment). Each point represents the mean + 95% CI of data from 
one experiment. Triplicates were used for each point-time.  
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7.2.2. HSV-1-infection of primary astrocytes co-cultured with microglia cells 
As aforementioned, a co-culture system using both HSV-1-infected astrocytes (at the bottom 
of the well) and microglial cells (insert-top compartment) was set up to study the influence of 
remote microglia on HSV-1-infection of astrocytes.  
By light microscopy we could observe that astrocyte cell density was not increased at 24 h-72 
h pi when co-cultured with microglial cells (seeded at 3x105 cells) (fig7.13-16) . At 72 h pi, 
the presence of microglia was shown to increase infected astrocyte cell density. This was seen 
in multiple 10 x magnification pictures (fig 7.15 and fig 7.16). The attached cell area can only 
be analysed by the software “ImageJ” by using 4 x magnification pictures (fig 7.17-18). The 
increase in astrocyte cell survival with microglia co-culture was also observed by analysis of 
attached cell area although more pictures are required for statistical significance (fig 7.18).  
At 72 h pi, no significant change in DAD-1 gene expression was detected between astrocytes 
cultured alone or in co-culture (fig 7.19). Microglia co-culture did not influence HSV-1 DNA 
abundance neither in astrocytes in culture medium or within astrocytes (fig 7.20-21).   
HSV DNA qPCR in microglial cell culture medium showed an increase in HSV DNA 
abundance over time (6-72 h pi) (fig 7.22). HSV DNA was detected by qPCR within microglial 
cells co-cultured with infected astrocytes (24 h-72 h pi) (data not shown). 
Altogether, there was no decrease in astrocyte cell number, as measured by qRT-PCR, 
“ImageJ” or observed by light microscopy when astrocytes were grown in co-culture with 
microglia. There was also no sustained change in HSV DNA abundance among the astrocytes 
during co-culture. 
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Figure 7.13. Microscopy pictures of HSV-1-infected astrocytes co-cultured with 
microglia at 24 h post-infection. HSV-1-infection was done in astrocytes at MOI=0.01. 
Pictures of primary astrocytes were taken 24h pi by light microscopy. A. Uninfected 
astrocytes. Cells are 100% confluent and exhibit classic morphologic features of astrocytes 
(long, thin, “star-like” ramifications). B. HSV-1-infected astrocytes. HSV-1 induced live 
astrocyte loss (gaps in the monolayer, loss of confluency) and morphologic changes 
(appearance of rounded cells) have appeared. C. Uninfected astrocytes co-cultured with 3x105. 
The monolayer is intact, similar to the one in A. D. HSV-1-infected astrocytes co-cultured 
with 3x105 microglia cells. The picture is similar as the one in C. 10x magnification. Scale 
bar: 50 µm. 
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Figure 7.14. Microscopy pictures of HSV-1-infected astrocytes co-cultured with 
microglia at 48 h post-infection. HSV-1-infection was done in astrocytes at MOI=0.01. 
Pictures of primary astrocytes were taken 48h pi by light microscopy. A. Uninfected 
astrocytes. Cells are 100% confluent and exhibit classic morphologic features of astrocytes 
(long, thin, “star-like” ramifications). B. HSV-1-infected astrocytes. HSV-1 infection course 
progressed with bigger gaps between cells and all cells looking round. C. Uninfected 
astrocytes co-cultured with 3x105 microglia cells. The picture is similar as the one in A. D. 
HSV-1-infected astrocytes co-cultured with 3x105 microglia cells. HSV-1 has also induced 
both live cell loss (gaps between cells, loss of confluency) and morphologic changes with 
majority cells looking round now. However, there are still some astrocytes with classic 
morphologic changes and a higher cell density compared to the picture B. Pictures are 
representative of 2 independent experiments. 10 x magnification. Scale bar: 50 µm. 
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Figure 7.15. Microscopy pictures of HSV-1-infected astrocytes co-cultured with 
microglia at 72 h post-infection (10 x magnification). HSV-1-infection was done in 
astrocytes at MOI=0.01. Pictures of primary astrocytes were taken 72h pi by light microscopy. 
A. Uninfected astrocytes. Cells are 100% confluent and exhibit classic morphologic features 
of astrocytes (long, thin, “star-like” ramifications). B. HSV-1-infected astrocytes. HSV-1 
infection course has still progressed with only few round cells left attached on the monolayer 
(around 10% confluent). C. Uninfected astrocytes co-cultured with 3x105 microglia cells. The 
picture is similar as the one in A. D. HSV-1-infected astrocytes co-cultured with 3x10^5 
microglia cells. All cells look round but many more cells are still alive and attached to the 
monolayer compared to B and C. Pictures are representative of 2 independent experiments. 
10x magnification. Scale bar: 50 µm. 
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Figure 7.16. Supplementary microscopy pictures of HSV -1-infected astrocytes co-
cultured with microglia at 72 h post-infection (10 x magnification). HSV-1-infection was 
done in astrocytes at MOI=0.01. Pictures of primary astrocytes were taken 72h pi by light 
microscopy. A, C, E. HSV-1-infected astrocytes. HSV-1 infection course has induced 
extensive cell death. Confluence is around 15-20% confluent in average. B, D, F. HSV-1-
infected astrocytes co-cultured with 3x105 microglia cells. All cells look round but many more 
cells are still alive and attached to the monolayer compared to A, C and E (. Pictures are 
representative of 2 independent experiments. 10 x magnification. Scale bar: 50 µm. 
A B 
C D 
E F 
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Figure 7.17. Microscopy pictures of HSV-1-infected astrocyte co-cultured with 
microglia at 72h post-infection (4 x magnification). HSV-1-infection was done in 
astrocytes at MOI=0.01. Inserts containing microglia cells were added following astrocyte 
infection. Pictures of primary astrocytes were taken 72h pi by light microscopy. A. Uninfected 
astrocytes. Cells are 100% confluent. B. HSV-1-infected astrocytes. HSV-1 infection course 
has still progressed with big gaps between cells (around 50% confluency). C. HSV-1-infected 
astrocytes co-cultured with 0.5x10^5 microglia cells. The picture is similar as picture B but 
with slightly lower cell density (around 30% confluency). D. HSV-1-infected astrocytes co-
cultured with 3x10^5 microglia cells. Confluency is still high (80-90%). Pictures are 
representative of 2 independent experiments. 4x magnification. Scale: 50 µm. 
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Figure 7.18. The effect of microglia co-culture on live cell area on microscopy pictures of 
HSV-1-infected primary astrocytes at 72 h post-infection. NI HA: Uninfected Human 
Astrocytes; HSV HA: HSV-1-infected Human Astrocytes; HSV HA + MG: HSV-1-infected 
astrocytes co-cultured with 300,000 microglial cells. HSV-1-infection was done at MOI=0.01 
in primary astrocytes. Areas of live primary astrocytes were measured by the software ImageJ 
from pictures taken at 72h post-infection. Data are expressed as mean of the area of live cells 
+95% CI and were obtained as described in the chapter 2 (Materials and Methods). One picture 
for NI HSV, two pictures for HSV HA and four for HSV + 300,000 MG were analysed. These 
pictures are representative of two experiments. Statistical analysis was not performed because 
of a really low number of replicates. 
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Figure 7.19. DAD-1 gene expression in HSV-1-infected astrocytes co-cultured with 
microglia. HSV-1-infection was done in astrocytes at MOI=0.01. DAD-1 gene expression was 
measured by qRT-PCR at 72h pi following nucleic extraction of astrocytes. The values 
represent Ct values after qRT-PCR targeting DAD-1 in uninfected (circle) or HSV-1-infected 
(squares) astrocytes co-cultured with microglia cells (filled in black) or not (in white). Each 
point represents the mean + 95% CI of data from 2 independent experiments. Duplicates (for 
uninfected and HSV-1-infected populations) and triplicates (for HSV-1-infected cells co-
cultured with microglia) were used in each experiment. ANOVA test statistically showed 
significant differences between the means of the different conditions (p<0.0001). (****) 
p<0.0005 (Mann-Whitney test). 
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Figure 7.20. The effect of microglia co-culture on HSV DNA abundance in astrocyte 
culture medium following HSV-1 infection in astrocytes. HSV-1-infection was done in 
astrocytes at MOI=0.01. HSV DNA abundance was measured in astrocyte culture medium at 
6h; 24h; 48h and 72h pi. The values represent Ct values after HSV DNA qPCR from culture 
medium of HSV-1infected astrocytes cultured with 300,000 microglia cells (squares filled in 
black), or not co-cultured (white circles). Each point represents the mean + 95% CI of data 
from 2 independent experiments. Triplicates were used for each point-time in each experiment 
except for the infected cells cultured alone (duplicates). (***) p<0.005 (multiple t-tests).  
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Figure 7.21. The effect of microglia co-culture on HSV DNA abundance within astrocytes 
following astrocyte HSV-1-infection. HSV HA: HSV-1-infected human astrocytes, HSV 
HA+MG: HSV-1-infected astrocytes co-cultured with 300,000 microglial cells.HSV-1-
infection was done in astrocytes at MOI=0.01. HSV DNA abundance was measured within 
astrocytes at 72 h pi. The values represent Ct values after HSV DNA qPCR following nucleic 
extraction from infected astrocytes co-cultured with microglia cells (squares filled in black) or 
not co-cultured (white squares). Each point represents the mean + 95% CI of data from 2 
independent experiments. Triplicates were used in each experiment. P>0.05 (t-test).  
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Figure 7.22. HSV DNA abundance in culture medium of microglia co-cultured with 
HSV-1-infected astrocytes. HSV-1 infection was done in astrocytes at MOI=0.01 (bottom 
compartment). HSV DNA abundance was measured in culture medium of microglia cells (top 
compartment) at 6h, 24h, 48h and 72 h pi. The values represent Ct values after HSV DNA 
qPCR from culture medium of microglia cells co-cultured with HSV-1-infected astrocytes. 
Each point represents the mean + 95% CI of data from 2 independent experiments. Triplicates 
were used in each experiment. (***) p<0.005; (****) p<0.0001 (multiple t-tests).  
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7.3. Discussion 
HSV-1 encephalitis seems to be due to both viral replication and detrimental immune response 
in brain tissue45, 49, 169, 37, 85, 170. The brain cells damaged are not only neurons but also astroglial 
cells including microglia and astrocytes cells. Crucially, all these brain cells interact between 
themselves85, 140. In HSV-1 encephalitis studies, the role of microglia cells seems crucial, in-
part through cytokine/chemokine release and recruitment of neutrophils and lymphocytes68, 85, 
98, 173, 86, 174, 142, 136, 99, 87. However, they have been shown to be both protective and detrimental 
during HSV-1 brain infection90, 136, 99.  
There is a crucial need to establish new HSE in vitro models using human brain cells to better 
understand the role of microglia in HSE pathogenesis and protection90, 136, 99. Of note, in the 
literature, there are no HSE in vitro studies using co-culture of human brain cells. Indeed, to 
my knowledge, only two co-culture studies investigated the interaction between two different 
brain cell type following HSV-1-infection136, 99. However, microglia and the brain cells 
targeted (mixed neural cell culture or neural progenitor cells) were all murine136, 99. Hence, in 
this chapter, I set up new HSV-1 brain infection in vitro systems using pore-containing inserts 
to culture two human brain cell types together (astrocytes/microglia or 
neuroblastomas/microglia). The major aim of this chapter was to study the remote influence 
of microglia cells on HSV-1-infected neuroblastomas or primary astrocytes. In each co-culture 
system, HSV-1-infection was performed at MOI=0.01 in neuroblastoma cells or astrocytes. 
The effects of the remote microglia co-culture on HSV-1-infected neuroblastoma cells or 
astrocytes were observed at 24, 48 and 72 h pi. 
Firstly, this chapter showed that the co-culture with microglia had no detrimental effect on 
HSV-1 infection of astrocytes. Indeed, the presence of microglia cells did not induce an 
increased live astrocyte loss when assessed by light microscopy observations (multiple 10 x 
magnification microscope pictures) or DAD-1 qRT-PCR. Microglia co-culture also did not 
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exacerbate HSV replication as observed by qPCR from culture medium and within cells (fig 
7.13-21 and fig 7.26-7.28). Of note, although showing the same trend, the analysis of attached 
cell area by ImageJ was done with too few 4 x magnification (only magnification used for 
quantifying attached cell area using ImageJ) images for statistical significance (fig 7.18). 
The data from the co-culture of infected neuroblastomas with microglia was only preliminary 
works. Obviously, they have to be interpreted more carefully since only one time-course 
experiment was performed. The presence of microglia was associated with an increase in 
infected neuroblastoma cell survival by multiple light microscopy observations and qRT-PCR 
targeting DAD-1 (fig7.2-7.7 and fig 7.9). Here too, the attached cell area analysis by ImageJ 
could not lead to trustworthy results as there were not enough 4 x magnification pictures 
analysed for statistical significance (fig 7.8). Interestingly, microglia culture induced a 
decrease in HSV DNA abundance within infected neuroblastomas at 72 h pi (fig7.11) but no 
effect on culture medium HSV DNA abundance (7.10). 
HSV DNA abundance was found in culture medium of microglia cells co-cultured with 
infected neuroblastomas or astrocytes (fig7.12, 7.22) confirming the fact that HSV-1 particles 
(typically around 200nm of diameter6) could pass through the pores (400 nm of diameter) and 
reach the top compartment (insert). Moreover, HSV DNA was found within microglia cells 
co-cultured with infected neuroblastomas and astrocytes (data not shown). This suggests that 
HSV-1 can also infect microglia cells after they reached the top compartment. 
The main limitation of this work is the lack of data coming from quantitative and accurate 
techniques for live cell viability. Indeed, the limitations of DAD-1 qRT-PCR sensitivity have 
already been stated in the previous chapters. Unfortunately, the WST-1 assay was optimised 
for 96 well-plates and not 12-well plates and could not be performed on these co-culture 
experiments. The analysis results of microscopy pictures by ImageJ could not be trusted as 
there were not enough 4 x magnification microscopy pictures of quality. However, a 
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reasonable amount of 10 x magnification microscopy pictures was included in this study. 
Unfortunately, they could not be analysed by “ImageJ” as I could not transform the images 
into satisfying proper negative pictures due to extensive brightness inside the intracellular 
compartment. More studies on these co-cultures repeating the same experiments with a better 
microscope or camera or using other techniques for cell viability quantification such as FACS 
would be interesting. 
Altogether, microglia cells were shown not to exacerbate HSV-1-infection of astrocytes. 
Although it needs further validation, in neuroblastomas, the presence of microglia appeared to 
protect against HSV-1-induced cell damage. This may be possible due to exchange of soluble 
molecules through pores of the membrane separating both compartments. Hence, microglia-
release factors are probably responsible for such an effect (if it was confirmed). In vitro, it has 
been shown that microglia cells, following HSV-1-infection, induce the production of TNF-α, 
IL-1B, IP-10 and RANTES, and to a lesser extent, that of IL-6, IL-8 and MIP-1a85. In mice, 
an TLR2-dependent-increase in the percentage of microglia cells producing TNF was also 
observed following HSV-1 challenge90. Interestingly, IL-6 has already been shown to have a 
protective role during HSV-1-infection of murine neural Progenitor Cell (NPC) (in a murine 
co-culture NPC/microglia model; MOI=0.0001, at 4 days pi)136. 
Finally, these two HSV-1 brain infection in vitro systems could also be used as platform to 
assess adjunctive therapies to aciclovir such as dexamethasone or infliximab. This would 
represent a unique opportunity to assess therapies in more complex HSE in vitro human 
models, closer to in vivo conditions. 
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Chapter 8 Discussion 
8.1. Rationale and aim of the thesis.  
Herpes simplex encephalitis (HSE) is a lethal brain infection induced by herpes simplex 
virus subtype 1 (HSV-1). Brain damage associated with HSE is reported to be caused 
directly by the virus and indirectly by the host immune responses. Aciclovir, the gold 
standard anti-viral therapy, targets HSV replication, but not brain inflammation. Hence, 
administration of anti-inflammatory drugs alongside aciclovir may improve outcome in 
HSE 129, 127, 175, 39.  
The debate on using anti-inflammatory drugs, especially corticosteroids, for treating HSE has 
been ongoing for decades. Several small clinical reports have shown a positive impact of 
corticosteroids on HSE patient outcome 131, 128, 158, 132, 129, 176. However, use of corticosteroids 
is questioned by some clinicians because dampening the immune response could lead to an 
increased viral replication and further HSV-induced brain damage177, 124. To date, there have 
been no large clinical trials confirming that corticosteroids are beneficial when given in 
combination with aciclovir in HSE patients.  
Murine knock-out models for TNF-α (missing the gene encoding for TNF-α) infected with 
HSV-1 exhibit more severe encephalitis and increased mortality compared to wild-type 
mice178. Similarly, in a mice model of Japanese Encephalitis, administering the TNF inhibitor   
etanercept, was shown to significantly increase mouse survival, while reducing brain 
inflammation134. In humans TNF-α is reported to be persistently elevated in the cerebrospinal 
fluid (CSF) of patients suffering with HSE.71 Together, these reports suggest anti-TNF agents 
may be a beneficial treatment for patients with HSE.  
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The main aim of my thesis was to study the effect of dexamethasone (a corticosteroid) and 
infliximab (an anti-TNF drug) alone or in combination with aciclovir in human brain cell 
models of HSE. 
My objectives were (i) to set up in vitro models of HSE using human brain cells and (ii) to 
assess the effects of aciclovir/dexamethasone and aciclovir/infliximab in HSV-1-infected 
neuroblastoma and microglial cells. These effects were assessed at the levels of cell viability, 
HSV DNA abundance and TNF relative gene expression. 
8.2. Main results 
In chapter 3, HSV-1 viral load (as measured by HSV DNA in culture medium) increased in 
the brain cell culture models with time from infection. As viral load increased, there was a 
decrease in cell mitochondrial activity and cell viability in both neuroblastoma and microglial 
cells. Different viral replication and mitochondrial metabolism dynamics were observed 
between microglial and neuroblastoma cells following HSV-1 infection. TNF-α and INF-γ 
relative gene expression was increased following HSV-1 infection in both cell types. However, 
no significant change in TNF protein abundance was detected during the infection time-course 
experiments with either brain cell type. In addition, primary astrocytes also showed decreased 
cell viability as HSV viral load increased (chapters 3 and 7). 
In chapter 4, it was shown that administration of aciclovir to the microglia cell culture model 
was associated with a reduction in total viral load (as measured by HSV DNA abundance in 
culture medium). Interestingly, no significant change in HSV DNA abundance was detected 
following administration of aciclovir into the neuroblastoma cell culture model.  However, 
taking a set volume of culture media (from the infected neuroblastoma cells) and adding this 
medium to an uninfected culture of Vero cells, showed that medium from the aciclovir-treated 
neuroblastoma cells was associated with significantly less cell death. This indicates aciclovir 
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treatment is associated with a reduction in the number of infective (active) viruses released 
from neuroblastoma cells. However, total HSV DNA (derived from either infective or non-
infective virus) can remain the same.  
Aciclovir treatment was also associated with an increase in cell viability and mitochondrial 
activity among both cell types.  
In chapter 5, administration of dexamethasone was not seen to be associated with any 
significant change in HSV DNA load when administered alone or in combination with 
aciclovir in the human brain cell models. Similarly, dexamethasone was not associated with 
any significant change in cell viability or mitochondrial activity when administered alone or 
in combination with aciclovir to the cell cultures.  
In chapter 6, infliximab, when administered on its own, was associated with an increase in cell 
viability and mitochondrial activity (48 h-72 h pi). It was also associated with an early decrease 
in viral load (HSV DNA) in both neuroblastoma and microglia cultures. The combination of 
aciclovir and infliximab was associated with a lower HSV DNA abundance in both infected 
microglial and neuroblastoma cells compared to aciclovir alone. Nonetheless, at 72 h pi, the 
combination of aciclovir and infliximab was not associated with any statiscally significant 
increase in cell viability or mitochondrial metabolism compared to aciclovir alone in both 
infected cell types (or also compared to untreated infected cells for microglia).  
In chapter 7, in vitro models of HSE were set up using co-culture of astrocytes with microglial 
cells and co-culture of neuroblastoma cells with microglia cells. Microglia co-culture did not 
appear to influence cell viability of primary astrocytes following HSV-1 infection. My data 
suggested that neuroblastoma cells exhibited more sustained cell numbers and less cell damage 
when grown in association with microglia. However, only a preliminary set of experiments 
was performed. Further work is required to robustly assess significance of these observations.  
  
 
228 
 
8.3. Interpretation of the results and their significance in the literature  
HSV-1 induced cell death in Kelly neuroblastoma cells, microglia and primary astrocytes 
(chapters 3 and 7). Hence, HSV-1-infection is directly responsible for cell death in these 
human brain cell types individually. It has previously been reported that HSV-1 induces brain 
cell death by both necrosis and apoptosis39. In my brain cell models, increased cell loss was 
associated with a rise in viral load in the culture medium. Rates of change in cell viability 
following exposure to HSV1 (MOI=0.01) varied between microglial and neuroblastoma cells.  
Microglia showed sustained mitochondrial activity and viability for a longer time period 
following HSV infection compared to neuroblastoma cells. My data also showed HSV DNA 
load initially increased more rapidly in microglia compared to neuroblastoma cells. However, 
HSV DNA load was not significantly different at 72 h pi between cell types. The findings 
suggest microglial cells are potentially more permissive to HSV-1 infection than 
neuroblastoma cells (microglial cells enable higher HSV-1 loads to be generated without loss 
of mitochondrial activity). In an in vitro study using human fœtal brain cells,  HSV-1 was 
reported to be  “extensively replicative” in neurons and astrocytes but exhibit only a “slight 
and short replication” in microglia85. The discrepancy between the former study and my results 
may reflect the different cell lines, HSV strains and MOI used. Thus, they used primary foetal 
microglia while I used transformed microglia cell line, originally from adult brains. The 
differences in the development stage as well the process of transformation may have resulted 
in the fact they activated different immune signalling pathways and/or that they activated the 
same but with different intensity. This could explain a different cytokine profile and the 
different ability of sustaining HSV-1 replication. Otherwise, we did not use the exact same 
strains neither. These two strains may simply have a difference in virulence that leads to 
different replication profiles in both studies adding another degree of complexity. 
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Chapter 4 confirmed that aciclovir effectively impairs HSV-1 infective virus production in 
both neuroblastoma and microglial cells in vitro. The experiments also confirmed aciclovir 
treatment was associated with increased cell viability and mitochondrial metabolism. In my 
experiments, aciclovir treatment was associated with a decrease in TNF gene expression in 
microglia but an increase among neuroblastoma cells.  
The observed increases in cell viability and mitochondrial metabolism observed in vitro reflect 
the well-known therapeutic effect of aciclovir in HSE patients124, 39, 125.  My human brain model 
results also reflect the findings from previous animal studies. Boivin et al. showed that the 
administration of valaciclovir (oral aciclovir) was associated with reduced inflammation in 
brain homogenates and  a 5-fold decrease in viral DNA in the tissue133. Wei et al. showed that 
the administration of aciclovir in a mouse model of HSE was associated with a decrease in 
TNF gene expression in brain tissue203. 
Chapter 5 showed that administering dexamethasone is not detrimental for HSV-1-infected 
human brain cells. This is the first time cell viability and HSV DNA load has been assessed in 
a human brain cell in vitro model. There have been several clinical reports and case series 
retrospectively examining use of glucorticoids as an adjuvant in HSE, that have shown 
improved patient outcome 130, 160, 128, 177. A retrospective study showed that glucocorticoid 
administration was a predictor of good outcome in HSE130. One case report observed an 
improvement in a 16-month old girl with HSE following treatment with high-dose 
dexamethasone at 9 days after admission; her condition had previously deteriorated on  
aciclovir treatment alone128. The clinical outcomes of few a sample of children (n=3) suffering 
from HSE also improved with glucocorticoids in a case-report129. However, to my knowledge, 
there have been no human studies with dexamethasone investigating brain cell (or tissue) 
viability or viral load following HSV-1-infection.  A few animal models of HSE have looked 
at viral load. In an in vivo mouse model of HSE, methyl-prednisolone (another glucortocoid) 
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in combination with aciclovir was compared to aciclovir alone. The study found that 
combining aciclovir with methyprednisolone reduced long-term (60-180 days pi) magnetic 
resonance imaging (MRI) abnormalities in mouse brains94. Of note, viral load in brain tissue 
was not exacerbated with methylprednisolone administration. Similarly, a rat model of focal 
HSE also concluded that adding dexamethasone to aciclovir did not increase brain HSV-1 load 
compared to aciclovir alone120. My viral load findings support these animal studies.  Together 
this information can be used to negate fears that glucocorticoids will exacerbate HSV viral 
load during HSE treatment.  
In contrast to previous animal studies, my acute infection human cell models did not show any 
benefit of dexamethasone on brain cell viability. One hypothesis for the non-efficacy of 
dexamethasone in my study is that my in vitro models, once again, are a simplified 
representation of acute phase of HSE infection (up to 72 hours pi). During the acute phase of 
infection, levels of HSV antigen in the brain are still high and tissue inflammation not 
extensive yet143. Similarly in HSE animal models and clinical studies, there is infiltration of 
immune cells (beyond microglia) into the brain tissue35, 143, 71, 69, 179, 180, 68. Such cell interaction 
was not captured in my monoculture models.  
In chapter 6, the administration of infliximab alone led both to a partial rescue of cell viability 
and a decrease in HSV DNA abundance in both neuroblastomas and microglia cell models. 
This is first time that infliximab has been shown to inhibit of HSV-1 replication and protect 
human brain cells. In a previous in vivo study of Japanese Encephalitis, it was shown that use 
of etanercept was associated with a decrease in Japanese encephalitis virus (JEV) load as well 
as a reduction in brain inflammation134. Interestingly, in a HIV-positive patient with Reiter’s 
syndrome (acute inflammatory arthritis), administering antiretroviral therapy with infliximab 
for 6 months, was associated with a maintenance of low levels of HIV titres together with the 
resolution of all complaints, regrowth of nails and rash clearance204. Beyond measuring TNF 
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transcript abundance, the mechanism of action of infliximab was not explored in this thesis. 
Infliximab may inhibit HSV-1 replication and/or viral release from cells. The reduced viral 
replication (and/or spread) in brain cells may secondarily limit cell death. The mechanism of 
action of infliximab now warrants further study. In Inflammatory bowel disease, at molecular 
and cellular levels, infliximab was shown to be involved in: (i) down-regulating inflammatory 
cytokines, (ii) inducing apoptosis of activated lymphocytes, (iii) downregulating Th1, (iv) 
inducing Treg and regulatory macrophages, (v) inhibiting NF-kB and (vi) promoting MAPK 
signalling168.  
Although infliximab use was associated with an initial decrease in HSV DNA abundance, it 
was not associated with any sustained improvement in cell viability or mitochondrial activity. 
A mouse model of HSE, demonstrated that the administration of etanercept combined with 
valaciclovir (oral aciclovir) led to a significant increase in mouse survival compared to 
valaciclovir alone133. In my in vitro HSE models, experiments lasted no more than 3 or 4 days 
after infection (MOI=0.01) and showed persistent high HSV DNA levels throughout. These 
experiments are more representative of acute HSE phase, in which viral load is high and 
inflammation low, than a post-acute phase when inflammation and immune cell infiltration 
become more apparent and viral load has fallen 71, 143, 35 . 
In a clinical study, CSF TNF-α levels were elevated throughout a patient’s HSE illness course, 
but reached maximum levels during the convalescence stage (2-6 weeks after disease onset) 
71. In my study, I did not detect any increase in TNF protein levels in the culture media of 
neuroblastomas or microglia cells. An in vitro study showed that a high concentration of TNF 
proteins was released by purified human foetal microglia but not by astrocytes or neurons 24-
72 h after HSV-1-infection (MOI=1) 85. The fact they were using human foetal cells, or a 100-
fold higher MOI could explain the discrepancy with my results. In this same study, they also 
observed an early increase in TNF mRNA expression (observed by RNase protein assay) in 
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human foetal microglia from 3 to 24 h post-infection. Another paper, published by the same 
group, showed, via real-time qPCR, a 600-fold increase in TNF transcript expression 
following HSV-1 infection in murine microglial cells at 5 h pi and at MOI=286. My data 
showed an increase in TNF relative gene expression following HSV-1 infection (MOI=0.01) 
in human microglial cells, but at 72 h pi (last time-point). Once again, the differences in MOI 
and cell lines could explain the delay in TNF gene expression between my experiments and 
these latter publications. Although, there was no consistent trend between TNF gene 
expression and cell viability in HSV-1-infected neuroblastoma and microglial cells, 
administering infliximab alone had an impact, albeit transiently, on cell viability. The 
mechanisms by which infliximab increased cell viability remain uncertain and may be due to 
a direct anti-HSV-1 action previously unknown, or to the blockage of TNF protein at cell 
membrane level (undetected by ELISA tests). 
Only preliminary studies on the effect of microglial cells on HSV-1-infected neuroblastomas 
have been performed. The data obtained suggested microglia protected HSV-1-infected 
neuroblastoma cells. Further studies need to be performed. A microglia-release factor, such as 
IL-6, could be responsible for this protective effect. Indeed, a HSE model using co-culture of 
murine brain cells demonstrated that the production of IL-6 by microglia protected neuronal 
loss upon differentiation of NPC following HSV-1-infection136.  
To my knowledge, this is the first time human-derived primary brain cells have been used in 
co-culture in HSE in vitro models. In my study, microglia co-culture did not exacerbate viral 
replication or protect primary astrocytes during HSV-1 infection. This may indicate, over the 
time frame of my study, astrocyte death is driven by viral factors rather than inflammatory 
factors (secreted by microglia) during HSE. Alternatively, it may suggest astrocyte death is 
induced by pro-inflammatory molecules released by other immune cells (macrophages, T 
lymphocytes). The setting up of the co-culture models of HSE offers an opportunity in the 
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future to assess treatments using different in vitro systems that closer model clinical or in vivo 
conditions. 
For the first time: 
-dexamethasone (0.5 µM) was found not to be detrimental in HSV-1-infected neuroblastoma 
and microglial cells (alone or combined with aciclovir). However, it did not improve cell 
viability or decrease HSV-1 replication when combined with aciclovir compared to aciclovir 
alone.  
-infliximab was used in a human HSE model. 
-infliximab (0.5mg/ml) was shown to decrease viral load and maintain cell viability in HSV-
1-infected microglial and neuroblastoma cells. However, infliximab did not show any 
additional benefit when used in combination with aciclovir compared to aciclovir alone. 
8.4. Technical challenges encountered during my PhD and limitations of my work 
8.4.1. Technical challenges encountered during my PhD 
During my PhD, a number of technical issues have been encountered and addressed. I started 
to work with primary astrocytes however their proliferation rate was very slow and their life-
time, short. Hence, my experimental design was adapted to the use of transformed cell lines 
rather than primary cells.  
Initially I assessed cell viability by cell counting using Trypan blue exclusion staining. This 
technique was not well suited to counting infected neuroblastoma cells. The cells formed 
clusters which were difficult to separate back into single cells. For this reason, the WST-1 
assay was introduced as an alternative technique to assess cell viability.  
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Monitoring infected cells by microscopy was undertaken in each experiment.  At each time-
point and each condition, numerous 10 x magnification microscopy images were taken. This 
magnification was used because I could clearly observe viral-induced damage in the cell 
monolayer. In contrast only a few lower magnification images (4x) were taken for each 
condition at each time-point, for a wider view of cell damage. However, later during analysis 
of these images, I discovered that despite a variety of imaging parameters being applied, the 
10 x magnification images were not suitable for quantification of attached cell area using the 
standard imaging software “ImageJ”.  
8.4.2. Limitations of my work 
In-part because of these technical challenges, my work includes limitations: 
(i) Use of neuroblastoma cells rather than neurons. Neurons do not multiply in cell culture. 
Pluripotent stem cells that transform into neurons can also be technically challenging to 
maintain. Instead, neuroblastomas have been used as proxy neuron-like cells in my models. 
(ii) An incomplete set of experimental results using primary astrocytes (explained in the part 
8.4.1). 
(iii) Use of transformed human microglia rather than primary human microglia. Primary 
human microglia cells are again slow to culture, and relatively difficult to replace if cultures 
suffer mycoplasma infection.  For these reasons, a human microglia cell line was preferred. 
(iv) Low numbers of (4 x magnification) microscopy images systematically analysed for 
attached cell area (explained in the part 8.4.1). 
 (v) Limited number of co-culture experiments performed. Due to complexity and time spent 
preparing these models (including re-passage of cells after mycoplasma infection) only two 
experiments were undertaken for each co-culture.  
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 (vi) In vitro work. The results of my data need to be interpreted cautiously, in the context of 
a relatively simple in vitro human brain cell study performed in three brain cell types 
(examined mainly in monoculture) during the acute phase of HSV infection (up to 72 h pi).  
8.5. Future directions 
The future directions of this work could include: 
 (i) Use a lower MOI to perform the same experiments over a longer time-course (several 
weeks) so that the models can examine the post-acute HSE phase. 
(ii) Consider measuring cell viability by FACS to confirm the data obtained by WST-1 assay 
and live cell area analysis by ImageJ. I began to explore this technique.  
(iii) Repeat experiments using other cell types, including neurons or primary microglia. 
Although more time-consuming and technically more challenging, the data obtained would 
potentially be closer to clinical and in vivo conditions. 
(iv) Assess other anti-inflammatory agents, including IFN-γ drugs, in HSV-1-infected brain 
cells. 
(v) Further develop the in vitro HSE human co-culture models. 
 8.6. Conclusion 
Several clinical reports and in vivo animal studies suggest that administering anti-TNF or 
glucocorticoid drugs in combination with aciclovir could have a beneficial impact on HSE 
patient outcome. There is limited data on the effect of these drugs on cell viability or HSV 
viral load in human brain cell models. This is the first study to assess the effect of 
dexamethasone or infliximab alone and in combination with aciclovir, in vitro, in HSV-1 
infected human neuroblastoma and microglial cells.  
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My study showed that neither dexamethasone nor infliximab, when combined with aciclovir 
or alone, impaired cell viability or mitochondrial activity during acute HSV-1-infection among 
neuroblastoma or microglial cell culture. The study also demonstrated use of these anti-
inflammatory agents did not enhance HSV-1 replication in these models. My data on viral load 
in human brain cell culture supports previous animal studies, indicating these agents can be 
safely given without exacerbating HSV replication during HSE.  
For the first time, I have shown that infliximab (in a single dose) is protective against HSV-1 
infection of human neuroblastoma and microglial cells. Infliximab treatment was associated 
with a rapid reduction of HSV DNA abundance in the culture medium of the infected 
cells and slowed the reduction in live cell number and mitochondrial activity. 
Nevertheless, neither dexamethasone nor infliximab, when used in combination with aciclovir 
showed any increase in cell viability compared to aciclovir alone. Finally, I have begun to set-
up models of HSE using primary astrocytes or neuroblastoma cells co-cultured with microglia 
cells. These models need further investigation. However, my preliminary findings on HSE co-
culture systems could be the basis for an interesting non-animal model, closer to in vivo 
conditions, for assessing treatments in the future. 
New treatments for HSE are still required. Mortality and morbidity among survivors remain 
unacceptably frequent in HSE patients worldwide. The results from my thesis offer new 
insights and new human cell models to be taken forward to further explore anti-inflammatory 
agents and other novel mediators for the benefit of future HSE treatment. 
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